Pyrimidines and methods of use thereof
By using specific compounds to inhibit the toxic aggregation of TDP-43 protein, the problem of poor efficacy in the treatment of neurodegenerative diseases such as ALS and FTD in the prior art has been solved, and the effect of significantly improving patients' quality of life and delaying disease progression has been achieved.
Patent Information
- Application Number
- CN202280089678.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-08
- Filing Date
- 2022-12-08
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively treat agents that cause neurodegenerative diseases such as ALS and FTD, and most therapies provide small relief, requiring the development of more effective methods to change the process of neurodegenerative diseases.
Provided is a compound including a specific compound of formula I and formula II or a pharmaceutically acceptable salt thereof for inhibiting toxic aggregation of TDP-43 proteins, for the treatment of such as ALS, FTLD-TDP, Al Neurological disorders such as Zheimer's disease.
By inhibiting the toxic aggregation of TDP-43 protein, the patient's quality of life is significantly improved, the frequency and severity of muscle spasms are reduced, the slow lung capacity is improved, the muscle strength and function assessment is improved, and the disease progression is delayed.
Smart Images

Figure CN118922188A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to heteroaromatic hydrocarbons and their use for therapeutic treatment of neurological disorders in patients, such as human patients. Background Art
[0002] An incomplete understanding of the molecular perturbations that cause disease and a limited reserve of robust model systems have resulted in the inability to generate successful disease-modifying therapies for common and progressive neurological disorders such as ALS and FTD. Progress is being made in many areas to find agents that can inhibit the progression of these conditions. However, for most, if not all, of these diseases, current therapies provide very little relief. Therefore, there is a need to develop therapies that can alter the course of neurodegenerative diseases. More generally, there is a need for better methods and compositions for treating neurodegenerative diseases to improve the quality of life of those suffering from these diseases. Summary of the invention
[0003] TDP-43 is a nuclear DNA / RNA binding protein involved in RNA splicing. Under pathological cellular stress, TDP-43 translocates to the cytoplasm and aggregates into stress granules and associated protein inclusions. These phenotypes are hallmarks of degenerating motor neurons and are found in 97% of all ALS cases. The highly penetrant nature of this pathology suggests that TDP-43 is widely involved in familial and sporadic ALS. Furthermore, TDP-43 mutations that promote aggregation are associated with a higher risk of developing ALS, suggesting that protein misfolding and aggregation are drivers of toxicity. TDP-43 toxicity can be recapitulated in a yeast model, in which the protein induces viability defects and localizes to stress granules.
[0004] In one aspect, the present disclosure provides compounds of Formula I:
[0005]
[0006] or a pharmaceutically acceptable salt thereof,
[0007] in
[0008] V is -NH-, -NR 5 -, -CH2NH-, -CH2NR 5 -, -O-, -CO-, or -CHOH-;
[0009] R 1 is optionally substituted morpholin-4-yl, pyridin-4-yl, pyridin-3-yl, optionally substituted 2-oxo-pyrrolidin-1-yl, optionally substituted piperidin-1-yl or optionally substituted pyridazin-4-yl;
[0010] R 2 It is a halogen, -(CH2)n OH, optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ; and R 3 is optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl; or R 2 and R 3 Together with the ring to which they are attached, they combine to form an optionally substituted C4-C 12 heteroaryl;
[0011] n is 1, 2, 3, 4, 5, or 6;
[0012] k is 0, 1, or 2;
[0013] R 4 is optionally substituted pyridin-4-yl, optionally substituted 1-methylpyridin-1-ium-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl, or -NHR 8 ;
[0014] R 5 is an optionally substituted C1-C6 alkyl group;
[0015] R 6 is H or optionally substituted C1-C6 alkyl;
[0016] R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl;
[0017] R 7c , R 7d and R 7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 an alkoxy group or a hydroxy group; and
[0018] R 8is optionally substituted phenyl or optionally substituted C3-C6 cycloalkyl.
[0019] In some embodiments, R 1 is an optionally substituted morpholin-4-yl. 1 is an optionally substituted pyridin-4-yl. 1 is optionally substituted pyridin-3-yl.
[0020] In some embodiments, R 1 yes In some embodiments, R 1 yes In some embodiments, R 1 is morpholin-4-yl. In some embodiments, R 1 is an optionally substituted piperidin-1-yl. 1 yes
[0021] In some embodiments, V is -NH-. In some embodiments, V is -CH2NH-. In some embodiments, V is -O-. In some embodiments, V is -CO-. In some embodiments, V is -CHOH-. In some embodiments, V is -NR 5 -. In some embodiments, V is -CH2NR 5 -.
[0022] In some embodiments, R 4 is an optionally substituted pyridin-4-yl, an optionally substituted 1-methylpyridin-1-ium-4-yl, an optionally substituted pyridin-3-yl, an optionally substituted 1-methylpiperidin-3-yl, an optionally substituted pyridazin-3-yl. In some embodiments, R 4 is optionally substituted pyridin-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl. In some embodiments, R 4 is an optionally substituted pyridin-4-yl or an optionally substituted pyridin-3-yl. 4 It is pyridin-4-yl or pyridin-3-yl.
[0023] In some embodiments, R 2 and R 3 Together with the ring to which they are attached, they combine to form an optionally substituted C4-C 12 In some embodiments, R 2 and R 3 Together with the ring to which they are attached they combine to form an optionally substituted C4-C9 heteroaryl.
[0024] In some embodiments, the compound has the following structure:
[0025]
[0026] or a pharmaceutically acceptable salt thereof.
[0027] In some embodiments, R 2 It is a halogen, -(CH2) n OH, optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e In some embodiments, R 2 is an optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e .
[0028] In some embodiments, R 2 is an optionally substituted C 1-6 In some embodiments, R 2 It is -OCH3.
[0029] In some embodiments, R 2 Yes - (CO)NR 7a R 7b In some embodiments, R 7a and R 7b Each is independently an optionally substituted C1-C6 alkyl. 7a and R 7b In some embodiments, R 7a and R 7b Together with the nitrogen atom to which they are attached, they combine to form an optionally substituted C2-C9 heterocyclyl. 7a R 7b yes
[0030] In some embodiments, R2 Yes-P(O)R 7c R 7d or -S(O) k R 7e In some embodiments, R 2 yes
[0031] In some embodiments, R 2 is an optionally substituted C2-C9 heteroaryl. 2 yes
[0032] In some embodiments, R 2 is halogen. In some embodiments, R 2 It is Cl.
[0033] In some embodiments, R 2 Yes - (CH2) n OH. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1.
[0034] In some embodiments, R 3 is optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl.
[0035] In some embodiments, R 3 is optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl or optionally substituted C6-C 10 Aryl.
[0036] In some embodiments, R 3 is an optionally substituted C6 aryl. 3 yes
[0037] In some embodiments, R 3 is an optionally substituted pyridin-3-yl or an optionally substituted pyridin-4-yl. 3 yes
[0038] In some embodiments, R 3is an optionally substituted pyridin-2-yl, an optionally substituted pyrazol-1-yl, an optionally substituted pyrazol-3-yl, an optionally substituted pyridazin-3-yl, or an optionally substituted pyrimidin-4-yl. 3 yes
[0039] In one aspect, the present disclosure provides compounds of Formula II:
[0040]
[0041] or a pharmaceutically acceptable salt thereof,
[0042] in
[0043] R 9 is optionally substituted morpholin-4-yl, optionally substituted morpholin-3-ylalkoxy, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted 1-methylpiperazin-2-yl, or optionally substituted C6-C 10 Aryl;
[0044] R 10 is an optionally substituted C 1-6 Alkoxy, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ;
[0045] R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl;
[0046] R 7c , R 7d and R 7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy or hydroxyl;
[0047] k is 0, 1, or 2;
[0048] R 11 is optionally substituted morpholin-4-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-4-yl, optionally substituted 1H-imidazol-2-yl, optionally substituted quinolin-6-yl or optionally substituted C6-C 10 aryl; and
[0049] R 12 is optionally substituted 1-methylpiperazin-2-one, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted N-(pyridin-3-ylmethyl)amine, optionally substituted N-(pyridin-4-yl)amine or optionally substituted C6-C 10 Aryl.
[0050] In some embodiments, R 9 It is morpholin-4-yl.
[0051] In some embodiments, R 9 is an optionally substituted morpholin-3-ylalkoxy. 9 yes
[0052] In some embodiments, R 9 is an optionally substituted 2-(pyridin-2-yl)alkoxy group. 9 yes
[0053] In some embodiments, R 9 is an optionally substituted 1-methylpiperazin-2-yl. 9 yes
[0054] In some embodiments, R 9 is an optionally substituted C6-C 10 In some embodiments, R 9 yes
[0055] In some embodiments, R 10 is an optionally substituted C 1-6 In some embodiments, R 10 It's a methoxy group.
[0056] In some embodiments, R 11 is an optionally substituted morpholin-4-yl. 11 is morpholin-4-yl. In some embodiments, R 11 is an optionally substituted pyridin-4-yl. 11 It is pyridin-4-yl.
[0057] In some embodiments, R 11 is an optionally substituted pyrazol-4-yl. 11 yes
[0058] In some embodiments, R11 is an optionally substituted 1H-imidazol-2-yl. 11 yes
[0059] In some embodiments, R 11 is an optionally substituted quinolin-6-yl. 11 yes
[0060] In some embodiments, R 11 is an optionally substituted C6-C 10 In some embodiments, R 11 yes
[0061] In some embodiments, R 12 is optionally substituted 1-methylpiperazin-2-one. 12 yes
[0062] In some embodiments, R 12 is an optionally substituted 2-(pyridin-2-yl)alkoxy group. 12 yes
[0063] In some embodiments, R 12 is an optionally substituted N-(pyridin-3-ylmethyl)amine. 12 yes
[0064] In some embodiments, R 12 is an optionally substituted N-(pyridin-4-yl)amine. 12 yes
[0065] In some embodiments, R 12 is an optionally substituted C6-C 10 In some embodiments, R 12 yes
[0066] In some embodiments, the compound has the structure of any one of compounds 1-78 in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds 1-3, 6-29, 31-36, 38-41, 43-51, 53-57, 59, 62, and 64-78 in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds 4, 5, 30, 37, 42, 52, 58, 60, 61, and 63 in Table 1, or a pharmaceutically acceptable salt thereof.
[0067] In one aspect, the compound has the structure of any one of Compounds 1-78 in Table 1, or a pharmaceutically acceptable salt thereof.
[0068] In one aspect, the compound has the structure of any one of Compounds 1-3, 6-29, 31-36, 38-41, 43-51, 53-57, 59, 62, and 64-78 in Table 1, or a pharmaceutically acceptable salt thereof.
[0069] In one aspect, the compound has the structure of any one of compounds 4, 5, 30, 37, 42, 52, 58, 60, 61 and 63 in Table 1, or a pharmaceutically acceptable salt thereof.
[0070] In one aspect, the compound has the structure of any one of Compounds 66 and 34 in Table 1, or a pharmaceutically acceptable salt thereof.
[0071] Table 1. Compounds of the present invention
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080] In one aspect, the present invention provides intermediates in the synthesis of some compounds of the present invention. Non-limiting examples of intermediates include compounds i-1 to i-4 in Table 2.
[0081] Table 2.
[0082]
[0083] In one aspect, the invention features a pharmaceutical composition including any of the foregoing compounds and a pharmaceutically acceptable excipient.
[0084] In one aspect, the invention features a method of treating a neurological disorder (e.g., frontotemporal dementia (FTLD-TDP), chronic traumatic encephalopathy, ALS, Alzheimer's disease, limbic dominant age-related TDP-43 encephalopathy (LATE), or frontotemporal lobar degeneration) in a subject in need thereof. The method comprises administering an effective amount of any of the foregoing compounds or pharmaceutical compositions.
[0085] In one aspect, the invention features a method of inhibiting toxicity associated with a protein (eg, TDP-43 or C9orf72) in a cell (eg, a mammalian neural cell). The method comprises administering an effective amount of any of the foregoing compounds or pharmaceutical compositions.
[0086] In one aspect, the invention features a method of treating a TDP-43-related disorder or a C9orf72-related disorder (e.g., FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration) in a subject in need thereof. The method comprises administering to the subject an effective amount of a compound described herein or a pharmaceutical composition containing one or more compounds described herein. In some embodiments, the method comprises administering to the subject in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound having the structure of any one of Compounds 1-3, 6-29, 31-36, 38-41, 43-51, 53-57, 59, 62, and 64-78 in Table 1, or a pharmaceutically acceptable salt thereof). In some embodiments, the method comprises administering to the subject in need thereof an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof (e.g., a compound having the structure of any one of Compounds 4, 5, 30, 37, 42, 52, 58, 60, 61, and 63 in Table 1, or a pharmaceutically acceptable salt thereof). In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a compound having the structure of any one of Compounds 1-78 in Table 1, or a pharmaceutically acceptable salt thereof.
[0087] In one aspect, the present invention is characterized by a method for inhibiting PIKfyve. The method includes contacting a cell with an effective amount of any of the foregoing compounds or pharmaceutical compositions. In some embodiments, the method includes administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof (e.g., a compound having a structure of any one of compounds 1-3, 6-29, 31-36, 38-41, 43-51, 53-57, 59, 62, and 64-78 in Table 1, or a pharmaceutically acceptable salt thereof) to a subject in need. In some embodiments, the method includes administering an effective amount of a compound of formula II or a pharmaceutically acceptable salt thereof (e.g., a compound having a structure of any one of compounds 4, 5, 30, 37, 42, 52, 58, 60, 61, and 63 in Table 1, or a pharmaceutically acceptable salt thereof) to a subject in need. In some embodiments, the method includes administering an effective amount of a compound having a structure of any one of compounds 1-78 in Table 1, or a pharmaceutically acceptable salt thereof, to a subject in need.
[0088] In another aspect, the invention features a method of treating a neurological disorder in a patient (e.g., a human patient) who has been identified as potentially benefiting from treatment with a compound of the invention based on TDP-43 toxicity. In this regard, the method may include (i) determining that the patient exhibits or is predisposed to TDP-43 toxicity, and (ii) providing the patient with a therapeutically effective amount of a compound of the invention. In some embodiments, the patient has previously been determined to exhibit or be predisposed to TDP-43 toxicity, and the method includes providing the patient with a therapeutically effective amount of a compound of the invention. For example, the patient's susceptibility to TDP-43 aggregation may be determined by determining whether the patient expresses a mutant subtype of TDP-43 containing a mutation associated with TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D. For example, this may be performed by determining the amino acid sequence of a TDP-43 subtype isolated from a sample obtained from the patient or by determining the nucleic acid sequence of a TDP-43 gene isolated from a sample obtained from the patient. In some embodiments, the method includes the step of obtaining a sample from the patient.
[0089] In another aspect, the invention features a method of treating a neurological disorder in a patient (e.g., a human patient) who has been identified as being likely to benefit from treatment with a compound of the invention based on TDP-43 expression. In this regard, the method includes (i) determining that the patient expresses a mutant form of TDP-43 having a mutation associated with TDP-43 aggregation (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D), and (ii) providing a therapeutically effective amount of a compound of the invention to the patient. In some embodiments, the patient has previously been identified as expressing a mutant form of TDP-43 having a mutation associated with TDP-43 aggregation (e.g., Q331K, M337V, Q343R, N345K, R361S, or N390D mutation), and the method includes providing a therapeutically effective amount of a compound of the invention to the patient.
[0090] In another aspect, the invention features a method of determining whether a patient (e.g., a human patient) with a neurological disorder is likely to benefit from treatment with a compound of the invention by (i) determining whether the patient exhibits or is predisposed to TDP-43 aggregation and (ii) if the patient exhibits or is predisposed to TDP-43 aggregation, identifying the patient as being likely to benefit from treatment with the compound of the invention. In some embodiments, the method further comprises the step of (iii) informing the patient whether he or she is likely to benefit from treatment with the compound of the invention. For example, the patient's susceptibility to TDP-43 aggregation can be determined by determining whether the patient expresses a mutant subtype of TDP-43 containing a mutation associated with TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D. For example, this can be performed by determining the amino acid sequence of a TDP-43 subtype isolated from a sample obtained from the patient or by determining the nucleic acid sequence of a TDP-43 gene isolated from a sample obtained from the patient. In some embodiments, the method comprises the step of obtaining a sample from the patient.
[0091] In another aspect, the invention features a method of determining whether a patient (e.g., a human patient) with a neurological disorder is likely to benefit from treatment with a compound of the invention by (i) determining whether the patient expresses a TDP-43 mutant having a mutation associated with TDP-43 aggregation (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D) and (ii) if the patient expresses the TDP-43 mutant, identifying the patient as likely to benefit from treatment with a compound of the invention. In some embodiments, the method further comprises the step of (iii) informing the patient whether he or she is likely to benefit from treatment with a compound of the invention. The TDP-43 subtype expressed by the patient can be assessed by, for example, isolating TDP-43 protein from a sample obtained from the patient and sequencing the protein using molecular biology techniques described herein or known in the art. In some embodiments, the TDP-43 subtype expressed by the patient is determined by analyzing the patient's genotype at the TDP-43 locus, for example, by sequencing the TDP-43 gene in a sample obtained from the patient. In some embodiments, the method includes the step of obtaining a sample from a patient.
[0092] In some embodiments of any of the above aspects, a compound of the invention is provided to a patient by administering a compound of the invention to the patient. In some embodiments, a compound of the invention is provided to a patient by administering a prodrug that is converted in vivo to a compound of the invention.
[0093] In some embodiments of any of the foregoing aspects, the neurological disorder is a neuromuscular disorder, such as a neuromuscular disorder selected from amyotrophic lateral sclerosis, congenital myasthenic syndrome, congenital myopathy, spastic fasciculation syndrome, Duchenne muscular dystrophy, glycogen storage disease type II, hereditary spastic paraplegia, inclusion body myositis, Isaac syndrome, Kearns-Sayre syndrome, Lambert-Eaton myasthenic syndrome, mitochondrial myopathy, muscular dystrophy, myasthenia gravis, myotonic dystrophy, peripheral neuropathy, spinal and bulbar muscular atrophy, spinal muscular atrophy, stiff-person syndrome, Troyer syndrome, and Guillain-Barre syndrome. In some embodiments, the neurological disorder is amyotrophic lateral sclerosis.
[0094] In some embodiments of any of the above aspects, the neurological disorder is selected from frontotemporal degeneration (also known as frontotemporal lobar degeneration and frontotemporal dementia), Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam Parkinsonism-dementia-amyotrophic lateral sclerosis complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy.
[0095] In some embodiments, the neurological disorder is amyotrophic lateral sclerosis, and after administering a compound of the invention to a patient, the patient exhibits one or more or all of the following reactions:
[0096] (i) an improvement in condition assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R), such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, weeks, or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, or 9 days after initial administration of the compound of the invention to the patient). patients' ALSFRS or ALSFRS-R scores improve within 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);
[0097] (ii) slow increase in lung capacity, such as slow increase in lung capacity in a patient within one or more days, weeks or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks after initial administration of the compound of the invention to the patient , 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or more) in patients with a slow increase in vital capacity over a period of 1 week or more;
[0098] (iii) a decrease in the decremental response exhibited by the patient following repeated neural stimulation, such as a decrease observed within one or more days, weeks, or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks after initial administration of the compound of the invention to the patient , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or more weeks);
[0099] (iv) improvement in muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated by reference as it relates to measuring a patient's response to a neurological disease treatment), such as an improvement observed within one or more days, weeks, or months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer after initial administration of a compound of the invention to a patient. within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer after the initial administration of a compound of this invention to a patient);
[0100] (v) improvement in quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, as observed within one or more days, weeks, or months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 68 days, 69 days, 70 days, 71 days, 72 weeks, 73 weeks, 74 weeks, 75 weeks, 76 weeks 3 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);
[0101] (vi) a decrease in the frequency and / or severity of muscle spasms, such as a decrease in the frequency and / or severity of spasms within one or more days, weeks, or months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 53 weeks, 54 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks, 66 weeks, 67 weeks, 68 weeks, 69 weeks, 70 weeks, 71 weeks, 72 weeks, 73 weeks, 74 weeks, 75 weeks, 57 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer); and / or
[0102] (vii) a decrease in TDP-43 aggregation, such as a decrease in TDP-43 aggregation within one or more days, weeks, or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer).
[0103] Chemical terms
[0104] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments and is not intended to be limiting.
[0105] Those skilled in the art will appreciate that certain compounds described herein may exist in one or more different isomers (e.g., stereoisomers, geometric isomers, tautomers) and / or isotopic (e.g., wherein one or more atoms have been substituted with different isotopes of atoms, such as hydrogen for deuterium) forms. Unless otherwise indicated or clear from the context, depicted structures may be understood to represent any such isomers or isotopic forms, alone or in combination.
[0106] In some embodiments, one or more compounds described herein may exist in different tautomeric forms. As is clear from the context, unless explicitly excluded, reference to such compounds encompasses all such tautomeric forms. In some embodiments, tautomeric forms are produced by the exchange of a single bond with an adjacent double bond and the concomitant migration of a proton. In certain embodiments, the tautomeric form may be a prototropic tautomer, which is an isomeric protonation state with the same empirical formula and total charge as the reference form. Examples of parts with prototropic tautomeric forms are keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and cyclic forms in which protons can occupy two or more positions of a heterocyclic system, such as 1H- and 3H-imidazoles, 1H-, 2H- and 4H-1,2,4-triazoles, 1H- and 2H-isoindoles, and 1H- and 2H-pyrazoles. In some embodiments, tautomeric forms may be balanced or spatially locked into one form by appropriate substitution. In certain embodiments, tautomeric forms arise from acetal interconversions, such as those shown in the following schemes:
[0107]
[0108] Those skilled in the art will appreciate that in some embodiments, isotopes of the compounds described herein can be prepared and / or utilized in accordance with the present invention. "Isotopes" refer to atoms having the same atomic number but different mass numbers resulting from different numbers of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, isotopic substitution (e.g., substitution of hydrogen with deuterium) can alter the physicochemical properties of a molecule, such as metabolic and / or racemization rates of chiral centers.
[0109] As is known in the art, many chemical entities (particularly many organic molecules and / or many small molecules) can adopt a variety of different solid forms, such as, for example, amorphous forms and / or crystalline forms (e.g., polymorphs, hydrates, solvates, etc.). In some embodiments, such entities can be utilized in any form, including any solid form. In some embodiments, such entities are utilized in a specific form, such as, for example, in a specific solid form.
[0110] In some embodiments, the compounds described and / or depicted herein may be provided and / or utilized in salt form.
[0111] In certain embodiments, the compounds described and / or depicted herein may be provided and / or utilized in the form of a hydrate or a solvate.
[0112] At various places in this specification, substituents of compounds of the present disclosure are disclosed in groups or ranges. The present disclosure is specifically intended to include each and every individual subcombination of the members of these groups and ranges. For example, the term "C1-C6 alkyl" is specifically intended to disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl individually. In addition, when a compound includes multiple positions where substituents are disclosed in groups or ranges, unless otherwise indicated, the present disclosure is intended to cover individual compounds and groups of compounds (e.g., genera and subgenera) containing each and every individual subcombination of members at each position.
[0113] As used herein, phrases of the form "optionally substituted X" (e.g., optionally substituted alkyl) are intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein the alkyl is optionally substituted"). It is not intended to indicate that the feature "X" (e.g., alkyl) itself is optional.
[0114] As used herein, the term "acyl" means hydrogen or alkyl as defined herein attached to the parent molecular group through a carbonyl as defined herein, and examples are formyl (i.e., carboxyaldehyde), acetyl, trifluoroacetyl, propionyl, and butyryl. Exemplary unsubstituted acyl groups include 1 to 6, 1 to 11, or 1 to 21 carbons.
[0115] As used herein, the term "alkyl" refers to a branched or straight chain monovalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms). An alkylene group is a divalent alkyl group.
[0116] As used herein, the term "alkenyl" alone or in combination with other groups, refers to a straight or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 or 2 carbon atoms).
[0117] As used herein, the term "alkynyl," alone or in combination with other groups, refers to a straight or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 or 2 carbon atoms).
[0118] As used herein, the term "amino" refers to -N(R N1 )2, where each R N1 are independently H, OH, NO2, N(R N2 2. SO2OR N2 、SO2R N2 、SOR N2, N-protecting groups, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or other groups described herein), wherein these R N1 Each of the groups may be optionally substituted; or both R N1 are combined to form an alkylene or heteroalkylene group, and wherein each R N2 are independently H, alkyl or aryl. The amino groups of the present invention can be unsubstituted amino (ie, -NH2) or substituted amino (ie, -N(R N1 )2).
[0119] As used herein, the term "aryl" refers to an aromatic monocyclic or polycyclic group of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.
[0120] As used herein, the term "arylalkyl" refers to an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups have 7 to 30 carbons (e.g., 7 to 16 or 7 to 20 carbons), such as C1-C6 alkyl C 6-10 Aryl, C1-C 10 Alkyl C 6-10 Aryl or C1-C 20 Alkyl C 6-10 In some embodiments, the alkyl and aryl groups can each be further substituted with 1, 2, 3 or 4 substituents as defined herein for the corresponding groups.
[0121] As used herein, the term "azido" refers to a -N3 group.
[0122] As used herein, the term "cyano" refers to a CN group.
[0123] As used herein, the term "carbocyclyl" refers to a non-aromatic C3-C 12 A monocyclic, bicyclic or tricyclic structure wherein the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl and unsaturated carbocyclyl.
[0124] As used herein, the term "cycloalkyl" refers to a saturated, non-aromatic, monovalent mono- or poly-carbocyclic group of 3 to 10, preferably 3 to 6 carbon atoms. The term is further exemplified by groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.
[0125] As used herein, the term "halo" refers to a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) group.
[0126] As used herein, the term "heteroalkyl" refers to an alkyl as defined herein, wherein one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen or sulfur. In some embodiments, the heteroalkyl may be further substituted by 1, 2, 3 or 4 substituents as described herein for the alkyl. An example of a heteroalkyl is "alkoxy", which, as used herein, refers to alkyl-O- (e.g., methoxy and ethoxy). Heteroalkylene is a divalent heteroalkyl.
[0127] As used herein, the term "heteroalkenyl" refers to an alkenyl as defined herein, wherein one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl may be further substituted with 1, 2, 3, or 4 substituents as described herein for alkenyl. An example of a heteroalkenyl is "alkenyloxy," which, as used herein, refers to alkenyl-O-. Heteroalkenylene is a divalent heteroalkenyl.
[0128] As used herein, the term "heteroalkynyl" refers to an alkynyl as defined herein, wherein one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl may be further substituted with 1, 2, 3, or 4 substituents as described herein for the alkynyl. An example of a heteroalkynyl is "alkynyloxy," which, as used herein, refers to alkynyl-O-. Heteroalkynylene is a divalent heteroalkynyl.
[0129] As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic group of 5 to 12 atoms having at least one aromatic ring and containing one, two, three or four ring heteroatoms selected from N, O and S, the remaining ring atoms being C. One or two ring carbon atoms of a heteroaryl group may be replaced by a carbonyl group. Examples of heteroaryl groups are pyridyl (e.g., pyridin-2-yl, pyridin-3-yl and pyridin-4-yl), pyrazolyl (e.g., pyrazol-1-yl and pyrazol-3-yl), pyrimidinyl (e.g., pyrimidin-4-yl), pyridazinyl (e.g., pyridazin-3-yl), benzoxazolyl, benzimidazolyl, benzothiazolyl, imidazolyl, oxazolyl and thiazolyl.
[0130] As used herein, the term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are 7 to 30 carbon atoms (e.g., 7 to 16 or 7 to 20 carbon atoms, such as C1-C6 alkyl, C2-C9 heteroaryl, C1-C 10 Alkyl C2-C9 heteroaryl or C1-C 20 In some embodiments, the alkyl and heteroaryl groups can each be further substituted with 1, 2, 3, or 4 substituents as defined herein for the corresponding groups.
[0131] As used herein, the term "heterocyclyl" refers to a monocyclic or polycyclic group having 3 to 12 atoms, having at least one ring containing one, two, three or four ring heteroatoms selected from N, O or S and having no aromatic rings. Examples of heterocyclyls include, but are not limited to, morpholinyl (e.g., morpholin-4-yl), thiomorpholinyl, furanyl, piperazinyl, piperidinyl (e.g., piperidin-1-yl), pyranyl, pyrrolidinyl (e.g., pyrrolidin-1-yl), tetrahydropyranyl, tetrahydrofuranyl and 1,3-dioxanyl. Heterocyclyls may be aromatic or non-aromatic. Aromatic heterocyclyls are also referred to as heteroaryls.
[0132] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are 7 to 30 carbon atoms (e.g., 7 to 16 or 7 to 20 carbon atoms, such as C1-C6 alkyl, C2-C9 heterocyclyl, C1-C 10 Alkyl C2-C9 heterocyclic group, or C1-C 20 In some embodiments, the alkyl and heterocyclyl groups can each be further substituted with 1, 2, 3, or 4 substituents as defined herein for the corresponding groups.
[0133] As used herein, the term "hydroxy" refers to an -OH group.
[0134] As used herein, the term "N-protecting group" refers to those groups intended to protect amino groups from undesired reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis", 3rd Edition (John Wiley & Sons, New York, 1999). N-protecting groups include acyl, aroyl or carbamoyl groups, such as formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthaloyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl and chiral auxiliaries, such as protected or unprotected D, L or D, L-amino acids, such as alanine, leucine and phenylalanine; sulfonyl-containing groups, such as benzenesulfonyl and p-toluenesulfonyl; carbamate-forming groups, such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5 -dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, diphenylmethoxycarbonyl, tert-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl and phenylthiocarbonyl, aralkyl groups such as benzyl, triphenylmethyl and benzyloxymethyl and silyl groups such as trimethylsilyl. Preferred N-protecting groups are allyloxycarbonyl (alloc), formyl, acetyl, benzoyl, pivaloyl, tert-butylacetyl, alanyl, phenylsulfonyl, benzyl, tert-butoxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
[0135] As used herein, the term "nitro" refers to a NO2 group.
[0136] As used herein, the term "oxaaryl" refers to a heteroaryl group having at least one bridging ring oxygen atom.
[0137] As used herein, the term "oxheterocyclyl" refers to a heterocyclic group having at least one bridging oxygen atom.
[0138] As used herein, the term "thiol" refers to a -SH group.
[0139] Alkyl, alkenyl, alkynyl, assorted alkyl, assorted alkenyl, assorted alkynyl, carbocyclic radical (for example cycloalkyl), aryl, heteroaryl and heterocyclic radical can be substituted or unsubstituted.When substituted, unless otherwise indicated, there are usually 1 to 4 substituents.Substituents include, for example: aryl (for example, substituted and unsubstituted phenyl), carbocyclic radical (for example, substituted and unsubstituted cycloalkyl), halogen (for example, fluorine), hydroxyl, oxo, assorted alkyl (for example, substituted and unsubstituted methoxy, ethoxy or thioalkoxy), heteroaryl, heterocyclic radical, amino (for example, NH2 or monoalkylamino or dialkylamino), azido, cyano, nitro or thiol.Aryl, carbocyclic radical (for example cycloalkyl), heteroaryl and heterocyclic radical can also be substituted by alkyl (unsubstituted and substituted, such as arylalkyl (for example substituted and unsubstituted benzyl)).
[0140] The compounds of the present invention may have one or more asymmetric carbon atoms and may exist in the form of optically pure enantiomers, mixtures of enantiomers, such as, for example, racemates, optically pure diastereomers, mixtures of diastereomers, racemates of diastereomers or mixtures of racemates of diastereomers. The optically active form may be obtained, for example, by resolving the racemate, by asymmetric synthesis or asymmetric chromatography (chromatography using a chiral adsorbent or eluent). That is, some disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, and the most common reason is that they contain asymmetrically substituted carbon atoms as chiral centers. "Enantiomers" means one of a pair of molecules that are mirror images and not superimposable to each other. Diastereomers are stereoisomers that are not related as mirror images, and the most common reason is that they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. The enantiomers of a compound can be prepared, for example, by separating enantiomers from racemates using one or more well-known techniques and methods (such as, for example, chiral chromatography and separation methods based thereon). One skilled in the art can easily determine the appropriate techniques and / or methods for separating the enantiomers of the compounds described herein from a racemic mixture. "Racemate" or "racemic mixture" means a compound containing two enantiomers, wherein such a mixture does not show optical activity; that is, they do not rotate the plane of polarized light. "Geometric isomer" means an isomer with different orientations of substituent atoms relative to a carbon-carbon double bond, a cycloalkyl ring, or a bridged bicyclic system. The atoms on each side of the carbon-carbon double bond (except H) can be in E (substituents on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. "R", "S", "S*", "R*", "E", "Z", "cis" and "trans" represent configurations relative to the core molecule. Certain disclosed compounds can exist in atropisomer form. Atropisomers are stereoisomers resulting from hindered rotation about a single bond, where the steric stress barrier to rotation is high enough to allow separation of conformers. The compounds of the invention can be prepared as individual isomers by isomer-specific synthesis or resolution from isomeric mixtures. Conventional resolution techniques include forming salts of the free bases of each isomer in an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming salts of the acid form of each isomer in an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming esters or amides of each isomer in an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving isomeric mixtures of the starting material or final product using various well-known chromatographic methods.When the stereochemistry of a disclosed compound is named or depicted by a structure, the stereoisomer named or depicted is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by a structure, the enantiomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% optically pure by weight. When a single diastereomer is named or depicted by a structure, the diastereomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight. The optical purity percentage is the ratio of the weight of an enantiomer to the weight of the enantiomer plus the weight of its optical isomers. Diastereomeric purity by weight is the ratio of the weight of one diastereomer to the weight of all diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. The percent purity by mole fraction is the ratio of the number of moles of enantiomer to the number of moles of enantiomer plus the number of moles of its optical isomers. Similarly, the percent purity of mole fraction is the ratio of the number of moles of diastereomer to the number of moles of diastereomer plus the number of moles of its isomers. When a disclosed compound is named or depicted by structure without reference to stereochemistry, and the compound has at least one chiral center, it is understood that the name or structure encompasses either enantiomer of the compound free of the corresponding optical isomer, a racemic mixture of the compound, or a mixture enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating stereochemistry and has two or more chiral centers, it is understood that the name or structure encompasses a diastereomer free of other diastereomers, multiple diastereomers free of other diastereomeric pairs, a mixture of diastereomers, a mixture of diastereomeric pairs, a mixture of diastereomers in which one diastereomer is enriched relative to the other diastereomers, or a mixture of diastereomers in which one or more diastereomers are enriched relative to the other diastereomers. The invention includes all of these forms.
[0141] definition
[0142] In this application, unless the context clearly indicates otherwise, (i) the term "a" or "an" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to cover the listed components or steps, whether presented alone or with one or more additional components or steps; and (iv) the terms "about" and "approximately" may be understood to allow for standard variations, as would be understood by a person of ordinary skill in the art; and (v) where a range is provided, the endpoints are included.
[0143] As used herein, the term "administering" refers to administering a composition (e.g., a compound, a complex, or a preparation comprising a compound or a complex as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) can be by any appropriate route. For example, in some embodiments, administration can be bronchial (including by bronchial instillation), oral, enteral, interdermal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, and vitreous.
[0144] As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to a person at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In some embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, a cow, a primate, and / or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and / or worms. In some embodiments, animals can be transgenic animals, genetically engineered animals, and / or clones.
[0145] As used herein, the terms "approximately" and "about" are each intended to encompass normal statistical variations that are appropriate for the relevant context as will be understood by those of ordinary skill in the art. In certain embodiments, the terms "approximately" or "about" each refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction of the value (greater than or less than), unless otherwise specified or otherwise apparent from the context (e.g., where such a numeral will exceed 100% of the possible values).
[0146] Two events or entities are "associated with" one another, as the term is used herein, if the presence, level, and / or form of one event or entity correlates with the presence, level, and / or form of another event or entity. For example, a particular entity (e.g., a polypeptide) is considered to be associated with a particular disease, disorder, or condition if the presence, level, and / or form of the particular entity correlates with the incidence and / or susceptibility of the disease, disorder, or condition (e.g., in a related population).
[0147] As used herein, the terms "benefit" and "response" are used interchangeably in the context of a subject, such as a human subject undergoing therapy for the treatment of a neurological disorder, such as amyotrophic lateral sclerosis, frontotemporal degeneration (also known as frontotemporal lobar degeneration and frontotemporal dementia), Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-parkinsonism ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy. The terms "benefit" and "response" refer to any clinical improvement in a subject's condition. In the case of a subject undergoing treatment for a neurological disorder using the compositions and methods described herein (e.g., in the case of a human subject undergoing treatment for a neurological disorder described herein (e.g., amyotrophic lateral sclerosis) using a FYVE-type zinc finger-containing phosphoinositide kinase (PIKfyve) inhibitor (e.g., an inhibitory small molecule, antibody, antigen-binding fragment thereof, or interfering RNA molecule) described herein), exemplary benefits include slowing and halting disease progression, and inhibiting one or more symptoms associated with the disease. In particular, in the context of patients (e.g., human patients) undergoing treatment with a compound of the invention for amyotrophic lateral sclerosis, examples of clinical "benefit" and "response" are (i) an improvement in the subject's condition as assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R) following administration of the compound of the invention, such as an improvement in the subject's ALSFRS or ALSFRS-R score within one or more days, weeks, or months following administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer following initial administration of the compound of the invention to the subject; an improvement in a subject's ALSFRS or ALSFRS-R score within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer after the initial administration of a compound of the invention to the subject;(ii) an increase in the slow lung capacity of a subject after administration of a compound of the invention, such as an increase in the slow lung capacity of a subject within one or more days, weeks, or months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks after initial administration of a compound of the invention to a subject (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks after initial administration of a compound of the invention to a subject) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 79 days, 80 days, 81 days, 81 days, 82 days, 83 days, 84 days, 85 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or more, (iii) a decrease in the decremental response exhibited by the subject following repeated neural stimulation, such as a decrease observed within one or more days, weeks, or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks after initial administration of the compound of the invention to the subject , 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);(iv) an improvement in the subject's muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated herein by reference as it relates to measuring a patient's response to a neurological disease treatment), such as an improvement observed within one or more days, weeks, or months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks after initial administration of the compound of the invention to the subject (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 2 months), or within about 1 day to about 48 weeks after initial administration of the compound of the invention to the subject (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 2 months). within about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks (v) an improvement in the subject's quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, as observed within one or more days, weeks, or months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after initial administration of a compound of the invention to a subject. an improvement in the subject's quality of life observed over 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);and (vi) a decrease in the frequency and / or severity of muscle spasms exhibited by the subject, such as a decrease in the frequency and / or severity of spasms within one or more days, weeks, or months following administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks following initial administration of the compound of the invention to the subject 48 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or more).
[0148] As used herein, the term "dosage form" refers to a physically discrete unit of an active compound (e.g., a therapeutic agent or a diagnostic agent) for administration to a subject. Each unit contains a predetermined amount of an active agent. In some embodiments, such an amount is a unit dose (or its overall fraction) suitable for administration according to a dosing regimen that has been determined to be associated with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). It is understood by those of ordinary skill in the art that the total amount of a therapeutic composition or compound administered to a particular subject is determined by one or more attending physicians and may involve the administration of multiple dosage forms.
[0149] As used herein, the term "dosage regimen" refers to a group of unit doses (usually more than one) administered separately to a subject, usually at intervals of a period of time. In some embodiments, a given therapeutic compound has a recommended dosing regimen, which may involve one or more doses. In some embodiments, the dosing regimen includes multiple doses, each of which is separated from each other by a time period of the same length; in some embodiments, the dosing regimen includes multiple doses and at least two different time periods separating a single dose. In some embodiments, all doses within the dosing regimen have the same dosage. In some embodiments, different doses within the dosing regimen have different amounts. In some embodiments, the dosing regimen includes a first dose of a first dosage, followed by one or more additional doses of a second dosage that is different from the first dosage. In some embodiments, the dosing regimen includes a first dose of a first dosage, followed by one or more additional doses of a second dosage that is the same as the first dosage. In some embodiments, the dosing regimen is associated with the desired or beneficial results when administered in a related population (i.e., a therapeutic dosing regimen).
[0150] In practicing the methods of the present invention, an "effective amount" of any one compound of the present invention or any combination of compounds of the present invention or pharmaceutically acceptable salts thereof is administered alone or in combination by any conventional and acceptable method known in the art.
[0151] As used herein, the term "pharmaceutical composition" means a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient and manufactured or sold as part of a therapeutic regimen for treating a disease in a mammal approved by a governmental regulatory agency. The pharmaceutical composition can be formulated, for example, for oral administration in a unit dosage form (e.g., tablets, capsules, caplets, soft gels, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate plugs and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.
[0152] As used herein, "pharmaceutically acceptable excipients" refers to any ingredient other than the compounds described herein (e.g., a solvent capable of suspending or dissolving the active compound) and having substantially non-toxic and non-inflammatory properties in patients. Excipients may include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dicalcium phosphate), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0153] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt of a compound of formula (I). For example, pharmaceutically acceptable salts of any compound described herein include those that are within the scope of reasonable medical judgment, suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use (ed. P. H. Stahl and C. G. Wermuth), Wiley-VCH, 2008. Salts can be prepared in situ during the final isolation and purification of the compounds described herein, or prepared separately by reacting the free base group with a suitable organic acid.
[0154] The compounds of the present invention may have ionizable groups so that they can be prepared as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids, or in the case of acidic forms of the compounds of the present invention, the salts may be prepared from inorganic or organic bases. Typically, the compounds are prepared or used as pharmaceutically acceptable salts, which are prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparing suitable salts are well known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic and organic acids and bases.
[0155] The terms "PIKfyve" and "phosphoinositide kinase containing a FYVE-type zinc finger" are used interchangeably herein and refer to an enzyme that catalyzes the phosphorylation of phosphatidylinositol 3-phosphate to produce phosphatidylinositol 3,5-bisphosphate, for example in a human subject. The terms "PIKfyve" and "phosphoinositide kinase containing a FYVE-type zinc finger" refer not only to the wild-type form of PIKfyve, but also to variants of the wild-type PIKfyve protein and nucleic acids encoding the same. The gene encoding PIKfyve can be obtained as NCBI reference sequence number NG_021188.1. Exemplary transcript sequences of wild-type forms of human PIKfyve can be obtained as NCBI reference sequence numbers NM_015040.4, NM_152671.3, and NM_001178000.1. Exemplary protein sequences of wild-type forms of human PIKfyve are available at NCBI reference sequence numbers NP_055855.2, NP_689884.1 and NP_001171471.1.
[0156] As used herein, the term "PIKfyve inhibitor" refers to a substance, such as a compound of Formula I. This type of inhibitor can competitively inhibit PIKfyve activity, for example by specifically binding to the PIKfyve enzyme (e.g., due to the inhibitor's affinity for the PIKfyve active site), thereby preventing, hindering or stopping one or more endogenous substrates of PIKfyve from entering the active site of the enzyme. Other examples of PIKfyve inhibitors that inhibit the activity of the PIKfyve enzyme include substances that can bind to PIKfyve at a site away from the active site and weaken the binding of endogenous substrates to the PIKfyve active site by changes in the spatial conformation of the enzyme when the inhibitor binds. In addition to covering substances that modulate PIKfyve activity, the term "PIKfyve inhibitor" refers to substances that reduce the concentration and / or stability of PIKfyve mRNA transcripts in vivo, as well as those that inhibit the translation of functional PIKfyve enzymes.
[0157] The term "pure" means substantially pure or free of unwanted components (eg, other compounds and / or other components of a cell lysate), material contamination, admixtures, or defects.
[0158] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.
[0159] A variety of clinical indicators can be used to identify patients as being "at risk" for developing a particular neurological disease. Examples of patients (e.g., human patients) who are "at risk" for developing a neurological disease (e.g., amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-parkinsonism ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy) include (i) subjects who exhibit or are prone to exhibit TAR-DNA binding protein (TDP)-43 aggregation, and (ii) subjects who express a mutant form of TDP-43 that contains a mutation associated with TDP-43 aggregation and toxicity (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D). For example, a subject "at risk" for developing ALS may exhibit one or both of these characteristics prior to the first administration of a PIKfyve inhibitor according to the compositions and methods described herein.
[0160] As used herein, the terms "TAR-DNA binding protein-43" and "TDP-43" are used interchangeably and refer to, for example, a transcriptional repressor protein that is involved in regulating alternative splicing of HIV-1 transcription and cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA transcripts in human subjects. The terms "TAR-DNA binding protein-43" and "TDP-43" refer not only to wild-type forms of TDP-43, but also to variants of wild-type TDP-43 proteins and nucleic acids encoding them. The amino acid sequence and corresponding mRNA sequence of the wild-type form of human TDP-43 are provided as NCBI reference sequence numbers NM_007375.3 and NP_031401.1, respectively.
[0161] As used herein, the terms "TAR-DNA binding protein-43" and "TDP-43" include, for example, a form of a human TDP-43 protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of NCBI Reference Sequence No. NP_031401.1 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% identical to the amino acid sequence of NCBI Reference Sequence No. NP_031401.1) and / or a form of a human TDP-43 protein that contains one or more substitutions, insertions and / or deletions (e.g., one or more conservative and / or non-conservative amino acid substitutions, such as up to 5, 10, 15, 20, 25 or more conservative or non-conservative amino acid substitutions) relative to a wild-type TDP-43 protein. For example, patients that can be treated for a neurological disorder as described herein (e.g., amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-Parkinsonism ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy) include human patients expressing a form of TDP-43 with a mutation associated with increased TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D. Similarly, the terms "TAR-DNA binding protein-43" and "TDP-43" as used herein include, for example, forms of the human TDP-43 gene encoding an mRNA transcript having a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of NCBI Reference Sequence No. NM_007375.3 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% identical to the amino acid sequence of NCBI Reference Sequence No. NM_007375.3).
[0162] As used herein, the term "subject" refers to any organism to which a composition according to the invention may be administered, e.g., for experimental, diagnostic, preventive and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals, such as mice, rats, rabbits, non-human primates, and humans). A subject may be a person or animal seeking or requiring treatment, requiring treatment, currently receiving treatment, receiving treatment in the future, or being cared for by a trained professional for a particular disease or condition.
[0163] A "therapeutic regimen" refers to a regimen of dosages that is administered in a relevant population and is associated with desired or beneficial therapeutic outcomes.
[0164] The term "therapeutically effective amount" means an amount sufficient to treat a disease, disorder and / or condition when applied to a group suffering from or susceptible to a disease, disorder and / or condition according to a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and / or severity of one or more symptoms of a disease, disorder and / or condition and / or delays its onset. It will be understood by those of ordinary skill in the art that the term "therapeutically effective amount" does not actually require successful treatment in a particular individual. On the contrary, a therapeutically effective amount can be an amount that provides a specific desired pharmacological response in a large number of subjects when applied to a patient who needs such treatment. It is particularly understood that, in fact, a specific subject may be "refractory" to a "therapeutically effective amount". To give just one example, a refractory subject may have a low bioavailability, making it impossible to obtain clinical efficacy. In some embodiments, reference to a therapeutically effective amount can be a reference to an amount measured in one or more specific tissues (e.g., tissues affected by a disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount can be formulated and / or administered in a single dose. In some embodiments, a therapeutically effective amount can be formulated and / or administered in multiple doses, for example, as part of a dosing regimen. BRIEF DESCRIPTION OF THE DRAWINGS
[0165] Figure 1 is a schematic diagram showing the method for generating a control TDP-43 yeast model (FAB1 TDP-43). The control yeast TDP-43 model was generated by integrating the human TDP-43 gene and the GAL1 promoter into the yeast genome. The yeast ortholog of human PIKFYVE is FAB1.
[0166] Figure 2 Schematic diagram showing the method for generating a humanized PIKFYVE TDP-43 yeast model (PIKFYVE TDP-43). The FAB1 gene was expressed by homologous recombination with a G418 resistance cassette (fab1::G418 R )( Figure 2 ). PIKFYVE was cloned downstream of the GPD promoter carried on a plasmid containing URA3 and introduced into the fab1::G418R ura3 strain. The pGAL7-TDP-43 construct was then introduced into the "humanized" yeast strain and cytotoxicity was assessed.
[0167] Figure 3 is a histogram generated from a flow cytometry-based viability assay of FAB1 TDP-43.
[0168] Figure 4 is a histogram generated from a flow cytometry-based viability assay of PIKFYVE TDP-43. Nonviable cells (rightmost population) increased significantly following TDP-43 induction, with a more pronounced effect in the PIKFYVE TDP-43 than in the FAB1 TDP-43 strain (see Figure 3 ).
[0169] Figure 5 is an overlay of histograms generated from a flow cytometry-based viability assay of FAB1 TDP-43 in the presence of APY0201.
[0170] Figure 6 is an overlay of histograms generated from a flow cytometry-based viability assay of PIKFYVE TDP-43 in the presence of APY0201.
[0171] Figure 7 is a scatter plot comparing the cytoprotective efficacy of PIKFYVE TDP-43 with the PIKfyve inhibitory activity of the test compounds. DETAILED DESCRIPTION
[0172] The invention features compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis and other neuromuscular disorders, as well as frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-parkinsonism ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy, etc. In particular, the invention provides inhibitors of phosphoinositide kinases containing FYVE-type zinc fingers (PIKfyve), which can be administered to a patient (e.g., a human patient) to treat or prevent a neurological disorder, such as one or more of the foregoing conditions. In the context of therapeutic treatment, a PIKfyve inhibitor may be administered to a patient to alleviate one or more symptoms of the disorder and / or to correct the underlying molecular pathology associated with the disease, such as inhibiting or preventing aggregation of TAR-DNA binding protein (TDP)-43.
[0173] The disclosure herein is based in part on the discovery that PIKfyve inhibition modulates TDP-43 aggregation in cells. Inhibition of TDP-43 aggregation plays a beneficial role in patients with neurological disorders. Many pathological conditions are associated with TDP-43-promoted aggregation and toxicity, such as amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, Lewy body dementia, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-parkinsonism ALS complex, Huntington's disease, IBMPFD, sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy. Without being limited by mechanism, by administering a PIKfyve inhibitor, for example, due to the suppression of TDP-43 aggregation induced by a PIKfyve inhibitor, patients with diseases associated with TDP-43 aggregation and toxicity can be treated.
[0174] Patients likely to respond to PIKfyve inhibition as described herein include patients with TDP-43 aggregation or at risk of developing TDP-43 aggregation, such as patients expressing mutant forms of TDP-43 associated with TDP-43 aggregation and in vivo toxicity. Examples of such mutations in TDP-43 associated with elevated TDP-43 aggregation and toxicity include Q331K, M337V, Q343R, N345K, R361S, and N390D, among others. Thus, the compositions and methods described herein provide additional clinical benefits of being able to identify patients who may respond to PIKfyve inhibitor therapy, and methods of treating these patients accordingly.
[0175] The following sections provide descriptions of exemplary PIKfyve inhibitors that can be used in conjunction with the compositions and methods disclosed herein. The following sections additionally provide descriptions of various exemplary routes of administration and pharmaceutical compositions that can be used to deliver these substances to treat neurological disorders.
[0176] PIKfyve inhibitors
[0177] Exemplary PIKfyve inhibitors described herein include compounds of Formula I:
[0178]
[0179] or a pharmaceutically acceptable salt thereof,
[0180] in
[0181] V is -NH-, -NR 5 -、-CH2NH-、-CH2NR 5 -, -O-, -CO-, or -CHOH-;
[0182] R 1is optionally substituted morpholin-4-yl, pyridin-4-yl, pyridin-3-yl, optionally substituted 2-oxo-pyrrolidin-1-yl, optionally substituted piperidin-1-yl or optionally substituted pyridazin-4-yl;
[0183] R 2 It is a halogen, -(CH2) n OH, optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ; and R 3 is optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl; or R 2 and R 3 Together with the ring to which they are attached, they combine to form an optionally substituted C4-C 12 heteroaryl;
[0184] n is 1, 2, 3, 4, 5, or 6;
[0185] k is 0, 1, or 2;
[0186] R 4 is optionally substituted pyridin-4-yl, optionally substituted 1-methylpyridin-1-ium-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl, or -NHR 8 ;
[0187] R 5 is an optionally substituted C1-C6 alkyl group;
[0188] R 6 is H or optionally substituted C1-C6 alkyl;
[0189] R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl;
[0190] R 7c , R 7d and R7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 an alkoxy group or a hydroxy group; and
[0191] R 8 is optionally substituted phenyl or optionally substituted C3-C6 cycloalkyl.
[0192] Exemplary PIKfyve inhibitors described herein also include compounds of Formula II:
[0193]
[0194] or a pharmaceutically acceptable salt thereof,
[0195] in
[0196] R 9 is optionally substituted morpholin-4-yl, optionally substituted morpholin-3-ylalkoxy, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted 1-methylpiperazin-2-yl, or optionally substituted C6-C 10 Aryl;
[0197] R 10 is an optionally substituted C 1-6 Alkoxy, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ;
[0198] R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl;
[0199] R 7c , R 7d and R 7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy or hydroxyl;
[0200] k is 0, 1, or 2;
[0201] R 11 is optionally substituted morpholin-4-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-4-yl, optionally substituted 1H-imidazol-2-yl, optionally substituted quinolin-6-yl or optionally substituted C6-C 10aryl; and
[0202] R 12 is optionally substituted 1-methylpiperazin-2-one, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted N-(pyridin-3-ylmethyl)amine, optionally substituted N-(pyridin-4-yl)amine or optionally substituted C6-C 10 Aryl.
[0203] Treatment
[0204] Inhibition of PIKfyve activity and TDP-43 aggregation for the treatment of neurological disorders
[0205] Using the compositions and methods described herein, PIKfyve inhibitors, such as small molecules described herein, can be administered to patients suffering from a neurological disorder to treat the disorder and / or inhibit one or more symptoms associated with the disorder. Exemplary neurological disorders that can be treated using the compositions and methods described herein are, but are not limited to, amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-parkinsonism ALS complex, Huntington's disease, IBMPFD, sporadic inclusion body myositis, myofibrillar myopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy, as well as neuromuscular diseases such as congenital myopathy. Myasthenic syndrome, congenital myopathy, spastic myosinosis, Duchenne muscular dystrophy, glycogen storage disease type II, hereditary spastic paraplegia, inclusion body myositis, Isaac syndrome, Kearns-Sayre syndrome, Lambert-Eaton myasthenic syndrome, mitochondrial myopathy, muscular dystrophy, myasthenia gravis, myotonic dystrophy, peripheral neuropathy, spinal and bulbar muscular atrophy, spinal muscular atrophy, stiff-person syndrome, Troyer syndrome and Guillain-Barré syndrome.
[0206] The present disclosure is based in part on the discovery that PIKfyve inhibitors, such as the agents described herein, are able to attenuate TDP-43 toxicity. TDP-43-promoted toxicity is associated with various neurological diseases. The discovery that PIKfyve inhibitors modulate TDP-43 aggregation provides important therapeutic benefits. Using PIKfyve inhibitors, such as the PIKfyve inhibitors described herein, patients suffering from neurological disorders or at risk of developing such disorders can be treated in a manner that remedies the underlying molecular cause of the disease. Without being limited by mechanism, for example, by inhibiting TDP-43 aggregation that promotes pathology, the compositions and methods described herein can be used to treat or prevent such neurological disorders.
[0207] In addition, the compositions and methods described herein provide the beneficial feature of being able to identify and treat patients who may respond to PIKfyve inhibitor therapy. For example, in some embodiments, a PIKfyve inhibitor is administered to a patient (e.g., a human patient suffering from or at risk of developing a neurological disease described herein, such as amyotrophic lateral sclerosis) if the patient is identified as likely to respond to this form of treatment. Patients can be identified based on, for example, susceptibility to TDP-43 aggregation. In some embodiments, patients are identified as likely to respond to PIKfyve inhibitor treatment based on the subtype of TDP-43 expressed by the patient. For example, patients expressing TDP-43 subtypes with mutations selected from Q331K, M337V, Q343R, N345K, R361S, and N390D are more likely to experience TDP-43-promoted aggregation and toxicity relative to patients who do not express these TDP-43 subtypes. Using the compositions and methods described herein, patients can be identified as likely to respond to PIKfyve inhibitor therapy based on expression of such TDP-43 isoforms, and can subsequently be administered a PIKfyve inhibitor to treat or prevent one or more neurological disorders, such as one or more neurological disorders described herein.
[0208] Assessing patient response
[0209] A variety of methods known in the art and described herein can be used to determine whether a patient with a neurological disorder (e.g., a patient at risk for developing TDP-43 aggregation, such as a patient expressing a mutant form of TDP-43 having a mutation associated with increased TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D) will respond favorably to PIKfyve inhibition. For example, successful treatment of a patient with a neurological disease such as amyotrophic lateral sclerosis with a PIKfyve inhibitor described herein can be signaled by:
[0210] (i) improvement in condition as assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R), such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, or more after initial administration of the PIKfyve inhibitor to the patient). an improvement in a patient's ALSFRS or ALSFRS-R score over 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);
[0211] (ii) an increase in slow lung capacity, such as an increase in slow lung capacity in a patient within one or more days, weeks, or months after administration of a PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or more) a patient's slow increase in vital capacity over a period of 1 week;
[0212] (iii) a decrease in the patient's decremental response to repeated neural stimulation, such as a decrease observed within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks after initial administration of the PIKfyve inhibitor to the patient). , 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or more weeks);
[0213] (iv) improvement in muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated herein by reference as it relates to measuring a patient's response to a neurological disease treatment), such as an improvement observed within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or more after initial administration of the PIKfyve inhibitor to the patient. over an extended period of time, such as improvements observed 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer after the initial administration of the PIKfyve inhibitor to the patient);
[0214] (v) an improvement in quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, as observed within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, or 9 days after initial administration of the PIKfyve inhibitor to the patient). improvement in the subject's quality of life observed over a period of 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);
[0215] (vi) a decrease in the frequency and / or severity of muscle spasms, such as a decrease in the frequency and / or severity of spasms within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 53 weeks, 54 weeks, 55 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 60 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks, 66 weeks, 67 weeks, 68 weeks, 69 weeks, 70 weeks, 71 weeks, 72 weeks, 7 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer);
[0216] (vii) a decrease in TDP-43 aggregation, such as a decrease in TDP-43 aggregation within one or more days, weeks, or months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., about 2 days to about 36 weeks, about 4 weeks to about 24 weeks, about 8 weeks to about 20 weeks, or about 12 weeks to about 16 weeks) or longer after the initial administration of the PIKfyve inhibitor to the patient, such as within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 53 weeks, 54 weeks, 55 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 60 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks, 66 weeks, weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks or longer).
[0217] Combination preparations and their uses
[0218] The compounds of the invention may be combined with one or more therapeutic agents. In particular, the therapeutic agent may be a therapeutic agent for the treatment or prophylactic treatment of any of the neurological disorders described herein.
[0219] Combination therapy
[0220] The compounds of the present invention can be used alone or in combination with other agents for treating neurological disorders or symptoms associated therewith, or in combination with other types of treatments to treat, prevent any neurological disorders and / or reduce the risk of any neurological disorders. In combination therapy, when administered alone, the dosage of one or more therapeutic compounds can be reduced from the standard dose. For example, the dosage can be empirically determined from drug combinations and arrangements, or can be derived by isobologram analysis (e.g., Black et al., Neurology 65: S3-S6, 2005). In this case, when combined, the dosage of the compound should provide a therapeutic effect.
[0221] Pharmaceutical composition
[0222] The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for in vivo administration. Thus, in another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention admixed with a suitable diluent, carrier or excipient.
[0223] The compounds of the present invention can be used in the form of free alkali, in the form of salt, solvate and as prodrug. All forms are within the scope of the present invention. According to the method of the present invention, as understood by those skilled in the art, the described compound or its salt, solvate or prodrug can be applied to the patient in various forms according to the selected route of administration. The compounds of the present invention can be applied, for example, by oral, parenteral, oral, sublingual, nasal, rectal, patch, pump or transdermal administration, and the pharmaceutical composition is formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical administration modes. Parenteral administration can be carried out by continuous infusion in a selected time period.
[0224] The compounds of the present invention can be administered orally, for example, with an inert diluent or with an absorbable edible carrier, or can be enclosed in a hard or soft shell gelatin capsule, or can be compressed into tablets, or can be directly admixed with the food of the diet. For oral therapeutic administration, the compounds of the present invention can be admixed with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups and wafers.
[0225] The compounds of the present invention can also be administered parenterally. Solutions of the compounds of the present invention can be prepared in water appropriately mixed with a surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, DMSO and mixtures thereof (with or without alcohol) and in oil. Under common storage and use conditions, these preparations may contain preservatives to prevent microbial growth. Conventional procedures and ingredients for selecting and preparing suitable preparations are described in, for example, Remington's Pharmaceutical Sciences (2003, 20th edition) and The United States Pharmacopeia: The National Formulary (USP 24NF 19), published in 1999.
[0226] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that it can be easily administered by syringe.
[0227] Compositions for nasal administration can be conveniently formulated into aerosols, drops, gels and powders. Aerosol preparations generally include solutions or fine suspensions of active substances in physiologically acceptable aqueous or non-aqueous solvents, and are generally present in a sealed container in a sterile form in a single dose or multiple doses, and the sealed container can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container can be a monomer dispensing device, such as a single dose nasal inhaler or an aerosol dispenser equipped with a metering valve, which is intended to be discarded after use. When the dosage form includes an aerosol dispenser, it contains a propellant, which can be a compressed gas, such as compressed air, or an organic propellant, such as fluorochlorocarbons. Aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for oral or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier (such as sugar, gum arabic, gum tragacanth, gelatin and glycerol). Compositions for rectal administration are conveniently in the form of suppositories containing conventional suppository bases (such as cocoa butter).
[0228] The compounds of the invention can be administered to animals, such as humans, alone or in combination with a pharmaceutically acceptable carrier as described herein, in proportions determined by the solubility and chemical properties of the compound, the chosen route of administration, and standard pharmaceutical practice.
[0229] dose
[0230] The dosage of the compounds of the present invention and / or compositions comprising the compounds of the present invention may vary according to many factors, such as the pharmacodynamic properties of the compounds; the mode of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the frequency of treatment and the type of concurrent treatment (if any); and the clearance rate of the compound in the animal to be treated. Those skilled in the art can determine the appropriate dosage based on the above factors. The compounds of the present invention may be initially administered at a suitable dosage, which may be adjusted as needed according to the clinical response. Typically, when the compounds of the present invention are administered to patients at a daily dosage of, for example, 0.05 mg to 3000 mg (measured in solid form), satisfactory results may be obtained. The dosage range includes, for example, 10-1000 mg.
[0231] Alternatively, the dosage may be calculated using the patient's body weight. For example, the dosage of the compound or pharmaceutical composition thereof administered to a patient may be in the range of 0.1-50 mg / kg.
[0232] The following examples are intended to illustrate the present invention. They are not intended to limit the present invention in any way.
[0233] Example
[0234]
[0235]
[0236] Example 1. Synthesis of 5-methoxy-2-morpholino-N-phenyl-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxamide (Compound 1):
[0237]
[0238] Step 1: Synthesis of 5-methoxy-2-morpholinopyrimidine-4,6-diol.
[0239] To a solution of morpholine-4-carboximidamide hydrochloride (2 g, 12.1 mmol) and dimethyl 2-methoxymalonate (1.95 g, 12.1 mmol) in MeOH (35 mL) was added MeONa (30% solution in MeOH, 6.8 mL, 36.3 mmol). After addition, the reaction mixture was stirred at 80 °C for 17 h and then concentrated to give 5-methoxy-2-morpholinopyrimidine-4,6-diol (2.5 g, 91%) as a brown solid, which was used directly in the next step without further purification.
[0240] Step 2: Synthesis of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine.
[0241] A mixture of 5-methoxy-2-morpholinopyrimidine-4,6-diol (2.5 g, 11 mmol) and phosphorus oxychloride (25 mL) was stirred at 110 ° C for 16 h and then concentrated. The resulting residue was diluted with ethyl acetate / water (20 mL / 20 mL) and extracted twice with ethyl acetate (20 mL). The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product obtained was purified by flash column chromatography (Biotage, 40 g silica gel; eluted with 20% to 40% ethyl acetate in petroleum ether) to give 4-(4,6-dichloro-5-methoxypyrimidine-2-yl)morpholine (1.5 g, 51.6%) as a light yellow solid. LCMS (ESI) m / z: 264.1 [M+H] + .
[0242] Step 3: Synthesis of 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-4-ol.
[0243] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.14 g, 0.53 mmol), 1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.16 g, 0.58 mmol), tris(dibenzylideneacetone)dipalladium (49 mg, 0.053 mmol), tricyclohexylphosphine (30 mg, 0.1 mmol) and cesium carbonate (0.34 g, 1.06 mmol) in dimethyl sulfoxide (20 mL) was stirred under nitrogen atmosphere at 130° C. for 16 h. The reaction was cooled and the mixture was diluted with ethyl acetate (20 mL) and filtered through a pad of celite. The filtrate was extracted with water (40 mL), and the aqueous phase was lyophilized to give 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-4-ol (0.15 g, 80%) as a white solid. LCMS (ESI) m / z: 354.1 [M+H] + .
[0244] Step 4: Synthesis of 4-(4-chloro-5-methoxy-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-2-yl)morpholine.
[0245] A mixture of 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-4-ol (0.15 g, 0.42 mmol) and phosphorus oxychloride (8 mL) was stirred at 110 ° C for 16 h. The mixture was concentrated, the residue was diluted with ethyl acetate / water (20 mL / 20 mL), and extracted twice with ethyl acetate (20 mL). The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (Biotage, 40 g silica gel, eluted with 20% to 40% ethyl acetate in petroleum ether) to give 4-(4-chloro-5-methoxy-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-2-yl)morpholine (0.11 g, 70.6%) as a white solid. LCMS (ESI) m / z: 372.1 [M+H] + .
[0246] Step 5: Synthesis of methyl 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylate.
[0247] A solution of 4-(4-chloro-5-methoxy-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-2-yl)morpholine (100 mg, 0.27 mmol), triethylamine (82 mg, 0.81 mmol), palladium (II) acetate (6 mg, 0.03 mmol) and 1,1'-bis(diphenylphosphino)ferrocene (30 mg, 0.06 mmol) in methanol (4 mL) and dimethyl sulfoxide (6 mL) was stirred at 80 ° C for 16 h under a carbon monoxide atmosphere. After cooling to room temperature, the reaction mixture was filtered through celite. The filtrate was diluted with ethyl acetate (30 mL), washed with water (20 mL×3) and brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with ethyl acetate to give methyl 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylate (25 mg, 23.4%) as a white solid. LCMS (ESI) m / z: 396.1 [M+H] + .
[0248] Step 6: Synthesis of 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylic acid.
[0249] To a solution of 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylic acid methyl ester (20 mg, 0.05 mmol) in tetrahydrofuran / methanol / water (4 mL / 1 mL / 1 mL) was added lithium hydroxide monohydrate (4 mg, 0.1 mmol) and the reaction mixture was stirred at room temperature for 2 h. It was concentrated and the residue was diluted with water (5 mL), the pH was adjusted to 3-4 with 2N HCl aqueous solution and extracted twice with ethyl acetate (10 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated to give 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylic acid (15 mg, 78.7%) as a white solid. LCMS (ESI) m / z: 382.2 [M+H] + .
[0250] Step 7: Synthesis of 5-methoxy-2-morpholino-N-phenyl-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxamide.
[0251] To a solution of 5-methoxy-2-morpholino-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxylic acid (15 mg, 0.039 mmol) and aniline (4 mg, 0.039 mmol) in N,N-dimethylformamide (5 mL) was added HATU (15 mg, 0.047 mmol) and DIPEA (10 mg, 0.08 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. The mixture was filtered and the filtrate was purified by preparative HPLC to give 5-methoxy-2-morpholino-N-phenyl-6-(1-phenyl-1H-pyrazol-3-yl)pyrimidine-4-carboxamide (4.3 mg, 24.2%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ10.62(s,1H),8.68(d,J=2.6Hz,1H),7.97(d,J=7.7Hz,2H),7.73(d,J=7.6Hz,2H),7.56(t,J=8.0Hz,2H),7.38(t,J= 7.8Hz, 3H), 7.22 (d, J = 2.5Hz, 1H), 7.14 (t, J = 7.4Hz, 1H), 3.84 (s, 3H), 3.76 (d, J = 5Hz, 4H), 3.71 (d, J = 4.9Hz, 4H); LCMS (ESI) m / z: 457.1[M+H] + .
[0252] Example 2. Synthesis of 4-(5-methoxy-4-(4-phenyl-1H-pyrazol-1-yl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (Compound 2):
[0253]
[0254] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine.
[0255] To a solution of pyridine-3-ol (0.18 g, 1.9 mmol) in tetrahydrofuran (20 mL) was added sodium hydride (60% in mineral oil, 0.11 g, 2.85 mmol) in portions at 0°C. After addition, the mixture was warmed and stirred at room temperature for 20 min. A solution of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.5 g, 1.9 mmol) in tetrahydrofuran (10 mL) was then added. The resulting mixture was heated to reflux for 16 h with stirring. It was cooled, diluted with ethyl acetate / water (20 mL / 20 mL) and extracted with ethyl acetate (20 mL*2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by flash chromatography (Biotage, 40 g silica gel, eluted with 50% to 70% ethyl acetate in petroleum ether) to give 4-(4-chloro-5-methoxy-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (0.46 g, 75.4%) as a white solid. LCMS (ESI) m / z: 323.1 [M+H] + .
[0256] Step 2: Synthesis of 4-(5-methoxy-4-(4-phenyl-1H-pyrazol-1-yl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine.
[0257] A mixture of 4-(4-chloro-5-methoxy-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (40 mg, 0.12 mmol), 4-phenyl-1H-pyrazole (18 mg, 0.12 mmol) and cesium carbonate (80 mg, 0.24 mmol) in N,N-dimethylacetamide (6 mL) was stirred at 100° C. for 4 h. The resulting mixture was filtered through a pad of celite and concentrated. The residue was subjected to preparative HPLC to give 4-(5-methoxy-4-(4-phenyl-1H-pyrazol-1-yl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (12.5 mg, 23.6%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.94(s,1H),8.60(d,J=2.7Hz,1H),8.50(dd,J=4.7,1.3Hz,1H),8.39(s,1H),7.85-7.73(m,3H),7.54( d,J=4.7Hz,1H),7.43(t,J=7.7Hz,2H),7.29(s,1H),3.86(s,3H),3.58(d,J=4Hz,4H),3.49(bs,4H),LCMS(ESI)m / z:431.1[M+H] + .
[0258] Example 3. Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 3):
[0259]
[0260] Step 1: Preparation of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine.
[0261] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.2 g, 0.76 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.21 g, 0.76 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (62 mg, 0.075 mmol) and cesium carbonate (0.62 g, 1.89 mmol) in 1,4-dioxane / water (20 mL / 4 mL) was stirred at 95 °C for 3 h under an argon atmosphere. It was concentrated, and the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude product obtained was purified by flash chromatography (Biotage, 40 g silica gel, eluted with petroleum ether in ethyl acetate 20% to 40%) to give 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (0.15 g, 51.3%) as a white solid. LCMS (ESI) m / z: 385.8 / 387.8 [M+H] + .
[0262] Step 2: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0263] A mixture of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (80 mg, 0.21 mmol), pyridin-4-amine (20 mg, 0.21 mmol), tris(dibenzylideneacetone)dipalladium (19 mg, 0.02 mmol), XPhos (20 mg, 0.04 mmol) and cesium carbonate (0.17 g, 0.52 mmol) in toluene (15 mL) was stirred at 95 ° C for 16 h under argon atmosphere. It was concentrated, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (17.8 mg, 19%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.36 (s, 1H), 8.44-8.42 (m, 3H), 7.91-7.86 (m, 4H), 7.77 (d, J = 2.2Hz, 1H), 7.52 ( t,J=7.6Hz,1H),6.71(d,J=2.2Hz,1H),3.90(s,3H),3.70(s,8H),3.45(s,3H); LCMS(ESI)m / z:443.9[M] + .
[0264] Example 4. Synthesis of 4-(5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (Compound 4):
[0265]
[0266] Step 1: Synthesis of 4-(2,6-dichloro-5-methoxypyrimidin-4-yl)morpholine.
[0267] To a solution of 2,4,6-trichloro-5-methoxypyrimidine (0.4 g, 1.88 mmol) and morpholine (0.16 g, 1.88 mmol) in tetrahydrofuran (20 mL) was added N,N-diisopropylethylamine (0.48 g, 3.77 mmol). The reaction mixture was stirred at room temperature for 2 h. It was concentrated and the resulting crude product was purified by column chromatography (on silica gel) to give 4-(2,6-dichloro-5-methoxypyrimidin-4-yl)morpholine (0.49 g, 98%) as a white solid. LCMS (ESI) m / z: 264.0 [M+H] + .
[0268] Step 2: Synthesis of 4-(2-chloro-5-methoxy-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine.
[0269] At 0 ° C, sodium hydride (60%, 91 mg, 2.28 mmol) was added to a solution of 2-(pyridin-2-yl)ethan-1-ol (0.19 g, 1.52 mmol) in tetrahydrofuran (20 mL) in batches. After addition, the mixture was stirred at 0 ° C for 30 min, and then 4-(2,6-dichloro-5-methoxypyrimidin-4-yl)morpholine (0.4 g, 1.52 mmol) in tetrahydrofuran (4 mL) was added dropwise at the same temperature. The resulting mixture was warmed and stirred at room temperature for 4 h, then diluted with ethyl acetate / water (20 mL / 20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phase was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product obtained was purified by flash chromatography (Biotage, 40 g silica gel, eluted with 20% to 40% 7N ammonia methanol in DCM) to give 4-(2-chloro-5-methoxy-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (0.26 g, 48.9%) as a white solid. LCMS (ESI) m / z: 351.1 [M+H] + . (Rt:1.81min.)
[0270] The positional isomer 4-(6-chloro-5-methoxy-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (0.14 g, 26.3%) was also obtained as a white solid. LCMS (ESI) m / z: 351.1 [M+H] + ; (Rt=1.68 min). The two isomers were confirmed by NOESY.
[0271] Step 3: Synthesis of 4-(5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine.
[0272] A mixture of 4-(2-chloro-5-methoxy-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (0.1 g, 0.28 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (81 mg, 0.28 mmol), tetrakis(triphenylphosphine)palladium (33 mg, 0.03 mmol) and cesium carbonate (0.23 g, 0.71 mmol) in dioxane / water (20 mL / 4 mL) was stirred at 90° C. for 16 h. The resulting mixture was filtered and concentrated. The residue was subjected to preparative HPLC to give 4-(5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (28.7 mg, 21.7%) as a white solid. 1 H NMR (400MHz, CDCl3) δ8.69(t,J=1.6Hz,1H),8.57(d,J=4.0Hz,1H),8.25(dt,J=4.0,1.6Hz,1H), 7.88(dt,J=4.0,1.6Hz,1H),7.61(td,J=7.7,1.8Hz,1H),7.45(t,J=8Hz,1H),7.41(d,J=1.6Hz, 1H),7.32(d,J=7.8Hz,1H),7.14(dd,J=7.0,5.4Hz,1H),6.62(d,J=2.2Hz,1H),4.93(t,J=6.6Hz ,2H),3.98(s,3H),3.83(s,8H),3.59(s,3H),3.37(t,J=6.6Hz,2H); LCMS(ESI)m / z:473.3[M+H] + .
[0273] Example 5. Synthesis of 4-(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (Compound 5):
[0274] The following compounds were synthesized according to the protocol described in Example 4 above:
[0275]
[0276] Example 6. Synthesis of N-cyclopropyl-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxamide (Compound 6):
[0277]
[0278] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine.
[0279] To a solution of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.26 g, 0.984 mmol) and 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.28 g, 0.984 mmol) in dioxane / water (10 mL / 2 mL) was added cesium carbonate (0.64 g, 1.97 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.073 g, 0.1 mmol). The resulting mixture was stirred at 90°C for 2 h, then poured into ice water and extracted with ethyl acetate (15 mL×3). The combined organic layers were washed with brine, dried and evaporated to dryness. The crude product was chromatographed on silica gel (petroleum ether / ethyl acetate = 20:1) to obtain the target product (200 mg, 53%) as a yellow solid. LCMS (ESI) m / z: 385.8 / 387.8 [M] + .
[0280] Step 2: Synthesis of methyl 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxylate.
[0281] A mixture of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (0.2 g, 0.52 mmol), triethylamine (0.16 g, 1.56 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.04 g, 0.05 mmol) in methanol / dimethyl sulfoxide (10 mL / 5 mL) was stirred at 75 ° C for 16 h under carbon monoxide. The reaction mixture was concentrated and the crude product obtained was purified by column chromatography (on silica gel, using petroleum ether / ethyl acetate = 2:1) to give the target product as a yellow solid (0.12 g, 56%). LCMS (ESI) m / z: 410.1 [M+H] + .
[0282] Step 3: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxylic acid.
[0283] A mixture of methyl 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxylate (0.12 g, 0.29 mmol) and lithium hydroxide hydrate (0.025 g, 0.58 mmol) in water (1 mL) / tetrahydrofuran (4 mL) was stirred at 25°C for 5 h. It was concentrated to give the desired product (0.1 g, 86%) as a yellow solid. LCMS (ESI) m / z: 396.1 [M+H] + .
[0284] Step 4: Synthesis of N-cyclopropyl-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxamide.
[0285] A solution of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidine-4-carboxylic acid (120 mg, 0.3 mmol), cyclopropylamine (52 mg, 0.91 mmol), N,N-diisopropylethylamine (120 mg, 0.91 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (171 mg, 0.45 mmol) in N,N-dimethylformamide (5 mL) was stirred at 25° C. for 2 h. The resulting mixture was filtered and concentrated. The residue was subjected to preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column, XBridge C18 3.5 μm 4.6x50 mm column, mobile phase was acetonitrile / 0.1% aqueous ammonium bicarbonate solution) to give the desired product as a white solid (42.6 mg, 32%). 1 H NMR(400MHz,DMSO-d6)δ8.65(d,J=4.5Hz,1H),8.41(t,J=1.5Hz,1H),7.97-7 .86(m,2H),7.77(d,J=2.2Hz,1H),7.53(t,J=7.8Hz,1H),6.73(d,J=2.2Hz,1 H),3.90(s,3H),3.70(d,J=3.6Hz,8H),3.48(d,J=6.2Hz,3H),2.83(pent,J= 4.1Hz,1H),0.76-0.69(m,2H),0.59-0.49(m,2H); LCMS(ESI)m / z:435.1[M+H] + .
[0286] Example 7. Synthesis of 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 7):
[0287]
[0288] Step 1: Synthesis of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0289] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.5 g, 1.89 mmol), pyridine-4-amine (0.16 g, 1.7 mmol), tris(dibenzylideneacetone)dipalladium (0.17 g, 0.19 mmol), X-Phos (0.18 g, 0.38 mmol) and cesium carbonate (1.54 g, 4.73 mmol) in toluene (25 mL) was stirred at 100 ° C under a nitrogen atmosphere for 16 h. The mixture was concentrated, the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The resulting crude product was purified by flash chromatography (eluting with 30% to 60% petroleum ether in ethyl acetate) to give 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.2 g, 36.7%) as a white solid. LCMS (ESI) m / z: 321.8 [M] + .
[0290] Step 2: Synthesis of 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0291] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (80 mg, 0.25 mmol), (5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)boronic acid (60.7 mg, 0.3 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (20 mg, 0.025 mmol) and cesium carbonate (0.2 g, 0.62 mmol) in 1,4-dioxane / water (15 mL / 3 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated, then water (20 mL) was added and the mixture was extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC to give 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (45 mg, 40.5%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.44(s,1H),9.07-9.06(m,2H),8.69(s,1H),8.43(d,J=6.1Hz,2H),7.89(d,J=6.2Hz,2H ),7.83(d,J=2.0Hz,1H),6.87(d,J=2.1Hz,1H),3.93(s,3H),3.71(s,8H),3.49(s,3H); LCMS(ESI)m / z:444.8[M] + .
[0292] Example 8. Synthesis of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 8):
[0293]
[0294] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (40 mg, 0.12 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (33.6 mg, 0.12 mmol), tetrakis(triphenylphosphine)palladium (14 mg, 0.012 mmol) and cesium carbonate (0.1 g, 0.31 mmol) in 1,4-dioxane / water (5 mL / 1 mL) was stirred at 95 ° C for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated, then diluted with water (10 mL) and extracted with ethyl acetate (10 mL×2). The combined organic phases were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC to give 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (17.8 mg, 33.3%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.42(s,1H),8.56(d,J=2.4Hz,1H),8.48(d,J=1.8Hz,1H),8.43(d,J=6.1Hz,2H),7.99-7.86(m,4 H),7.79(d,J=1.6Hz,1H),7.63(t,J=7.9Hz,1H),6.62-6.55(m,1H),3.71(s,8H),3.48(s,3H); LCMS(ESI)m / z:430.2[M+H] + .
[0295] Example 9. Synthesis of 5-methoxy-6-(3-(3-methyl-1H-pyrazol-1-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 9):
[0296]
[0297] A solution of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.28 mmol), 3-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (48 mg, 0.32 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.0028 mmol) and cesium carbonate (209 mg, 0.84 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred at 100° C. for 2 h under a nitrogen atmosphere. Water (20 mL) was then added and the mixture was extracted with ethyl acetate (50 mL×3). The organic layer was dried and concentrated to give a crude product. It was then purified by preparative TLC (petroleum ether:ethyl acetate 50:1 to 10:1) to give 4-(3-(3-(1H-pyrazol-1-yl)phenyl)-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (23.4 mg, 34%) as a white solid. 1 HNMR(400MHz,DMSO-d6)δ9.45(s,1H),8.42(dd,J=4.6,2.8Hz,4H),7.94-7.85(m,4H), 7.59(t,J=7.9Hz,1H),3.71(s,8H),3.47(s,3H),2.29(s,3H); LCMS(ESI)m / z:443.9[M] + .
[0298] Example 10. Synthesis of 5-methoxy-2-morpholino-6-(3-(pyridazin-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 10), 3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-N,N-dimethylbenzamide (Compound 11) and 6-(5,6-dimethoxypyridin-3-yl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 12):
[0299] The following compounds were synthesized according to the protocol in Example 9 above.
[0300]
[0301]
[0302] Example 11. Synthesis of 6-(3,4-dimethoxyphenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 13):
[0303]
[0304] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (55 mg, 0.17 mmol), (3,4-dimethoxyphenyl)boric acid (37.6 mg, 0.20 mmol), tetrakis(triphenylphosphine)palladium (20 mg, 0.017 mmol) and cesium carbonate (0.14 g, 0.43 mmol) in 1,4-dioxane / water (10 mL / 2 mL) was stirred at 95 ° C for 16 h under an argon atmosphere. The reaction mixture was concentrated, diluted with water (15 mL) and extracted with ethyl acetate (15 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC to give 6-(3,4-dimethoxyphenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (63.9 mg, 88.9%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ9.29(s,1H),8.40(d,J=6.3Hz,2H),7.87(dd,J=4.9,1.4Hz,2H),7.78(s,2H),7.0 9(d,J=9.1Hz,1H),3.82(d,J=6.7Hz,6H),3.70(d,J=3.0Hz,8H),3.49(s,3H); LCMS(ESI)m / z:424.6[M+H] + .
[0305] Example 12. Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 14):
[0306]
[0307] Step 1: Synthesis of 4-bromo-2-(1-methyl-1H-pyrazol-3-yl)pyridine.
[0308] A mixture of 2,4-dibromopyridine (472 mg, 2 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (416 mg, 2 mmol), tetrakis(triphenylphosphine)palladium (347 mg, 0.3 mmol) and cesium carbonate (1.956 g, 6 mmol) in water (3 mL) and dioxane (30 mL) was stirred at 80 ° C for 16 h under an argon atmosphere. The reaction mixture was cooled and concentrated. The crude product was purified by silica gel column chromatography (methanol / dichloromethane=0%-3%) to give 4-bromo-2-(1-methyl-1H-pyrazol-3-yl)pyridine (450 mg, 61%) as a yellow oil. LCMS (ESI) m / z: 238.0 [M+H] + .
[0309] Step 2: Synthesis of 2-(1-methyl-1H-pyrazol-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine.
[0310] A mixture of 4-bromo-2-(1-methyl-1H-pyrazol-3-yl)pyridine (95 mg, 0.4 mmol), bis(pinacolato)diboron (122 mg, 0.48 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (33 mg, 0.04 mmol) and potassium acetate (118 mg, 1.2 mmol) in dioxane (10 mL) was stirred at 90°C for 16 h. The resulting mixture was used directly in the next step. LCMS (ESI) m / z: 286.2 [M+H] + .
[0311] Step 3: Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0312] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (128 mg, 0.4 mmol), tetrakis(triphenylphosphine)palladium (46 mg, 0.04 mmol), cesium carbonate (391 mg, 1.2 mmol) and water (0.5 mL) was added to the reaction mixture from the above step and the resulting mixture was stirred at 95° C. for 16 h under argon. It was concentrated and purified by preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm 120A, mobile phase acetonitrile / 0.1% ammonium bicarbonate) to give 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (76.1 mg, 34%) as a yellow solid. 1 H NMR(400MHz, DMSO-d6)δ9.43(bs,1H),8.70(d,J=5.2Hz,1H),8.52(s,1H),8.43(d,J=6.3Hz,2H),7.87(d,J=6.4Hz,1H)7.80( d,J=2.4Hz,1H),7.83-7.79(m,2H),6.85(d,J=2.2Hz,1H),3.94(s,3H),3.71(s,8H),3.50(s,3H).LCMS(ESI)m / z:445.2[M+H] + .
[0313] Example 13. Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one (Compound 15):
[0314]
[0315] Step 1: Synthesis of 4-(3-bromophenyl)-1-methylpiperazin-2-one.
[0316] A mixture of 1-methylpiperazine-2-one (1 g, 8.76 mmol), 1,3-dibromobenzene (6.2 g, 26.28 mmol), cesium carbonate (11.42 g, 35.04 mmol), palladium (II) acetate (0.39 g, 1.75 mmol) and 1.1'-binaphthyl-2.2'-diphenylphosphine (1.64 g, 2.63 mmol) in toluene (25 mL) was stirred at 100°C for 16 h. The reaction mixture was concentrated and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1) to give 4-(3-bromophenyl)-1-methylpiperazine-2-one (1.5 g, 64%) as a yellow solid. LCMS (ESI) m / z: 269.1 [M+H]+ .
[0317] Step 2: Synthesis of 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one.
[0318] A mixture of 4-(3-bromophenyl)-1-methylpiperazin-2-one (0.4 g, 1.49 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (0.57 g, 2.23 mmol), potassium acetate (0.37 g, 3.72 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.14 g, 0.15 mmol) and 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.11 g, 0.23 mmol) in 1,4-dioxane (15 mL) was stirred at 85 °C for 4 h. The reaction mixture was then filtered, the filtrate was concentrated, and the crude product thus obtained was purified by silica gel column chromatography (petroleum ether:ethyl acetate=10:1) to give 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one (0.3 g, 64%) as a yellow solid. LCMS (ESI) m / z: 317.1 [M+H] + .
[0319] Step 3: Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one.
[0320] To a solution of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.1 g, 0.31 mmol) and 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one (0.14 g, 0.44 mmol) in dioxane / water (5 mL / 1 mL) was added cesium carbonate (0.2 g, 0.62 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.022 g, 0.03 mmol). The resulting mixture was stirred at 90° C. for 2 h and poured into ice water. The aqueous medium was extracted with ethyl acetate (15 mL*3), and the combined organic layers were washed with brine, dried and concentrated. The crude product obtained was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column. The elution system used was a 5%-95% gradient of 2ml / min within 1.5min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to obtain 4-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one (51.3mg, 35%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.34(s,1H),8.41(d,J=6.2Hz,2H),7.88(d,J=6.4Hz,2H),7.56(s,1H),7.47(d,J=7.6Hz,1H),7.37(t,J=7.9Hz,1H),7 .09(d,J=8.2Hz,1H),3.80(s,2H),3.69(d,J=3.3Hz,8H),3.54(t,J=8Hz,2H),3.46(s,2H),3.45(s,3H),2.91(s,3H).LCMS(ESI)m / z:475.8[M] + .
[0321] Example 14. Synthesis of 5-methoxy-2-morpholino-N-(pyridin-4-yl)-6-(3-(pyrimidin-2-yl)phenyl)pyrimidin-4-amine (Compound 16):
[0322]
[0323] Step 1: Synthesis of 2-(3-bromophenyl)pyrimidine.
[0324] A solution of 2-bromopyrimidine (300 mg, 2.0 mmol), (3-bromophenyl)boronic acid (400 mg, 2.1 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (240 mg, 0.28 mmol) and cesium carbonate (1960 mg, 6.0 mmol) in 1,4-dioxane (20 mL) and water (2 mL) was stirred for 2 h at 100 ° C under a nitrogen atmosphere. Water (20 mL) was then added and the mixture was extracted with ethyl acetate (50 mL×3). The combined organic layers were dried and concentrated. The crude product thus obtained was purified by preparative TLC (petroleum ether: ethyl acetate 50: 1 to 10: 1) to obtain 2-(3-bromophenyl)pyrimidine (210 mg, 47%) as a yellow oil. LCMS (ESI) m / z: 234.8 [M+H] + .
[0325] Step 2: Synthesis of 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidine.
[0326] To a solution of 2-(3-bromophenyl)pyrimidine (200 mg, 0.9 mmol) in dioxane (20 mL) at 25°C was added bis(pinacol)diboron (300 mg, 1.2 mmol), [1'1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (82 mg, 0.09 mmol) and potassium acetate (877 mg, 2.7 mmol). The reaction mixture was stirred at 100°C under a nitrogen atmosphere for 16 h and concentrated. The resulting residue was subjected to silica gel column chromatography (2% methanol in dichloromethane) to give 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidine (180 mg, 71.0%) as a white solid. LCMS (ESI) m / z: 283.2 [M+H] + .
[0327] Step 3: Synthesis of 5-methoxy-2-morpholino-N-(pyridin-4-yl)-6-(3-(pyrimidin-2-yl)phenyl)pyrimidin-4-amine.
[0328] A solution of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.28 mmol), 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidine (48 mg, 0.32 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.0028 mmol) and cesium carbonate (209 mg, 0.84 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was stirred at 100° C. for 2 h under a nitrogen atmosphere. Water (20 mL) was added to the mixture, and it was extracted with ethyl acetate (50 mL×3). The organic layer was dried, concentrated and the resulting crude product was purified by preparative TLC (petroleum ether:ethyl acetate 50:1 to 10:1) to give 5-methoxy-2-morpholino-N-(pyridin-4-yl)-6-(3-(pyrimidin-2-yl)phenyl)pyrimidin-4-amine (13.4 mg, 11%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.40(s,1H),9.13(s,1H),8.95(d,J=4.8Hz,2H),8.52-8.42(m,3H),8.16(d,J=7.9Hz,1H),7. 90(d,J=6.1Hz,2H),7.68(t,J=7.8Hz,1H),7.49(t,J=4.8Hz,1H),3.72(s,8H),3.47(s,3H).LCMS(ESI)m / z:441.8[M] + .
[0329] Example 15. Synthesis of 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridazin-3-yl)-2-morpholino-N-(p-tolyl)pyrimidin-4-amine (Compound 17):
[0330]
[0331] Step 1: Synthesis of 6-chloro-5-methoxy-2-morpholino-N-(p-tolyl)pyrimidin-4-amine.
[0332] To a solution of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (530 mg, 2.0 mmol) in N,N-dimethylformamide (10 mL) was added p-toluidine (214 mg, 2.0 mmol) and potassium carbonate (556 mg, 4.0 mmol). The mixture was stirred at 100 ° C for 20 h, then quenched with water (15 mL) and extracted with ethyl acetate (20 mL * 3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography (petroleum ether: ethyl acetate = 75: 25) to give 6-chloro-5-methoxy-2-morpholino-N-(p-tolyl) pyrimidin-4-amine as a yellow solid (340 mg, 50.5%). LCMS (ESI) m / z: 335.1 [M + H] + .
[0333] Step 2: Synthesis of 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridazin-3-yl)-2-morpholino-N-(p-tolyl)pyrimidin-4-amine.
[0334] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(p-tolyl)pyrimidin-4-amine (0.1 g, 0.3 mmol), 3-chloro-5-(1-methyl-1H-pyrazol-3-yl)pyridazine (0.1 g, 0.51 mmol), hexamethyldistanane (0.17 g, 0.51 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.03 g, 0.06 mmol) in 1,4-dioxane (4 mL) was stirred under nitrogen atmosphere at 100° C. for 16 h. The mixture was concentrated and the residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column. The elution system used was a 5%-95% gradient in 1.5min at 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridazin-3-yl)-2-morpholino-N-(p-tolyl)pyrimidin-4-amine as a yellow solid (3.4mg, 2.5%). 1 H NMR (400MHz, DMSO-d6) δ9.64(d,J=2.1Hz,1H),8.45(d,J=2.1Hz,1H),7.76(d,J=2.4Hz,1H),7.60(d,J=8.4Hz,2H),7.16 (d,J=8.3Hz,2H),7.01(d,J=2.4Hz,1H),4.02(s,3H),3.75(s,8H),3.63(s,3H),2.33(s,3H).LCMS(ESI)m / z:459.1[M+H] + .
[0335] Example 16. Synthesis of 6-(5,6-dimethoxypyridin-3-yl)-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 18):
[0336]
[0337] Step 1: Synthesis of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0338] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.5 g, 1.89 mmol), pyridine-3-amine (0.16 g, 1.7 mmol), tris(dibenzylideneacetone)dipalladium (0.17 g, 0.19 mmol), 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.18 g, 0.38 mmol) and cesium carbonate (1.54 g, 4.73 mmol) in toluene (25 mL) was stirred at 100 ° C for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to flash chromatography (eluting with 30% to 60% petroleum ether in ethyl acetate) to afford 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (0.2 g, 36.7%) as a white solid. LCMS (ESI) m / z: 321.8 [M] + .
[0339] Step 2: Synthesis of 6-(5,6-dimethoxypyridin-3-yl)-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0340] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (80 mg, 0.25 mmol), 2,3-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (79.5 mg, 0.3 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (20 mg, 0.025 mmol) and cesium carbonate (0.2 g, 0.62 mmol) in 1,4-dioxane / water (15 mL / 3 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated, the residue was diluted with water (20 mL), and the mixture was extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to preparative HPLC to give 6-(5,6-dimethoxypyridin-3-yl)-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (27.6 mg, 26%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.17(s,1H),8.98(d,J=2.6Hz,1H),8.47(d,J=1.8Hz,1H),8.22(d,J=4.7Hz,1H),8.18(d,J=9.2Hz,1H),7.89 (d,J=1.8Hz,1H),7.36(dd,J=8.3,4.6Hz,1H),3.94(s,3H),3.86(s,3H),3.66(d,J=5.8Hz,8H),3.54(s,3H).LCMS(ESI)m / z:424.8[M] + .
[0341] Example 17. Synthesis of Compounds 19-24
[0342] The following compounds were synthesized according to the protocol described in Example 16 above: 5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 19), 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 20), 5-methoxy-2-morpholino-6-(3-(pyridazin-3-yl)phenyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 21), yl)-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 21), 6-(3,4-dimethoxyphenyl)-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 22), 3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)benzonitrile (Compound 23) and 3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)-N,N-dimethylbenzamide (Compound 24).
[0343]
[0344]
[0345] Example 18. Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 25):
[0346]
[0347] Step 1: Synthesis of 2-(1-methyl-1H-pyrazol-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine.
[0348] A mixture of 4-bromo-2-(1-methyl-1H-pyrazol-3-yl)pyridine (71 mg, 0.3 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane (91 mg, 0.36 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (24 mg, 0.03 mmol) and potassium acetate (88 mg, 0.01 mmol) in 1,4-dioxane (8 mL) was stirred at 90° C. for 16 h. The reaction mixture was cooled and used directly in the next step. LCMS (ESI) m / z: 279.1 [M-4] + .
[0349] Step 2: Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0350] To the mixture from step 1 was added 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (96 mg, 0.3 mmol), tetrakis(triphenylphosphine)palladium (35 mg, 0.03 mmol), cesium carbonate (293 mg, 0.9 mmol) and water (1 mL), and the resulting mixture was stirred at 95° C. for 16 h under argon atmosphere. It was then concentrated and subjected to preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (34.6 mg, 19%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ9.27(s,1H),8.99(d,J=2.4Hz,1H),8.69(d,J=5.2Hz,1H),8 .52(s,1H),8.25(dd,J=4.6,1.3Hz,1H),8.20(ddd,J=8.4,2.3,1.5Hz,1H),7.82(dd ,J=5.2,1.6Hz,1H),7.80(d,J=2.2Hz,1H),7.39(dd,J=8.3,4.7Hz,1H),6.85(d,J=2 .2Hz,1H),3.94(s,3H),3.67(d,J=4.5Hz,8H),3.52(s,3H).LCMS(ESI)m / z:444.8[M] + .
[0351] Example 19. Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-3-ol (Compound 26):
[0352]
[0353] Step 1: Synthesis of 1-(3-bromophenyl)pyrrolidin-3-ol.
[0354] A mixture of 1,3-dibromobenzene (2.34 g, 10.0 mmol), pyrrolidin-3-ol (870 mg, 10.0 mmol), tris(dibenzylideneacetone)-dipalladium(0) (458 mg, 0.5 mmol), 1,1'-binaphthyl-2,2'-diphenylphosphine (622 mg, 1.0 mmol) and potassium tert-butoxide (2.24 g, 20.0 mmol) in 1,4-dioxane (40 mL) was stirred at 100 ° C for 16 h under a nitrogen atmosphere. The mixture was then poured into water and extracted with dichloromethane (200 mL*2). The combined organic phases were concentrated and the resulting residue was subjected to silica gel column chromatography (70% ethyl acetate in petroleum ether) to give 1-(3-bromophenyl)pyrrolidin-3-ol (1.3 g, 46%) as a gray solid. LCMS (ESI) m / z: 241.6 / 243.8 [M+H] + .
[0355] Step 2: Synthesis of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-3-ol.
[0356] A mixture of 1-(3-bromophenyl)pyrrolidin-3-ol (1,2 g, 5.0 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (2.54 g, 10.0 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (408 mg, 0.5 mmol) and potassium acetate (980 mg, 10.0 mmol) in 1,4-dioxane (40 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The resulting mixture was poured into water and extracted with ethyl acetate (150 mL*2). The combined organic phases were concentrated and subjected to silica gel column chromatography (60% ethyl acetate in petroleum ether) to give 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-3-ol (1.4 g, 97%) as a brown oil. LCMS (ESI) m / z: 289.9 [M] + .
[0357] Step 3: Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-3-ol.
[0358] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (100 mg, 0.38 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-3-ol (136 mg, 0.47 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (201 mg, 0.62 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred under nitrogen atmosphere at 100° C. for 16 h. The mixture was then poured into water and extracted with ethyl acetate (100 mL*2). The combined organic phases were concentrated and subjected to silica gel column chromatography (15% methanol in dichloromethane) followed by preparative HPLC (column Xbridge 21.2*250mm C18, 10 μm, mobile phase A: water (10 mmol / L ammonium bicarbonate) B: acetonitrile) to give 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-3-ol (60.3 mg, 42%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ9.11(s,1H),8.99(d,J=1.9Hz,1H),8.20(t,J=5.9Hz,2H),7.36(d d,J=8.2,4.7Hz,1H),7.26(d,J=5.5Hz,2H),7.19(s,1H),6.60(d,J=3.4Hz,1H),4.97(d,J =3.6Hz,1H),4.43(s,1H),3.65(d,J=9.8Hz,8H),3.49-3.42(m,4H),3.37(d,J=7.5Hz,2H) ,3.11(d,J=9.1Hz,1H),2.10-2.03(m,1H),1.93(d,J=3.5Hz,1H); LCMS(ESI)m / z:448.8[M] + .
[0359] Example 20. Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one (Compound 27):
[0360]
[0361] Step 1: Synthesis of 4-(3-bromophenyl)-1-methylpiperazin-2-one.
[0362] A mixture of 1,3-dibromobenzene (1000 mg, 4.24 mmol), 1-methylpiperazine-2-one (320.2 mg, 2.82 mmol), tris(dibenzylideneacetone)dipalladium (250 mg, 0.28 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (260 mg, 0.56 mmol) and cesium carbonate (2700 mg, 8.46 mmol) in 1,4-dioxane (10 mL) was stirred at 85 ° C for 16 h under an argon atmosphere. The mixture was then filtered and the filtrate was concentrated. The residue was subjected to preparative TLC (dichloromethane / methanol=10 / 1) to give 4-(3-bromophenyl)-1-methylpiperazine-2-one (550 mg, 50%) as a white solid. LCMS (ESI) m / z: 271.0 [M+H] + .
[0363] Step 2: Synthesis of 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one.
[0364] A mixture of 4-(3-bromophenyl)-1-methylpiperazin-2-one (230 mg, 0.85 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (324 mg, 1.28 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (58 mg, 0.08 mmol) and potassium carbonate (351 mg, 2.55 mmol) in 1,4-dioxane (5 mL) was stirred at 85° C. for 16 h under an argon atmosphere. The resulting mixture was filtered and the filtrate was concentrated. The residue was subjected to preparative TLC (dichloromethane / methanol = 10 / 1) to give 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one (150 mg, 55%) as a white solid. LCMS (ESI) m / z: 317.2 [M+H] + .
[0365] Step 3: Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one.
[0366] A mixture of 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-2-one (95 mg, 0.3 mmol), 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (100 mg, 0.3 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (21 mg, 0.03 mmol) and cesium carbonate (195 mg, 0.6 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was stirred at 85 ° C for 16 h under argon atmosphere. Water (50 mL) was added to the reaction mixture, and it was extracted with ethyl acetate (50 mL×3). The combined organic layer was dried and concentrated. The resulting residue was subjected to preparative HPLC to give 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)-1-methylpiperazin-2-one (18 mg, 13%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.14(s,1H),9.00(s,1H),8.20(d,J=9.4Hz,2H),7.56(s,1H),7.47(d,J=7.2Hz,1H),7.36(t,J=7.8Hz,2H), 7.08(d,J=7.8Hz,1H),3.80(s,2H),3.65(d,J=8.9Hz,8H),3.53(d,J=5.7Hz,2H),3.46(s,5H),2.91(s,3H).LCMS(ESI)m / z:475.8[M] + .
[0367] Example 21. Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)morpholin-3-one (Compound 28):
[0368]
[0369] Step 1: Synthesis of 4-(3-bromophenyl)morpholin-3-one.
[0370] A mixture of 1,3-dibromobenzene (1.4 g, 5.94 mmol), morpholine-3-one (500 mg, 4.95 mmol), cuprous iodide (95 mg, 0.5 mmol) and potassium carbonate (1.4 g, 9.9 mmol) in DMF (8 mL) was stirred at 130 ° C under microwave irradiation for 2 h. The resulting mixture was filtered and the filtrate was concentrated. The residue was then subjected to preparative TLC (dichloromethane / methanol=10 / 1) to give 4-(3-bromophenyl)morpholine-3-one (800 mg, 53%) as a colorless oil. LCMS (ESI) m / z: 258.0 [M+H] + .
[0371] Step 2: Synthesis of 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholin-3-one.
[0372] A mixture of 4-(3-bromophenyl)morpholin-3-one (330 mg, 1.28 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (489 mg, 1.93 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (95 mg, 0.13 mmol) and potassium carbonate (529 mg, 3.84 mmol) in dioxane (5 mL) was stirred at 85° C. for 16 h under an argon atmosphere. The mixture was filtered and the filtrate was concentrated. The residue was subjected to preparative TLC (dichloromethane / methanol=10 / 1) to give 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl)morpholin-3-one (250 mg, 64%) as a white solid. LCMS (ESI) m / z: 304.3 [M+H] + .
[0373] Step 3: Synthesis of 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)morpholin-3-one.
[0374] A mixture of 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholin-3-one (91 mg, 0.3 mmol), 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (100 mg, 0.3 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (21 mg, 0.03 mmol) and cesium carbonate (195 mg, 0.6 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred at 85 ° C for 16 h under argon atmosphere. Water (50 mL) was added to the reaction mixture, and it was extracted with ethyl acetate (50 mL×3). The combined organic layer was dried and concentrated. The crude product thus obtained was purified by preparative HPLC to give 4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)morpholin-3-one (32 mg, 23%) as a white solid. 1 H NMR(400MHz, DMSO-d6)δ9.15(s,1H),8.98(d,J=2.3Hz,1H),8.20(dd,J=14.7,6.9Hz,2H),8.05(s,1H),7.94(d,J=7.4Hz,1H),7.57-7.47(m,2H ),7.37(dd,J=8.3,4.6Hz,1H),4.24(s,2H),4.05–3.98(m,2H),3.83-3.78(m,2H),3.65(d,J=7.6Hz,8H),3.50(s,3H).LCMS(ESI)m / z:462.8[M] + .
[0375] Example 22. Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-2-one (Compound 29):
[0376]
[0377] Step 1: Synthesis of 1-(3-bromophenyl)pyrrolidin-2-one.
[0378] A mixture of 1,3-dibromobenzene (2.34 g, 10.0 mmol), pyrrolidin-2-one (850 mg, 10.0 mmol), palladium acetate (112 mg, 0.5 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (578 mg, 1.0 mmol) and cesium carbonate (6.5 g, 20.0 mmol) in dioxane (40 mL) was stirred at 100 ° C for 16 h under a nitrogen atmosphere. The resulting mixture was poured into water and extracted with dichloromethane (200 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (70% ethyl acetate in petroleum ether) to give 1-(3-bromophenyl)pyrrolidin-2-one (1.1 g, 46%) as a gray solid. LCMS (ESI) m / z: 240.8 / 242.8 [M+H] + .
[0379] Step 2: Synthesis of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one.
[0380] A mixture of 1-(3-bromophenyl)pyrrolidin-2-one (1.0 g, 4.1 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (2.0 g, 8.2 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (334 mg, 0.41 mmol) and potassium acetate (804 mg, 8.2 mmol) in dioxane (40 mL) was stirred under nitrogen atmosphere at 100° C. for 16 h. The resulting mixture was poured into water and extracted with ethyl acetate (150 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (50% ethyl acetate in petroleum ether) to afford 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (1.2 g) as a light yellow solid. LCMS (ESI) m / z: 287.9 [M+H] + .
[0381] Step 3: Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-2-one.
[0382] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (100 mg, 0.38 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (135 mg, 0.47 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (201 mg, 0.62 mmol), dioxane (5 mL) and water (0.5 mL) was stirred under a nitrogen atmosphere at 100° C. for 16 h. The resulting mixture was poured into water and extracted with ethyl acetate (100 mL*2). The combined organic phases were concentrated and the residue was first subjected to silica gel column chromatography (15% methanol in dichloromethane) and then to preparative HPLC (column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to give 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidin-2-one (36.4mg, 26.1%) as a gray solid. 1 H NMR(400MHz,DMSO-d6)δ9.17(s,1H),8.99(d,J=2.1Hz,1H),8.40(s,1H),8.25- 8.17(m,2H),7.80(d,J=7.7Hz,1H),7.72(d,J=7.6Hz,1H),7.49(t,J=8.0Hz,1H ),7.37(dd,J=8.3,4.7Hz,1H),3.89(t,J=7.0Hz,2H),3.65(d,J=7.8Hz,8H),3. 49(s,3H),2.54(d,J=8.0Hz,2H),2.13–2.05(m,2H); LCMS(ESI)m / z:446.9[M+H] + .
[0383] Example 23. Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine (Compound 30):
[0384]
[0385] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine.
[0386] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.45 g, 1.70 mmol), pyridin-4-ylboronic acid (0.21 g, 1.70 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.14 g, 0.17 mmol) and cesium carbonate (1.39 g, 4.26 mmol) in 1,4-dioxane / water (20 mL / 3 mL) was stirred at 95 ° C for 16 h under a nitrogen atmosphere. It was concentrated and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (eluting with 30% to 60% petroleum ether in ethyl acetate) to give 4-(4-chloro-5-methoxy-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine (0.2 g, 38.4%) as a light yellow solid. LCMS (ESI) m / z: 307.1 [M+H] + .
[0387] Step 2: Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine.
[0388] A mixture of 4-(4-chloro-5-methoxy-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine (100 mg, 0.33 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (92.8 mg, 0.33 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (27 mg, 0.033 mmol) and cesium carbonate (0.27 g, 0.82 mmol) in 1,4-dioxane / water (8 mL / 1 mL) was stirred at 95° C. for 16 h. It was concentrated, and the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (basic) to give 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-yl)pyrimidin-2-yl)morpholine (40.8 mg, 28.9%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.76(d,J=5.8Hz,2H),8.43(s,1H),8.00(d,J=6.0Hz,2H),7.92(dd,J=7.8,1.6Hz,2H),7.77(d,J=2.1Hz,1H),7.55 (t,J=7.8Hz,1H),6.74(d,J=2.2Hz,1H),3.91(s,3H),3.78(d,J=5.0Hz,4H),3.72(d,J=4.8Hz,4H),3.28(s,3H).LCMS(ESI)m / z:429.3[M+H] + .
[0389] Example 24. Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridazin-3-ylmethyl)pyrimidin-4-amine (Compound 31)
[0390]
[0391] A mixture of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (150 mg, 0.390 mmol), pyridazin-3-ylmethylamine.2HCl (71 mg, 0.390 mmol), tris(dibenzylideneacetone)dipalladium (30 mg, 0.05 mmol), X-Phos (56 mg, 0.06 mmol) and sodium tert-butoxide (75 mg, 0.780 mmol) in toluene (5 mL) was stirred at 110° C. for 16 h under a nitrogen atmosphere. The reaction was then quenched with water (15 mL) and extracted with ethyl acetate (20 mL*3). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. Preparative HPLC of the residue gave 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridazin-3-ylmethyl)pyrimidin-4-amine (25.3 mg, 14.2%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.12(dd,J=4.7,1.6Hz,1H),8.37(s,1H),7.88-7.74(m,4H),7.62(ddd,J=10.1,8.5,3.2Hz,2H),7.47(t,J=7.7Hz,1H) , 6.69 (d, J = 2.2Hz, 1H), 4.84 (d, J = 5.9Hz, 2H), 3.90 (s, 3H), 3.53 (d, J = 4Hz, 4H), 3.49 (d, J = 4Hz, 4H), 3.45 (s, 3H); LCMS (ESI) m / z: 459.0 [M+H]+.
[0392] Example 25. Synthesis of (5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)(pyridin-4-yl)methanol (Compound 32):
[0393]
[0394] Step 1: Synthesis of 4-(4-iodo-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine.
[0395] A solution of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (0.3 g, 0.78 mmol) in hydrogen iodide (5 mL) was stirred at 25 ° C for 2 h under an argon atmosphere. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (25 mL*3). The combined organic layers were concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1) to give 4-(4-iodo-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-pyrimidin-2-yl)morpholine (0.3 g, 54%) as a yellow solid. LCMS (ESI) m / z: 477.1 [M+H] + .
[0396] Step 2: Synthesis of (5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)(pyridin-4-yl)methanol.
[0397] Isopropylmagnesium chloride (1.3M in tetrahydrofuran, 0.65 mL, 0.84 mmol) was added to a solution of 4-(4-iodo-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (100 mg, 0.21 mmol) in anhydrous tetrahydrofuran (3 mL) at -78 °C under a nitrogen atmosphere. The reaction mixture was stirred at -78 °C for 30 min, and then isonicotinaldehyde (90 mg, 0.84 mmol) in tetrahydrofuran (1.0 mL) was added at the same temperature. The reaction mixture was warmed and stirred at room temperature for 2 h. It was then quenched with aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (20 mL*3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated to give a crude product. It was then purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column XBridge C18 3.5μm 4.6x50mm column. The elution system used was a 5%-95% gradient at 2ml / min within 1.5min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give (5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)(pyridin-4-yl)methanol (34.3mg, 36%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.54(dd,J=4.5,1.6Hz,2H),8.37(t,J=1.5Hz,1H),7.93-7.82(m,2H),7.76(d,J=2.2Hz,1H),7.52(t,J=7.8Hz,1H),7.49 -7.44(m,2H),6.72(d,J=2.3Hz,1H),6.11(bs,1H),5.97(s,1H),3.89(d,J=8.1Hz,3H),3.74–3.63(m,8H),3.36(s,3H); LCMS(ESI)m / z:458.5[M] + .
[0398] Example 26. Synthesis of N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxamide (Compound 33):
[0399]
[0400] Step 1: Synthesis of 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester.
[0401] A solution of LDA (2.0 M in THF, 1.92 mL) was added dropwise to a solution of 4-(4,6-dichloropyrimidin-2-yl)morpholine (750 mg, 3.20 mmol) in anhydrous THF (10 mL) at -70 ° C, and the resulting mixture was stirred under a nitrogen atmosphere for 1 h. Ethyl chloroformate (670 mg, 6.17 mmol) was then added via a syringe, and the mixture was stirred for another 2 h at -70 ° C, and stirred at 20 ° C for 30 min. The reaction mixture was poured into ice water (15 mL), and the aqueous phase was extracted with ethyl acetate (15 mL*3). The combined organic phase was washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. This was purified by flash column (ISCO 20 g silica, 0-20% ethyl acetate in petroleum ether, gradient over 20 min) to give 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester (900 mg, 92%) as a white solid.
[0402] Step 2: Synthesis of ethyl 4-chloro-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0403] To a solution of pyridine-4-amine (120 mg, 1.28 mmol) in DMSO (10 mL) at 0°C was added NaH (131 mg, 3.27 mmol). The mixture was warmed and stirred at 20°C for 0.5 h and cooled to 0°C again. A solution of 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester (500 mg, 1.63 mmol) in DMSO (5 mL) was added, the mixture was warmed and stirred at 20°C for 2 h. The mixture was then poured into a saturated aqueous NH4Cl solution (15 mL) and extracted with ethyl acetate (15 mL*3). The combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to give 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (500 mg, 84%) as a yellow solid.
[0404] Step 3: Synthesis of ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0405] Under nitrogen atmosphere, 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (297 mg, 1.10 mmol), Cs2CO3 (1.07 g, 3.30 mmol) and Pd(dppf)Cl2 (80 mg, 110 umol) were added to a solution of ethyl 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylate (400 mg, 1.10 mmol) in dioxane (8 mL) and H2O (1.4 mL). The resulting mixture was stirred at 100° C. for 2 h, then cooled to 15° C. and poured into ice water (10 mL). The aqueous phase was extracted with ethyl acetate (15 mL×3), and the combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. It was then purified by flash column chromatography (ISCO 40 g silica, 0-80% ethyl acetate in petroleum ether, gradient over 20 min) to afford ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylate (300 mg, 58%) as a yellow solid.
[0406] Step 4: Synthesis of 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid.
[0407] To a solution of ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylate (250 mg, 530 umol) in MeOH (0.5 mL) and THF (1 mL) and H2O (0.5 mL) was added LiOH.H2O (67 mg, 1.59 mmol). The mixture was stirred at 20°C for 12 h and concentrated. It was then diluted with water (1 mL) and the aqueous phase was extracted with ethyl acetate (1 mL*3). The pH of the aqueous phase was then brought to ~5 with saturated citric acid solution and the resulting precipitate was collected by filtration and dried to give 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (130 mg, 55%) as a light yellow solid.
[0408] Step 5: Synthesis of N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxamide.
[0409] To a solution of 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (80 mg, 180 umol) in DMF (1 mL) was added N-methylmethylamine (2.0 M, 90 uL), HATU (69 mg, 180 umol) and DIPEA (70 mg, 541 umol). The resulting mixture was stirred at 20 ° C for 2 h. The crude product in DMF was separated by subjecting it to preparative HPLC (Waters Xbridge BEH C18 100*30 mm*10 um column; 10%-50% acetonitrile and 10 mM aqueous ammonium bicarbonate solution in 0.05% ammonia solution, 8 min gradient) to give N, N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxamide (31 mg, 36%) as a light yellow solid. 1 H NMR (400MHz, chloroform-d) δ9.15(bs,1H),8.49(d,J=6.3Hz,2H),8.11(s,1H),7.99(d,J=2.4Hz,1H),7.86(d,J=7.9Hz,1H),7.77(d,J=1.5Hz ,1H),7.66(bs,2H),7.60-7.46(m,2H),6.52(t,J=1.9Hz,1H),3.94(s,4H),3.84(t,J=4.8Hz,4H),2.88(s,3H),2.42(s,3H).LCMS(ESI C25H26N8O2)[M+H] + :471.1.
[0410] Example 27. Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-amine (Compound 34):
[0411]
[0412] Step 1: Synthesis of 5-methoxy-2-(pyridin-4-yl)pyrimidine-4,6-diol.
[0413] A mixture of isonicotinamide hydrochloride (2 g, 12.7 mmol), methanol (10 mL) and sodium methoxide in methanol (25% wt, 4.6 ml, 25.4 mmol) was heated to reflux for 30 min, and then diethyl 2-methoxymalonate (2.4 g, 12.7 mmol) was added. The resulting mixture was refluxed for another 5 h. The reaction mixture was then cooled, poured into ice / water (~50 mL), and acidified with 2N HCl to give a precipitate. It was collected by filtration and air-dried to give 5-methoxy-2-(pyridin-4-yl)pyrimidine-4,6-diol (1.5 g, 54%) as a yellow solid. LCMS (ESI) m / z: 220.1 [M+H] + .
[0414] Step 2: Synthesis of 4,6-dichloro-5-methoxy-2-(pyridin-4-yl)pyrimidine.
[0415] To a mixture of 5-methoxy-2-(pyridin-4-yl)pyrimidine-4,6-diol (1 g, 4.56 mmol) in phosphoryl chloride (30 mL) was added N,N-diisopropylethylamine (2.0 mL). The resulting mixture was stirred at 90 ° C for 5 h. The volatiles were evaporated and further azeotroped with toluene (2×100 mL). The resulting residue was subjected to flash chromatography (petroleum ether / ethyl acetate=2:1) to give 4,6-dichloro-5-methoxy-2-(pyridin-4-yl)pyrimidine (0.2 g, 17%) as a yellow solid. LCMS (ESI) m / z: 256.1 [M+H] + .
[0416] Step 3: Synthesis of 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(pyridin-4-yl)pyrimidine.
[0417] To a solution of 4,6-dichloro-5-methoxy-2-(pyridin-4-yl)pyrimidine (0.2 g, 0.78 mmol) and 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.2 g, 0.7 mmol) in dioxane / water (5 mL / 1.5 mL) was added cesium carbonate (0.51 g, 1.56 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.058 g, 0.08 mmol), and the resulting mixture was stirred at 90° C. for 2 h. The mixture was then poured into ice water and extracted with ethyl acetate (15 mL*3). The organic layer was washed with brine, dried and concentrated. The obtained crude product was purified by silica gel flash chromatography (petroleum ether / ethyl acetate = 10:1) to give 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(pyridin-4-yl)pyrimidine (100 mg, 34%) as a yellow solid. LCMS (ESI) m / z: 378.1 [M+H] + .
[0418] Step 4: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-amine formate.
[0419] A mixture of 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(pyridin-4-yl)pyrimidine (0.08 g, 0.2 mmol), pyridin-3-amine (0.04 g, 0.42 mmol), cesium carbonate (0.21 g, 0.64 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.02 g, 0.02 mmol) and 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (0.015 g, 0.03 mmol) in toluene (4 mL) was stirred at 100 °C for 4 h. It was concentrated; the crude product was dissolved in DMF and subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column. The elution system used was a 5%-95% gradient of 2ml / min in 1.5min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-amine as a yellow solid (38.6mg, 42%). 1HNMR(400MHz,DMSO-d6)δ9.63(s,1H),9.11(d,J=2.4Hz,1H),8.76(dd,J=4.5,1.5Hz,2H), 8.54(t,J=1.5Hz,1H),8.36-8.33(m,3H),8.20(dd,J=4.5,1.6Hz,2H),8.04-8.02(m,1H), 7.95-7.93(m,1H),7.79(d,J=2.2Hz,1H),7.61(t,J=7.8Hz,1H),7.49(dd,J=8.2,4.7Hz,1 H),6.78(d,J=2.2Hz,1H),3.93(d,J=6.6Hz,3H),3.63(s,3H).LCMS(ESI)m / z:435.8[M+H] + .
[0420] Example 28. Synthesis of 4-((1-methylpiperidin-3-yl)oxy)-2-morpholino-8-phenyl-6H-pyrazolo[1,5-d]pyrimido[5,4-b][1,4]oxazine (Compound 35):
[0421]
[0422] Step 1a: Synthesis of 1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-one.
[0423] A mixture of 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran (1.0 g, 7.13 mmol), benzoyl chloride (1.0 g, 7.13 mmol), cuprous iodide (67 mg, 0.36 mmol) and bis(triphenylphosphine)palladium(II) chloride (50 mg, 0.07 mmol) in triethylamine (15 mL) was stirred at 25° C. for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (1.2 g, 69%) as a yellow solid. LCMS (ESI) m / z: 245.0 [M+H] + .
[0424] Step 1b: Synthesis of 3-phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazole.
[0425] A mixture of 1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-one (1 g, 4.1 mmol) and hydrazine hydrate (1 mL) in methanol (15 mL) was stirred at 25 ° C for 2 h. The reaction mixture was concentrated and the resulting crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1) to give the title compound (0.6 g, 57%) as a yellow solid. LCMS (ESI) m / z: 259.0 [M+H] + .
[0426] Step 1: Synthesis of 4-(4,5,6-trichloropyrimidin-2-yl)morpholine.
[0427] To a solution of 4-(4,6-dichloropyrimidin-2-yl)morpholine (5 g, 21.3 mmol) in 1-methyl-2-pyrrolidone (100 mL) was added N-chlorosuccinimide (5.7 g, 42.7 mmol) portionwise at room temperature. The resulting mixture was stirred at 60 °C for 16 h. It was cooled, the mixture was diluted with ethyl acetate / water (20 mL / 20 mL), the organic layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to flash chromatography (Biotage, 40 g silica gel; eluted with 20% to 30% ethyl acetate in petroleum ether) to give 4-(4,5,6-trichloropyrimidin-2-yl)morpholine (5.1 g, 89.7%) as an off-white solid.
[0428] Step 2: Synthesis of 4-(4,5-dichloro-6-((1-methylpiperidin-3-yl)oxy)pyrimidin-2-yl)morpholine.
[0429] Sodium hydride (60%, 0.23 g, 5.87 mmol) was added portionwise to a solution of 1-methylpiperidin-3-ol (0.45 g, 3.91 mmol) in tetrahydrofuran (20 mL) at 0 ° C. After addition, the reaction mixture was stirred at 0 ° C for 30 min, and then a solution of 4-(4,5,6-trichloropyrimidin-2-yl)morpholine (1 g, 3.91 mmol) in tetrahydrofuran (10 mL) was added dropwise. The resulting mixture was warmed and stirred at room temperature for 16 h. It was then diluted with ethyl acetate / water (20 mL / 20 mL), the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (20 mL×2). The combined organic phase was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product thus obtained was purified by flash chromatography (Biotage, 40 g silica gel, eluting with 20% to 40% ethyl acetate in petroleum ether) to give 4-(4,5-dichloro-6-((1-methylpiperidin-3-yl)oxy)pyrimidin-2-yl)morpholine (1.2 g, 88.7%) as a white solid. LCMS (ESI) m / z: 347.1 [M+H] + .
[0430] Step 3: Synthesis of 4-(5-chloro-4-((1-methylpiperidin-3-yl)oxy)-6-(3-phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)morpholine.
[0431] A mixture of 4-(4,5-dichloro-6-((1-methylpiperidin-3-yl)oxy)pyrimidin-2-yl)morpholine (0.5 g, 1.45 mmol), 3-phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazole (0.37 g, 1.45 mmol) and cesium carbonate (0.94 g, 2.89 mmol) in N,N-dimethylacetamide (25 mL) was stirred at 95 ° C for 16 h. The reaction was cooled, the mixture was diluted with ethyl acetate / water (20 mL / 20 mL), the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to flash chromatography (Biotage, 40 g silica gel, eluted with 15% to 30% methanol in dichloromethane: dichloromethane = 1: 10) to give 4-(5-chloro-4-((1-methylpiperidin-3-yl)oxy)-6-(3-phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)morpholine (0.4 g, 48.6%) as a white solid. LCMS (ESI) m / z: 569.2 [M+H] + .
[0432] Step 4: Synthesis of (1-(5-chloro-6-((1-methylpiperidin-3-yl)oxy)-2-morpholinopyrimidin-4-yl)-3-phenyl-1H-pyrazol-5-yl)methanol.
[0433] To a solution of 4-(5-chloro-4-((1-methylpiperidin-3-yl)oxy)-6-(3-phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)morpholine (0.4 g, 0.7 mmol) in methanol (20 mL) was added hydrochloric acid (3.0 M in methanol, 2 mL), and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, the residue was diluted with dichloromethane (10 mL), and the pH of the medium was increased to above 7 using sodium bicarbonate solution. The organic layer was separated and the aqueous layer was extracted with dichloromethane (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated to give (1-(5-chloro-6-((1-methylpiperidin-3-yl)oxy)-2-morpholinopyrimidin-4-yl)-3-phenyl-1H-pyrazol-5-yl)methanol (0.28 g, 82.6%) as a white foam. LCMS (ESI) m / z: 485.1 [M+H] + .
[0434] Step 5: Synthesis of 4-((1-methylpiperidin-3-yl)oxy)-2-morpholino-8-phenyl-6H-pyrazolo[1,5-d]pyrimido[5,4-b][1,4]oxazine.
[0435] A mixture of (1-(5-chloro-6-((1-methylpiperidin-3-yl)oxy)-2-morpholinopyrimidin-4-yl)-3-phenyl-1H-pyrazol-5-yl)methanol (0.11 g, 0.23 mmol) and cesium carbonate (0.15 g, 0.46 mmol) in NMP (3 mL) was stirred at 125° C. for 5 h. The resulting reaction mixture was filtered and the filtrate was subjected to preparative HPLC (BOSTON pHlexODS10um 21.2x250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give the title compound (1.1 mg, 1%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.63 (s, 1H), 9.11 (d, J = 2.4Hz, 1H), 8.76 (dd, J = 4.5, 1.5Hz, 2H), 8.54(t,J=1.5Hz,1H),8.36-8.33(m,3H),8.20(dd,J=4.5,1.6Hz,2H),8.04-8.02(m,1H), 7.95-7.93(m,1H),7.79(d,J=2.2Hz,1H),7.61(t,J=7.8Hz,1H),7.49(dd,J=8.2,4.7Hz,1 H),6.78(d,J=2.2Hz,1H),3.93(d,J=6.6Hz,3H),3.63(s,3H).LCMS(ESI)m / z:435.8[M+H] + .
[0436] Example 29. Synthesis of 4-[5-methoxy-6-morpholino-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]-1-methyl-piperazin-2-one (Compound 36) and 4-[5-methoxy-4-morpholino-6-(3-pyrazol-1-ylphenyl)pyrimidin-2-yl]-1-methyl-piperazin-2-one (Compound 37):
[0437]
[0438] Step 1: Synthesis of 4-[2-chloro-5-methoxy-6-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]morpholine and 4-[6-chloro-5-methoxy-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]morpholine.
[0439] To a solution of 4-(2,6-dichloro-5-methoxy-pyrimidin-4-yl)morpholine (500 mg, 1.89 mmol) in dioxane (1 mL) and H2O (0.1 mL) under a nitrogen atmosphere were added 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (511 mg, 1.89 mmol), Na2CO3 (2M, 2.84 mL) and Pd(PPh3)4 (219 mg, 189 umol), and the resulting mixture was stirred at 100°C for 24 h. The mixture was then filtered, and the filtrate was subjected to preparative HPLC (Waters Xbridge Prep OBD C18 150*40mm*10um column; 30-70% acetonitrile in 0.04% ammonia solution, 8 minutes gradient) to give 4-[2-chloro-5-methoxy-6-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]morpholine (170 mg) and 4-[6-chloro-5-methoxy-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]morpholine (40 mg) as yellow solids. LCMS (ESI) m / z: 372.1 [M+H] + (two isomers).
[0440] Step 2: Synthesis of 4-[5-methoxy-6-morpholino-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]-1-methyl-piperazin-2-one (Compound 37).
[0441] 1-Methylpiperazine-2-one (157 mg, 1.37 mmol) and DIPEA (177 mg, 1.37 mmol) were added to a solution of 4-[6-chloro-5-methoxy-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]morpholine (170 mg, 457 umol) in DMSO (3 mL). The resulting mixture was stirred at 110 ° C for 12 h. Water (5 mL) was then added to the reaction mixture, and it was extracted with ethyl acetate (3 mL*2). The combined organic layer was washed with brine (5 mL) and dried over Na2SO4. After concentration, the residue was subjected to preparative HPLC (Waters Xbridge BEH C18100*25mm*5um column; 40%-75% acetonitrile in 10 mM aqueous ammonium bicarbonate solution, 10 minute gradient) to give 4-[5-methoxy-6-morpholino-2-(3-pyrazol-1-ylphenyl)pyrimidin-4-yl]-1-methyl-piperazin-2-one (86 mg, 42%) as a light yellow solid. 1H NMR (400 MHz, CHLOROFORM-d) δ8.57 (s, 1H), 8.27 (d, J = 7.9 Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.82-7.73 (m, 2H), 7.51 (t, J = 8 Hz, 1H), 6.51 (t, J = 2.1 Hz, 1H), 4.41 (s, 2H), 4.02 (t, J = 5.3 Hz, 2H), 3.89-3.72 (m, 8H), 3.65 (s, 3H), 3.52 (t, J = 5.4 Hz, 2H), 3.04 (s, 3H). LCMS (ESI) (C23H27N7O3) [M+H] + :450.1.
[0442] Step 3: Synthesis of 4-[5-methoxy-4-morpholino-6-(3-pyrazol-1-ylphenyl)pyrimidin-2-yl]-1-methyl-piperazin-2-one (Compound 38):
[0443] Compound 38 was synthesized according to the protocol described for compound 37 and isolated as a white solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ8.31 (t, J = 2.0 Hz, 1H), 8.00 (d, J = 2.2 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.82-7.73 (m, 2H), 7.52 (t, J = 8.0 Hz, 1H), 6.49 (t, J = 2.1 Hz, 1H), 4.41 (s, 2H), 4.09 (bs, 2H), 3.82 (m, 8H), 3.46 (t, J = 5.2 Hz, 2H), 3.42 (s, 3H), 3.05 (s, 3H). LCMS (ESI) (C23H27N7O3) [M+H] + :450.2.
[0444] Example 30. Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[4′,3′:4,5]pyrano[3,2-d]pyrimidin-4-amine (Compound 38):
[0445]
[0446] Step 1: Synthesis of ethyl 4-chloro-6-(1-methyl-1H-pyrazol-3-yl)nicotinate.
[0447] 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.84 g, 13.63 mmol), cesium carbonate (8.88 g, 27.27 mmol) and tetrakis(triphenylphosphine)palladium (0.95 g, 0.82 mmol) were added to a mixture of 4,6-dichloronicotinate (3 g, 13.63 mmol) in 1,4-dioxane / water (50 mL / 10 mL). The reaction mixture was stirred at 100 ° C for 4 h under an argon atmosphere. It was then filtered, diluted with water and extracted with ethyl acetate (50 mL×3). The organic layers were combined, concentrated, and purified by silica gel column (petroleum ether: ethyl acetate = 2: 1) to obtain 4-chloro-6-(1-methyl-1H-pyrazole-3-yl)nicotinate (2 g, 55%) as a yellow solid. LCMS (ESI) m / z: 266.1 [M+H] + .
[0448] Step 2: Synthesis of (5-(ethoxycarbonyl)-2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)boronic acid and ethyl 6-(1-methyl-1H-pyrazol-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate.
[0449] A mixture of ethyl 4-chloro-6-(1-methyl-1H-pyrazol-3-yl)nicotinate (1.28 g, 4.82 mmol), 4,4,4',4',5,5,5'-heptamethyl-2,2'-bis(1,3,2-dioxaborolane) (6.12 g, 24.09 mmol), potassium acetate (1.28 g, 13.01 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.44 g, 0.48 mmol) and 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.34 g, 0.72 mmol) in 1,4-dioxane (15 mL) was stirred at 100° C. for 4 h. The mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (dichloromethane:methanol=10:1) to obtain a mixture of (5-(ethoxycarbonyl)-2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)boronic acid and 6-(1-methyl-1H-pyrazol-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate (0.9 g, 68%) as a yellow solid. LCMS (ESI) m / z: 276.1 [M+H] + ,358.1[M+H] + .
[0450] Step 3: Synthesis of ethyl 4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)nicotinate.
[0451] To a solution of 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.3 g, 0.72 mmol) and a mixture from step 2 [(5-(ethoxycarbonyl)-2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)boronic acid and ethyl 6-(1-methyl-1H-pyrazol-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate] (0.69 g, 2.51 mmol) in N,N-dimethylformamide (10 mL) was added potassium phosphate (0.56 g, 2.51 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.05 g, 0.07 mmol). The resulting mixture was stirred at 100°C for 3 h. The reaction mixture was filtered, and the filtrate was diluted with water (30 mL) and extracted with ethyl acetate (20 mL*3). The organic layer was concentrated, and the residue was subjected to silica gel flash chromatography (dichloromethane: methanol = 10: 1) to obtain 4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)nicotinate as a yellow solid (0.13 g, 35%). LCMS (ESI) m / z: 521.3 [M+H] + .
[0452] Step 4: Synthesis of (4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)methanol.
[0453] Under nitrogen atmosphere, lithium aluminum hydride (1.0M in THF, 2.56mL, 2.56mmol) was added to a solution of 4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)nicotinate (130mg, 0.25mmol) in anhydrous tetrahydrofuran (5mL) at 0°C. The mixture was then warmed and stirred at 25°C for 1.5h. The reaction was then quenched by carefully adding sodium sulfate decahydrate under ice bath cooling. Tetrahydrofuran (50mL) was added to the reaction mixture, stirred for 15min, and the resulting solid was filtered out. The filtrate was concentrated, and the resulting residue was subjected to silica gel flash chromatography (dichloromethane:methanol=10:1) to give (4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)methanol (50 mg, 80%) as a yellow solid. LCMS (ESI) m / z: 479.3 [M+H] + .
[0454] Step 5: Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[4′,3′:4,5]pyrano[3,2-d]pyrimidin-4-amine.
[0455] To a mixture of ((4-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)methanol (0.06 g, 0.13 mmol) in toluene (2.5 mL) was added cesium carbonate (0.08 g, 0.25 mmol), palladium(II) acetate (0.006 g, 0.03 mmol) and racemic-2-di-tert-butylphosphino-1,1'-binaphthyl (0.026 g, 0.06 mmol). The reaction mixture was stirred at 110 °C for 5 h under argon atmosphere. The resulting mixture was filtered to remove solids, the filtrate was concentrated and the residue was subjected to preparative HPLC (BOSTON pHlex ODS10um 21.2x250mm 120A, mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[4′,3′:4,5]pyrano[3,2-d]pyrimidin-4-amine as an off-white solid (4.0 mg, 7%). 1H NMR (400MHz, DMSO-d6) δ9.45(s,1H),8.58(s,1H),8.41(d,J=6.1Hz,2H),8.35(s,1H),7.87(d,J=6.2Hz,2H),7.80( d,J=2.2Hz,1H),6.84(d,J=2.1Hz,1H),5.37(s,2H),3.96(s,3H),3.73(d,J=8.5Hz,8H).LCMS(ESI)m / z:443.3[M+H] + .
[0456] Example 31. Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-N,2-di(pyridin-4-yl)pyrimidin-4-amine (Compound 39):
[0457]
[0458] Step 1: Synthesis of 6-chloro-5-methoxy-N,2-di(pyridin-4-yl)pyrimidin-4-amine.
[0459] A mixture of pyridine-4-amine (0.11 g, 1.2 mmol) and sodium hydride (0.06 g, 2.4 mmol) in dimethyl sulfoxide was stirred at 25 ° C for 0.5 h. 4,6-dichloro-5-methoxy-2-(pyridin-4-yl)pyrimidine (0.31 g, 1.2 mmol) was added to the mixture, and the reaction mixture was stirred at 25 ° C for another 2 h. The mixture was then poured into ice water and extracted with ethyl acetate (15 mL * 3). The combined organic phases were washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by silica gel flash chromatography (dichloromethane: methanol = 20: 1) to give 6-chloro-5-methoxy-N, 2-di(pyridin-4-yl)pyrimidine-4-amine (70 mg, 18%) as a yellow solid. LCMS (ESI) m / z: 314.1 [M + H] + .
[0460] Step 2: Synthesis of (2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)boronic acid.
[0461] To a solution of 4-bromo-2-(1-methyl-1H-pyrazol-3-yl)pyridine (0.08 g, 0.34 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (0.11 g, 0.44 mmol) in 1,4-dioxane (7 mL) was added potassium acetate (0.067 g, 0.68 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.025 g, 0.034 mmol). The resulting mixture was stirred at 90 ° C for 16 h and cooled. The reaction mixture was used directly in the next step without further purification. LCMS (ESI) m / z: 204.1 [M+H] + .
[0462] Step 3: Synthesis of 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-N,2-di(pyridin-4-yl)pyrimidin-4-amine.
[0463] To the mixture from step 2 was added 5 mL of 1,4-dioxane / water (4 mL / 1 mL), followed by 6-chloro-5-methoxy-N,2-di(pyridin-4-yl)pyrimidin-4-amine (0.08 g, 0.25 mmol), cesium carbonate (0.16 g, 0.5 mmol) and tetrakis(triphenylphosphine)palladium (0.03 g, 0.025 mmol). The resulting reaction mixture was stirred at 90 ° C for 16 h under an argon atmosphere and concentrated. The residue was then subjected to preparative HPLC (BOSTON Phlex ODS10um 21.2x250mm 120A, mobile phase acetonitrile / 0.1% ammonium bicarbonate) to give 5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4-yl)-N,2-di(pyridin-4-yl)pyrimidin-4-amine as an off-white solid (3.7 mg, 3%). 1 H NMR (400MHz, DMSO-d6) δ9.86(s,1H),8.80(dd,J=8.3,3.7Hz,3H),8.61(s,1H),8.55(d,J=6.3Hz,2H),8.26(dd,J=4.5,1.5Hz,2H),8.05(dd,J=4 .9,1.5Hz,2H),7.96(dd,J=5.1,1.7Hz,1H),7.83(d,J=2.2Hz,1H),6.89(d,J=2.2Hz,1H),3.96(s,3H),3.67(s,3H).LCMS(ESI)m / z:437.3[M+H] + .
[0464] Example 32. Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[3',2':4,5]pyrano[3,2-d]pyrimidin-4-amine (Compound 40):
[0465]
[0466] Step 1: Synthesis of ethyl 5-bromo-3-chloropicolinate.
[0467] To a solution of 5-bromo-3-chloropicolinic acid (5 g, 21.2 mmol) in ethanol (50 mL) was added sulfuric acid (0.1 mL). The reaction mixture was stirred at 80 °C for 16 h and concentrated. The residue was dissolved in ethyl acetate (100 mL), filtered and concentrated to give ethyl 5-bromo-3-chloropicolinate as a yellow oil (3.5 g, 63%). LCMS (ESI) m / z: 264.1 [M+H] + .
[0468] Step 2: Synthesis of ethyl 3-chloro-5-(1-methyl-1H-pyrazol-3-yl)picolinate.
[0469] To a mixture of 5-bromo-3-chloropicolinic acid ethyl ester (1.5 g, 5.67 mmol) in N, N-dimethylformamide (25 mL) was added 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.06 g, 5.10 mmol), tripotassium phosphate (0.66 g, 0.57 mmol) and tetrakis(triphenylphosphine)palladium (0.66 g, 0.57 mmol). The resulting reaction mixture was stirred at 85 ° C for 4 h under a nitrogen atmosphere. The reaction mixture was then cooled, filtered, and the filtrate was diluted with water and extracted with ethyl acetate (50 mL×3). The organic layers were combined, concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain 3-chloro-5-(1-methyl-1H-pyrazol-3-yl)picolinic acid ethyl ester as a yellow solid (1 g, 66%). LCMS (ESI) m / z: 266.1 [M+H] + .
[0470] Step 3: Synthesis of ethyl 5-(1-methyl-1H-pyrazol-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate.
[0471] A mixture of ethyl 3-chloro-5-(1-methyl-1H-pyrazol-3-yl)picolinate (1.28 g, 4.82 mmol), 4,4,4',4',5,5,5'-heptamethyl-2,2'-bis(1,3,2-dioxaborolane) (6.12 g, 24.09 mmol), potassium acetate (1.28 g, 13.01 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.44 g, 0.48 mmol) and 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.34 g, 0.72 mmol) in 1,4-dioxane (15 mL) was stirred at 85 °C for 4 h. The resulting mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (dichloromethane:methanol=10:1) to obtain 5-(1-methyl-1H-pyrazol-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinic acid ethyl ester as a yellow solid (0.9 g, 68%). LCMS (ESI) m / z: 276.1 [M+H] + .
[0472] Step 4: Synthesis of ethyl 3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)picolinate.
[0473] To a solution of 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.3 g, 0.72 mmol) and ethyl 5-(1-methyl-1H-pyrazol-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate (0.9 g, 2.51 mmol) in N,N-dimethylformamide (10 mL) were added potassium phosphate (0.53 g, 2.51 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.05 g, 0.07 mmol). The resulting mixture was stirred at 100°C for 3 h and cooled. It was filtered to remove the solid, and the filtrate was diluted with water (30 mL) and extracted with ethyl acetate (20 mL*3). The combined organic phases were concentrated, and the residue was subjected to silica gel flash chromatography (dichloromethane:methanol=10:1) to give ethyl 3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)picolinate as a yellow solid (0.11 g, 29%). LCMS (ESI) m / z: 521.3 [M+H] + .
[0474] Step 5: Synthesis of (3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)pyridin-2-yl)methanol.
[0475] At 0°C, a solution of lithium aluminum hydride (1.0 M in THF, 2.56 mL, 2.56 mmol) was added to a solution of 3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)picolinic acid ethyl ester (130 mg, 0.25 mmol) in anhydrous tetrahydrofuran (5 mL), and the mixture was stirred for 1.5 h at 25°C under a nitrogen atmosphere. The reaction mixture was then quenched by carefully adding sodium sulfate decahydrate under ice bath cooling. It was further diluted with THF (50 mL), stirred for 15 min, filtered and the filtrate was collected. After concentration, the residue was subjected to silica gel flash chromatography (dichloromethane:methanol=10:1) to give (3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)pyridin-2-yl)methanol (60 mg, 50%) as a yellow solid. LCMS (ESI) m / z: 479.3 [M+H] + .
[0476] Step 6: Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[3',2':4,5]pyrano[3,2-d]pyrimidin-4-amine.
[0477] To a mixture of (3-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-5-(1-methyl-1H-pyrazol-3-yl)pyridin-2-yl)methanol (0.045 g, 0.09 mmol) in toluene (2.5 mL) was added cesium carbonate (0.06 g, 0.19 mmol), palladium (II) acetate (0.004 g, 0.02 mmol) and racemic-2-di-tert-butylphosphino-1,1'-binaphthyl (0.019 g, 0.05 mmol). The mixture was stirred at 110 ° C for 5 h under an argon atmosphere. The mixture was then filtered and the filtrate was concentrated. The residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2x250mm 120A, mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-pyrido[3',2':4,5]pyrano[3,2-d]pyrimidin-4-amine as an off-white solid (10.0 mg, 24%). 1H NMR (400MHz, DMSO-d6) δ9.42(s,1H),9.01(d,J=2.1Hz,1H),8.60(d,J=2.1Hz,1H),8.40(d,J=6.2Hz,2H),7.87(d,J=6.4Hz,2 H),7.83(d,J=2.2Hz,1H),6.93(d,J=2.3Hz,1H),5.35(s,2H),3.94(s,3H),3.73(d,J=4.0Hz,8H).LCMS(ESI)m / z:443.3[M+H] + .
[0478] Example 33. Synthesis of 6-(3-(1,4-dimethyl-1H-pyrazol-3-yl)phenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 41):
[0479]
[0480] Step 1: Synthesis of 3-bromo-1,4-dimethyl-1H-pyrazole.
[0481] To a solution of 3-bromo-4-methyl-1H-pyrazole (800 mg, 5 mmol) and potassium carbonate (1.3 g, 10 mmol) in tetrahydrofuran (25 mL) was added iodomethane (710 mg, 5 mmol) dropwise at 0 ° C, and the resulting reaction mixture was stirred at 0 ° C for 0.5 hours. It was then filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether: acetate = 1: 4) to give 3-bromo-1,4-dimethyl-1H-pyrazole (700 mg, 80%) as a white solid. LCMS (ESI) m / z: 175.1 [M + H] + .
[0482] Step 2: Synthesis of 3-(3-bromophenyl)-1,4-dimethyl-1H-pyrazole.
[0483] A mixture of 3-bromo-1,4-dimethyl-1H-pyrazole (194 mg, 0.82 mmol), (3-bromophenyl)boronic acid (165 mg, 0.82 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (66 mg, 0.082 mmol) and cesium carbonate (668 mg, 2.05 mmol) in 1,4-dioxane / water (5 mL / 1 mL) was stirred at 90 ° C for 16 h under an argon atmosphere. The mixture was concentrated and the residue was subjected to silica gel column chromatography (petroleum ether: acetate = 10: 1) to give 3-(3-bromophenyl)-1,4-dimethyl-1H-pyrazole as a white solid (140 mg, 64%). LCMS (ESI) m / z: 251.1 [M+H] + .
[0484] Step 3: Synthesis of 1,4-dimethyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole.
[0485] A mixture of 3-(3-bromophenyl)-1,4-dimethyl-1H-pyrazole (140 mg, 0.52 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (21 mg, 0.026 mmol), potassium acetate (153 mg, 1.56 mmol) and bis(pinacolato)diboron (172 mg, 3.7 mmol) in 1,4-dioxane (5 mL) was stirred at 110° C. for 16 h. The mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether:acetate=4:1) to give 1,4-dimethyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole as a light yellow oil (100 mg, 61%). LCMS (ESI) m / z: 299.3 [M+H] + .
[0486] Step 4: Synthesis of 6-(3-(1,4-dimethyl-1H-pyrazol-3-yl)phenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0487] A mixture of 1,4-dioxane (5 mL) and 1,4-dimethyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (100 mg, 0.31 mmol), 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.31 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (245 mg, 0.75 mmol) in water (1 mL) was stirred at 90°C for 16 h under argon atmosphere. The reaction mixture was filtered and the filtrate was subjected to preparative HPLC [Welch Xtimate C18 21.2x250mm, 10um, mobile phase acetonitrile / water (10mM NH4HCO3 and NH3·H2O)] to give 6-(3-(1,4-dimethyl-1H-pyrazol-3-yl)phenyl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (20.0mg, 14%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),8.41(s,2H),8.37(s,1H),7.96(d,J=7.3Hz,1H),7.90(s,2H),7.77(d,J=7.6 Hz,1H),7.57(s,1H),7.54(s,1H),3.84(s,3H),3.70(s,8H),3.48(s,3H),2.23(s,3H).LCMS(ESI)m / z:458.1[M+H] + .
[0488] Example 34. Synthesis of (R)-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(morpholin-3-ylmethoxy)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 42):
[0489]
[0490] A mixture of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (60 mg, 0.14 mmol), (S)-morpholin-3-ylmethanol (97 mg, 0.82 mmol), cesium fluoride (63 mg, 0.41 mmol) in anhydrous acetonitrile (4 mL) was stirred at 120 °C in a sealed tube for 16 hours. The reaction mixture was filtered, concentrated and purified by preparative HPLC (BOSTON pHlex ODS10um 21.2x250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give (R)-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(morpholin-3-ylmethoxy)-N-(pyridin-4-yl)pyrimidin-4-amine (17.2 mg, 0.036 mmol, yield: 26%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.60 (s, 1H), 8.52-8.40 (m, 3H), 7.98-7.87 (m, 4H), 7.78 (d, J = 2.2H z,1H),7.56(t,J=7.8Hz,1H),6.73(d,J=2.2Hz,1H),4.21(d,J=5.9Hz,2H),3.91(s,3H),3. 84(dd,J=10.8,2.8Hz,1H),3.68(d,J=10.9Hz,1H),3.51(s,3H),3.40(dd,J=14.0,6.7Hz,1 H),3.26(d,J=10.2Hz,1H),3.15(s,1H),2.79(d,J=13.1Hz,2H).LCMS(ESI)m / z:474.1[M+H] + .
[0491] Example 35. Synthesis of (R)-(4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)morpholin-3-yl)methanol (Compound 43):
[0492]
[0493] Step 1: Synthesis of 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)pyrimidine.
[0494] A mixture of 4,6-dichloro-5-methoxy-2-(methylthio)pyrimidine (1 g, 4.46 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (1.26 g, 4.44 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.36 g, 0.44 mmol) and cesium carbonate (3.6 g, 11 mmol) in 1,4-dioxane / water (40 mL / 4 mL) was stirred at 95° C. for 16 h under a nitrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica gel (eluting with 20% to 40% ethyl acetate in petroleum ether) to give 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)pyrimidine (0.75 g, 48.6%) as a white solid. LCMS (ESI) m / z: 347.0 [M+H] + .
[0495] Step 2: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0496] A mixture of 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)pyrimidine (0.66 g, 1.91 mmol), pyridin-4-amine (0.18 g, 1.91 mmol), tris(dibenzylideneacetone)dipalladium (0.17 g, 0.19 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (0.18 g, 0.38 mmol) and cesium carbonate (1.55 g, 4.77 mmol) in anhydrous 1,4-dioxane (40 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The reaction mixture was filtered, concentrated, and the residue was chromatographed on silica gel (eluting with 20%-40% 7N ammonia methanol in dichloromethane) to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine (0.6 g, 78.2%) as a white solid. LCMS (ESI) m / z: 405.1 [M+H] + .
[0497] Step 3: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0498] To a solution of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine (0.53 g, 1.31 mmol) in methanol (15 mL) was added dropwise a solution of oxone (1.61 g, 2.62 mmol) in water (7.5 mL) at 0°C. After addition, the reaction mixture was stirred at room temperature for 3 hours and the resulting precipitate was collected by filtration. The solid was further dispersed in aqueous sodium bicarbonate solution and stirred at room temperature for 20 min. The resulting solid was again collected by filtration, washed with water and dried in vacuo to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (0.4 g, 70%) as a white solid. LCMS (ESI) m / z: 437.1 [M+H] + .
[0499] Step 4: Synthesis of (R)-(4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)morpholin-3-yl)methanol.
[0500] A mixture of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (50 mg, 0.11 mmol), (R)-morpholin-3-ylmethanol (80 mg, 0.69 mmol), cesium fluoride (52 mg, 0.34 mmol) in anhydrous acetonitrile (2 mL) was stirred in a sealed tube at 120 °C for 16 h. The reaction mixture was filtered to remove solids, the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give (R)-(4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)morpholin-3-yl)methanol (4 mg, 7.7%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.32 (s, 1H), 8.45 (s, 1H), 8.38 (d, J = 6.2Hz, 2H), 7.93-7.81 (m, 4 H),7.77(d,J=2.1Hz,1H),7.52(t,J=7.7Hz,1H),6.71(d,J=2.2Hz,1H),4.91(t,J=5.1Hz, 1H),4.39(s,1H),4.26(d,J=13.8Hz,1H),4.11(d,J=11.2Hz,1H),4.00-3.90(m,4H),3.7 9(d,J=5.7Hz,1H),3.57-3.40(m,6H),3.16(t,J=16.3Hz,1H).LCMS(ESI)m / z:474.2[M+H] + .
[0501] Example 36. Synthesis of 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)pyrrolidin-2-one (Compound 44):
[0502]
[0503] Step 1: Synthesis of 5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-ol.
[0504] A solution of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (180 mg, 0.413 mmol) in 2.0 M sodium hydroxide (5 mL) was stirred at room temperature for 6 h under a nitrogen atmosphere. The mixture was triturated with water, and the resulting precipitate was collected by filtration and dried in vacuo to give 5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-ol (152 mg, 88.64%) as a white solid. LCMS (ESI) m / z: 375.0 [M+H] + .
[0505] Step 2: Synthesis of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0506] A solution of 5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-ol (132 mg, 0.353 mmol) in phosphoryl chloride (4 ml) was stirred at 100 ° C for 16 h under a nitrogen atmosphere. The mixture was cooled and neutralized by the addition of saturated aqueous sodium bicarbonate. The phases were separated and the aqueous phase was extracted with 20 mL of dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel chromatography, eluting with a linear gradient of 0% to 63% ethyl acetate in petroleum ether to give 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (40 mg, 25.95%) as a white solid. LCMS (ESI) m / z: 393.0 [M+H] + .
[0507] Step 3: Synthesis of 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-2-ylamino)pyrimidin-2-yl)pyrrolidin-2-one.
[0508] A mixture of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (40 mg, 0.102 mmol), pyrrolidin-2-one (13 mg, 0.153 mmol), tris(dibenzylideneacetone)dipalladium (9 mg, 0.01 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (9 mg, 0.02 mmol) and potassium carbonate (84 mg, 0.255 mmol) in anhydrous 1,4-dioxane (6 ml) was stirred at 90° C. for 16 h under a nitrogen atmosphere. The mixture was filtered to remove solids, the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)pyrrolidin-2-one (8.1 mg, 18.04%) as a white solid. 1H NMR(400MHz,DMSO-d6)δ10.17(s,1H),8.64(s,2H),8.54(d,J=6.4Hz,2H),8 .51(s,1H),7.94(dd,J=15.3,7.8Hz,2H),7.78(d,J=2.2Hz,1H),7.58(t,J=7 .8Hz,1H),6.74(d,J=2.2Hz,1H),4.08(t,J=7.0Hz,2H),3.91(s,3H),3.56( s,3H),2.61(t,J=8.0Hz,2H),2.10-2.04(m,2H).LCMS(ESI)m / z:442.0[M+H] + .
[0509] Example 37. Synthesis of dimethyl (4- (3- (1-methyl-1H-pyrazol-3-yl) phenyl) -2-morpholino-6- (pyridin-3-ylamino) pyrimidin-5-yl) phosphine oxide (Compound 45):
[0510]
[0511] Step 1: Synthesis of 5-bromo-6-iodo-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0512] To a mixture of pyridine-3-amine (376 mg, 4.0 mmol) in dimethyl sulfoxide (15 mL) was added sodium hydride (320 mg, 8.0 mmol) at 0 ° C. The mixture was warmed and stirred at 28 ° C for 20 min, and then 4-(5-bromo-4,6-diiodopyrimidin-2-yl)morpholine (2.0 g, 4.0 mmol) was added. Stirring was continued for another 30 min at 28 ° C, and then the mixture was poured into dilute hydrochloric acid (cooled with crushed ice). The formed precipitate was collected by filtration and dried under vacuum to give 5-bromo-6-iodo-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (500 mg, 24.2%). LCMS (ESI) m / z: 461.9 / 464.9 [M+H] + .
[0513] Step 2: Synthesis of 5-bromo-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0514] To a mixture of 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.28 g, 0.97 mmol) in acetonitrile / water (15 mL / 3 mL) was added 5-bromo-6-iodo-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (0.5 g, 1.1 mmol), potassium carbonate (0.37 g, 2.71 mmol) and tetrakis(triphenylphosphine)palladium (0.13 g, 0.11 mmol). The resulting reaction mixture was stirred at 85° C. for 3 h under argon atmosphere and cooled. It was filtered to remove the solid, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (dichloromethane:methanol=15:1) to give 5-bromo-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine as a yellow solid (0.12 g, 23%). LCMS (ESI) m / z: 492.1 [M+H] + .
[0515] Step 3: Synthesis of dimethyl(4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-5-yl)phosphine oxide.
[0516] To a mixture of dimethylphosphine oxide (0.023 g, 0.29 mmol) in N,N-dimethylformamide (5 mL) was added 5-bromo-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (0.12 g, 0.24 mmol), tripotassium phosphate (0.062 g, 0.29 mmol), palladium(II) acetate (0.006 g, 0.024 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.028 g, 0.048 mmol). The resulting mixture was stirred at 150° C. for 3 h under an argon atmosphere and cooled. The mixture was filtered to remove solids, the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A, mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give dimethyl (4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-5-yl)phosphine oxide (2.6 mg, 2%) as an off-white solid. 1H NMR (400MHz, DMSO-d6) δ11.97(s,1H),8.71(d,J=2.4Hz,1H),8.24(d,J=4.7Hz,1H),7.9 9(d,J=8.5Hz,1H),7.90(d,J=7.9Hz,1H),7.75(d,J=1.9Hz,2H),7.48(t,J=7.7Hz,1H),7 .39(dd,J=8.2,4.7Hz,1H),7.28(d,J=7.6Hz,1H),6.77(d,J=2.2Hz,1H),3.88(s,3H),3 .70(d,J=4.7Hz,4H),3.64(s,4H),1.36(s,3H),1.33(s,3H).LCMS(ESI)m / z:490.2[M+H] + .
[0517] Example 38. Synthesis of 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)piperidin-4-ol (Compound 46)
[0518]
[0519] Step 1: Synthesis of 6-hydroxy-5-methoxy-2-thione-2,5-dihydropyrimidin-4(3H)-one.
[0520] To a solution of thiourea (4.7 g, 61.7 mmol) and dimethyl 2-methoxymalonate (10 g, 61.7 mmol) in methanol (50 mL) was added sodium methoxide solution (30% solution in methanol, 11.6 mL, 61.7 mmol). After addition, the reaction mixture was stirred at 80 °C for 20 h. It was cooled and used directly in the next step without further purification. LCMS (ESI) 174.7 [M+H] + .
[0521] Step 2: Synthesis of 5-methoxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione.
[0522] To the reaction mixture from the above step was added iodomethane (10.5 g, 74 mmol) dropwise. After addition, the reaction mixture was stirred at room temperature for 20 h and concentrated. The residue was triturated with water (30 mL), the precipitate was collected by filtration, the solid was washed with water (30 mL) and dried under vacuum to give 5-methoxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione (7.5 g, 64.7% for two steps) as a white solid. LCMS (ESI) 188.7 [M+H] + .
[0523] Step 3: Synthesis of 4,6-dichloro-5-methoxy-2-(methylthio)pyrimidine.
[0524] A mixture of 5-methoxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione (7 g, 37.2 mmol) and phosphorus oxychloride (50 mL) was stirred at 110 °C for 3 h and concentrated. The residue was slowly poured into warm water (~40 °C) under vigorous stirring. After addition, the mixture was extracted twice with ethyl acetate (50 mL). The combined organic phases were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (eluted with 20% to 40% ethyl acetate in petroleum ether) to give 4,6-dichloro-5-methoxy-2-(methylthio)pyrimidine (7 g, 84%) as a white solid. LCMS (ESI) m / z: 224.9 [M+H] + .
[0525] Step 4: Synthesis of 6-chloro-5-methoxy-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0526] At 0 ° C, sodium hydride (60%, 0.18 g, 4.5 mmol) was added portionwise to a solution of pyridine-4-amine (0.28 g, 3 mmol) in N, N-dimethylformamide (10 mL). After addition, the mixture was stirred at room temperature for 30 minutes and cooled to 0 ° C again. Then a solution of 4,6-dichloro-5-methoxy-2-(methylthio)pyrimidine (0.7 g, 3.13 mmol) in N, N-dimethylformamide (5 mL) was added dropwise. The reaction mixture was warmed to room temperature and stirred for another 16 h. It was diluted with ethyl acetate and water (20 mL / 20 mL), the organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate (20 mL). The combined organic phase was dried over sodium sulfate, filtered and the filtrate was concentrated. The residue was subjected to silica gel column chromatography (eluted with 5% to 15% 7N ammonia methanol in dichloromethane) to give 6-chloro-5-methoxy-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine (0.4 g, 47.3%) as a brown solid. LCMS (ESI) m / z: 282.8 [M+H] + .
[0527] Step 5: Synthesis of 6-chloro-5-methoxy-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0528] To a solution of 6-chloro-5-methoxy-2-(methylthio)-N-(pyridin-4-yl)pyrimidin-4-amine (0.4 g, 1.42 mmol) in methanol (15 mL) was added dropwise a solution of potassium persulfate (1.74 g, 2.8 mmol) in water (8 mL) at 0°C. After addition, the reaction mixture was stirred at room temperature for 3 h. It was then neutralized with aqueous sodium bicarbonate to pH = 7-8, and the resulting solid was collected by filtration, washed with water and dried in vacuo to give 6-chloro-5-methoxy-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (0.25 g, 56.3%) as a brown solid. LCMS (ESI) m / z: 314.7 [M+H] + .
[0529] Step 6: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0530] A mixture of 6-chloro-5-methoxy-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (0.25 g, 0.8 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.23 g, 0.8 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (65 mg, 0.08 mmol) and cesium carbonate (0.65 g, 2 mmol) in 1,4-dioxane / water (25 mL / 4 mL) was stirred at 95° C. for 16 h under a nitrogen atmosphere. The resulting reaction mixture was concentrated, diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (eluted with 5% to 15% 7N ammonia methanol in dichloromethane) to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (0.18 g, 51.6%) as a yellow solid. LCMS (ESI) m / z: 437.1 [M+H] + .
[0531] Step 7: Synthesis of 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)piperidin-4-ol.
[0532] A mixture of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(methylsulfonyl)-N-(pyridin-4-yl)pyrimidin-4-amine (80 mg, 0.18 mmol), piperidin-4-ol (37 mg, 0.36 mmol) and N,N-diisopropylethylamine (71 mg, 0.55 mmol) in 1,4-dioxane (5 mL) was stirred at 100° C. for 64 h. The reaction mixture was concentrated and the residue was subjected to preparative HPLC (base) to give 1-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(pyridin-4-ylamino)pyrimidin-2-yl)piperidin-4-ol (6.5 mg, 8%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.29 (s, 1H), 8.47-8.35 (m, 3H), 7.87 (dt, J = 7.0, 5.0Hz, 4 H),7.77(d,J=2.2Hz,1H),7.52(t,J=7.8Hz,1H),6.70(d,J=2.2Hz,1H),4.72(d,J =4.3Hz,1H),4.28(d,J=13.6Hz,2H),3.90(s,3H),3.73(s,1H),3.44(s,3H),3.26 (t,J=10.2Hz,2H),1.82(s,2H),1.39(d,J=9.5Hz,2H).LCMS(ESI)m / z:458.3[M+H] + .
[0533] Example 39. Synthesis of 5-methoxy-6-(3-(4-methoxy-1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 47):
[0534]
[0535] Step 1: Synthesis of 3-iodo-4-methoxy-1H-pyrazole.
[0536] A mixture of 4-methoxy-1H-pyrazole (600 mg, 6.0 mmol) and N-iodosuccinimide (1.08 g, 4.8 mmol) in N,N-dimethylformamide (50 mL) was stirred at 25°C for 24 h under a nitrogen atmosphere. The reaction mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 12:78) to obtain 3-iodo-4-methoxy-1H-pyrazole (800 mg, 60%) as a white solid. LCMS (ESI) m / z: 225.1 [M+H] + .
[0537] Step 2: Synthesis of 3-iodo-4-methoxy-1-methyl-1H-pyrazole.
[0538] At 0°C, sodium hydride (60%, 171.36 mg, 4.28 mmol) was added portionwise to a solution of 3-iodo-4-methoxy-1H-pyrazole (800 mg, 3.57 mmol) in tetrahydrofuran (25 mL). After addition, the mixture was stirred for another 30 min. It was then filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 1: 4) to give 3-iodo-4-methoxy-1-methyl-1H-pyrazole (194 mg, 19%) as a white solid. LCMS (ESI) m / z: 239.1 [M+H] + .
[0539] Step 3: Synthesis of 3-(3-bromophenyl)-4-methoxy-1-methyl-1H-pyrazole.
[0540] A mixture of 3-iodo-4-methoxy-1-methyl-1H-pyrazole (194 mg, 0.82 mmol), (3-bromophenyl)boronic acid (165 mg, 0.82 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (66 mg, 0.082 mmol) and cesium carbonate (668 mg, 2.05 mmol) in 1,4-dioxane / water (5 mL / 1 mL) was stirred at 90 ° C for 16 h under an argon atmosphere. The mixture was concentrated and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1) to give 3-(3-bromophenyl)-4-methoxy-1-methyl-1H-pyrazole (140 mg, 64%) as a white solid. LCMS (ESI) m / z: 269.0 [M+H] + .
[0541] Step 4: Synthesis of 4-methoxy-1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole.
[0542] A mixture of 3-(3-bromophenyl)-4-methoxy-1-methyl-1H-pyrazole (140 mg, 0.52 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (21 mg, 0.026 mmol), potassium acetate (153 mg, 1.56 mmol) and bis(pinacolato)diboron (172 mg, 3.7 mmol) in 1,4-dioxane (5 mL) was stirred at 110° C. for 16 h. The mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether:ethyl acetate=4:1) to give 4-methoxy-1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole as a light yellow oil (100 mg, 61%). LCMS (ESI) m / z: 315.3 [M+H] + .
[0543] Step 5: Synthesis of 5-methoxy-6-(3-(4-methoxy-1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0544] A mixture of 4-methoxy-1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (100 mg, 0.31 mmol), 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.31 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (245 mg, 0.75 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was stirred at 90 °C for 16 h under argon atmosphere. The reaction mixture was filtered and the filtrate was subjected to preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 5-methoxy-6-(3-(4-methoxy-1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (58.8 mg, 40%) as a yellow solid. 1H NMR (500MHz, DMSO-d6) δ9.35(s,1H),8.63(s,1H),8.41(d,J=6.2Hz,2H),7.91(t,J=7.6Hz,2H),7.88(d,J=6.3Hz,2H),7.6 3(s,1H),7.50(t,J=7.8Hz,1H),3.82(s,3H),3.78(s,3H),3.71(d,J=1.8Hz,8H),3.47(s,3H).LCMS(ESI)m / z:474.2[M+H] + .
[0545] Example 40. Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol (Compound 48):
[0546]
[0547] Step 1: Synthesis of 1-(3-bromophenyl)piperidin-4-ol.
[0548] A mixture of 1,3-dibromobenzene (2.34 g, 10.0 mmol), piperidine-4-ol (870 mg, 10.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (458 mg, 0.5 mmol), 1,1'-binaphthyl-2,2'-diphenylphosphine (622 mg, 1.0 mmol) and potassium tert-butoxide (2.24 g, 20.0 mmol) in 1,4-dioxane (40 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The mixture was poured into water and extracted with dichloromethane (200 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (10% methanol in dichloromethane) to give 1-(3-bromophenyl)piperidin-4-ol (300 mg, 12%) as a red oil. LCMS (ESI) m / z: 255.9 / 257.9 [M+H] + .
[0549] Step 2: Synthesis of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol.
[0550] A mixture of 1-(3-bromophenyl)piperidin-4-ol (275 mg, 1.1 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (559 mg, 2.2 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (90 mg, 0.11 mmol) and potassium acetate (216 mg, 2.2 mmol) in dioxane (10 mL) was stirred for 4 h at 100° C. under a nitrogen atmosphere. The mixture was poured into water and extracted with ethyl acetate (150 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (5% methanol in dichloromethane) to give 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol (250 mg, 74.5%) as a brown oil. LCMS (ESI) m / z: 304.2 [M+H] + .
[0551] Step 3: Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol.
[0552] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (160 mg, 0.5 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol (227 mg, 0.75 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (41 mg, 0.05 mmol) and cesium carbonate (325 mg, 1.0 mmol) in dioxane (6 mL) and water (0.6 mL) was stirred at 100° C. for 2 h under a nitrogen atmosphere. The mixture was poured into water and extracted with dichloromethane (100 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (15% methanol in dichloromethane) and preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 1-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol (45.5 mg, 19.6%) as a light yellow solid. 1H NMR(500MHz,DMSO-d6)δ9.29(s,1H),8.40(d,J=6.3Hz,2H),7.87(d,J=6.4Hz,2H) ,7.58(s,1H),7.39(d,J=7.7Hz,1H),7.31(t,J=7.9Hz,1H),7.06(dd,J=8.2,2.0Hz ,1H),4.69(d,J=4.3Hz,1H),3.70-3.67(m,9H),3.58-3.53(m,2H),3.44(s,3H),2. 93-2.86(m,2H),1.86-1.81(m,2H),1.53-1.44(m,2H); LCMS(ESI)m / z:463.2[M+H] + .
[0553] Example 41. Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-isochromeno[4,3-d]pyrimidin-4-amine (Compound 49):
[0554]
[0555] Step 1: Synthesis of ethyl 2-bromo-4-iodobenzoate.
[0556] To a solution of 2-bromo-4-iodobenzoic acid (5 g, 15.3 mmol) in ethanol (100 mL) was added sulfuric acid (5 mL), and the reaction mixture was stirred at 80 ° C for 16 h. The mixture was concentrated, and the residue was subjected to silica gel column chromatography (5% to 10% ethyl acetate in petroleum ether) to give ethyl 2-bromo-4-iodobenzoate (5.3 g, 97.8%) as a yellow oil. LCMS (ESI) m / z: 355.0, 357.0 [M+H] +.
[0557] Step 2: Synthesis of ethyl 2-bromo-4-(1-methyl-1H-pyrazol-3-yl)benzoate.
[0558] A mixture of ethyl 2-bromo-4-iodobenzoate (2 g, 5.63 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g, 4.8 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.46 g, 0.56 mmol) and cesium carbonate (4.6 g, 14.1 mmol) in 1,4-dioxane / water (50 mL / 5 mL) was stirred at 85 ° C for 16 h under an argon atmosphere. It was concentrated, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to flash chromatography (eluting with 30% to 60% ethyl acetate in petroleum ether) to give ethyl 2-bromo-4-(1-methyl-1H-pyrazol-3-yl)benzoate (1.45 g, 83.6%) as a white solid. LCMS (ESI) m / z: 310.6 [M+H] + .
[0559] Step 3: Synthesis of ethyl 4-(1-methyl-1H-pyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate.
[0560] A mixture of ethyl 2-bromo-4-(1-methyl-1H-pyrazol-3-yl)benzoate (1.1 g, 3.57 mmol), bis(pinacolato)diboron (1.36 g, 5.36 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.29 g, 0.36 mmol) and potassium acetate (0.87 g, 8.92 mmol) in 1,4-dioxane (25 mL) was stirred at 90° C. for 16 h. The mixture was then concentrated and the residue was subjected to flash chromatography (eluting with 30% to 60% ethyl acetate in petroleum ether) to give ethyl 4-(1-methyl-1H-pyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1 g, 78.7%) as a white solid. LCMS (ESI) m / z: 357.1 [M+H] + .
[0561] Step 4: Synthesis of ethyl 2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)benzoate.
[0562] To a solution of 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.26 g, 0.62 mmol) and ethyl 4-(1-methyl-1H-pyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzoate (0.27 g, 0.75 mmol) in 1,4-dioxane / water (7 mL / 2 mL), cesium carbonate (0.41 g, 1.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.044 g, 0.06 mmol) were added. The mixture was stirred at 90 ° C for 2 h under an argon atmosphere and cooled. It was poured into ice water, and the mixture was extracted with ethyl acetate (15 mL*3). The combined organic layer was washed with brine, dried over sodium sulfate and concentrated. The residue was subjected to silica gel flash chromatography (dichloromethane:methanol=10:1) to give ethyl 2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)benzoate (0.19 g, 59%) as a yellow solid. LCMS (ESI) m / z: 520.3 [M+H] + .
[0563] Step 5: Synthesis of (2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)phenyl)methanol.
[0564] At 0°C, a solution of lithium aluminum hydride (1.0 M in THF, 2.56 mL, 2.56 mmol) was added to a solution of ethyl 2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)benzoate (190 mg, 0.37 mmol) in anhydrous tetrahydrofuran (8 mL), and the resulting mixture was warmed and stirred at 25°C under nitrogen for 1.5 h. The reaction was then quenched by carefully adding sodium sulfate decahydrate under ice bath cooling. Tetrahydrofuran (50 mL) was added to the reaction mixture, stirred for 15 minutes, filtered, and the solid was washed with tetrahydrofuran (50 mL), and the filtrate was collected. The combined filtrates were concentrated to give (2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)phenyl)methanol (140 mg, 80%) as a yellow solid. LCMS (ESI) m / z: 478.3 [M+H] + .
[0565] Step 6: Synthesis of 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-isochromeno[4,3-d]pyrimidin-4-amine.
[0566] A mixture of (2-(5-chloro-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-4-yl)-4-(1-methyl-1H-pyrazol-3-yl)phenyl)methanol (0.11 g, 0.23 mmol) and potassium tert-butoxide (0.92 mL, 0.92 mmol in tetrahydrofuran) in dimethyl sulfoxide (6 mL) was stirred at 100° C. for 4 h. The mixture was then filtered, the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS10um; 21.2×250 mm 120A, mobile phase acetonitrile / 0.1% ammonium bicarbonate) to give 9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-6H-isochromeno[4,3-d]pyrimidin-4-amine (12.7 mg, 13%) as a yellow solid. 1 HNMR (400MHz, DMSO-d6) δ9.32(s,1H),8.39(d,J=6.1Hz,3H),7.88(dd,J=9.1,3.2Hz,3H),7.77(d,J=2.1Hz,1H),7.38(d,J=7.9H z,1H),6.78(d,J=2.2Hz,1H),5.29(s,2H),3.92(s,3H),3.75(d,J=4.6Hz,4H),3.72(d,J=4.7Hz,4H).LCMS(ESI)m / z:442.3[M+H] + .
[0567] Example 42. Synthesis of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-chloro-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 50):
[0568]
[0569] Step 1: Synthesis of 4-(4,6-diiodopyrimidin-2-yl)morpholine.
[0570] A mixture of 4-(4,6-dichloropyrimidin-2-yl)morpholine (3 g, 12.8 mmol) and hydroiodic acid (30 mL) was stirred at 25 ° C for 24 h. The reaction mixture was filtered, and the solid was dissolved in dichloromethane and ethyl acetate, washed with water and concentrated. The residue was subjected to silica gel column chromatography (eluted with dichloromethane: methanol = 10: 1) to give 4-(4,6-diiodopyrimidin-2-yl)morpholine as a yellow solid (2.5 g, 47%). LCMS (ESI) m / z: 418.1 [M+H] + .
[0571] Step 2: Synthesis of 4-(5-chloro-4,6-diiodopyrimidin-2-yl)morpholine.
[0572] N-chlorosuccinimide (1.6 g, 12 mmol) was added portionwise to a solution of 4-(4,6-diiodopyrimidin-2-yl)morpholine (2.5 g, 6 mmol) in 1-methyl-2-pyrrolidone (40 mL). After addition, the reaction mixture was stirred at 25 ° C for 16 h. It was diluted with ethyl acetate / water (20 mL / 20 mL), the organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate (20 mL). The combined organic phase was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to column chromatography (Biotage, 40 g silica gel, eluted with 20% to 30% ethyl acetate in petroleum ether) to give 4-(5-chloro-4,6-diiodopyrimidin-2-yl)morpholine (1.8 g, 67%) as an off-white solid. LCMS (ESI) m / z: 452.1 [M + H] + .
[0573] Step 3: Synthesis of 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0574] A mixture of pyridin-4-amine (0.21 g, 2.22 mmol) and sodium hydride (0.177 g, 4.43 mmol) in dimethyl sulfoxide (5 mL) was stirred at 25 ° C for 0.5 h. 4-(5-chloro-4,6-diiodopyrimidin-2-yl)morpholine (1 g, 2.22 mmol) was added to the resulting mixture and stirring was continued for another 2 h. The mixture was then poured into ice water and extracted with ethyl acetate (15 mL*3). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was subjected to silica gel chromatography (dichloromethane: methanol = 20: 1) to give 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (400 mg, 43%) as a yellow solid. LCMS (ESI) m / z: 418.1 [M+H] + .
[0575] Step 4: Synthesis of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-chloro-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0576] To a solution of 5-chloro-6-iodo-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (0.05 g, 0.12 mmol) and 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (0.035 g, 0.13 mmol) in 1,4-dioxane / water (1.5 mL / 0.4 mL) at room temperature were added cesium carbonate (0.078 g, 0.24 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.007 g, 0.01 mmol). The resulting mixture was heated and stirred at 90°C for 2 h. It was concentrated and the residue was subjected to preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm 120A, mobile phase is acetonitrile / 0.1% ammonium bicarbonate) to give 6-(3-(1H-pyrazol-1-yl)phenyl)-5-chloro-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine as a yellow solid (28.3 mg, 54%). 1 H NMR (400MHz, DMSO-d6) δ9.25(s,1H),8.57(d,J=2.5Hz,1H),8.46(d,J=6.3Hz,2H),8.13(s,1H),7.96(dt,J=7.3,2.1Hz,1H ),7.83-7.79(m,2H),7.78(d,J=1.6Hz,1H),7.64-7.59(m,2H),6.59-6.56(m,1H),3.68(s,8H).LCMS(ESI)m / z:434.3[M+H] + .
[0577] Example 43. Synthesis of 6-(5,6-dimethoxypyridin-2-yl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 51):
[0578]
[0579] Step 1: Synthesis of 2-bromo-6-iodo-3-methoxypyridine.
[0580] A solution of 2-bromo-6-iodopyridin-3-ol (1 g, 3.36 mmol), iodomethane (955 mg, 6.72 mmol), and potassium carbonate (464 mg, 3.36 mmol) in DMF (40 mL) was stirred at 100 ° C for 2 h under a nitrogen atmosphere. The mixture was cooled to room temperature, treated with water (30 mL) and stirred for 0.5 h. The resulting precipitate was separated by filtration and dried to give 2-bromo-6-iodo-3-methoxypyridine (0.92 g, 87.5%) as a brown solid. LCMS (ESI) m / z: 313.9 [M+H] + .
[0581] Step 2: Synthesis of 6-iodo-2,3-dimethoxypyridine.
[0582] A solution of 2-bromo-6-iodo-3-methoxypyridine (0.92 g, 2.94 mmol) and sodium methoxide (320 mg, 5.9 mmol) in anhydrous methanol (30 mL) was stirred at 100 ° C for 2 h under a nitrogen atmosphere. The mixture was cooled to room temperature and then distributed between saturated aqueous sodium bicarbonate solution and dichloromethane. The organic phase was washed with water, dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography and eluted with a linear gradient of 0% to 10% ethyl acetate in petroleum ether to give 6-iodo-2,3-dimethoxypyridine (664 mg, 85.1%) as a brown solid. LCMS (ESI) m / z: 266.0 [M + H] + .
[0583] Step 3: Synthesis of 3-dimethoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine.
[0584] A solution of 6-iodo-2,3-dimethoxypyridine (200 mg, 0.75 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (230 mg, 0.9 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (61 mg, 0.075 mmol) and potassium acetate (180 mg, 1.5 mmol) in anhydrous 1,4-dioxane (10 mL) was stirred at 90° C. for 16 h under a nitrogen atmosphere. The reaction mixture was used directly in the next step without further purification. LCMS (ESI) m / z: 266.0 [M+H] + .
[0585] Step 4: Synthesis of 6-(5,6-dimethoxypyridin-2-yl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine.
[0586] To the reaction mixture from the above step was added 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (50 mg, 0.156 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II):dichloromethane complex (12 mg, 0.015 mmol), potassium carbonate (146 mg, 0.45 mmol) and water (1 mL). The resulting mixture was stirred under nitrogen atmosphere at 90° C. for 16 h. It was then filtered to remove the solid; the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 6-(5,6-dimethoxypyridin-2-yl)-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (20.6 mg, 31.2%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ9.31(s,1H),8.40(s,2H),7.88(d,J=4.6Hz,2H),7.70(d,J=8.1Hz,1H),7.41(d, J=8.2Hz,1H),3.95(s,3H),3.85(s,3H),3.69(d,J=6.4Hz,8H),3.65(s,3H).LCMS(ESI)m / z:425.2[M+H] + .
[0587] Example 44. Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)morpholine (Compound 52):
[0588]
[0589] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine.
[0590] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (90 mg, 0.341 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (88 mg, 0.31 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (245 mg, 0.75 mmol) in 1,4-dioxane / water (5 mL / 1 mL) was stirred under argon atmosphere at 90°C for 16 h. The mixture was filtered, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether: acetate = 3:1) to give 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (80 mg, 61%) as a white solid. LCMS (ESI) m / z: 386.2 [M+H] + .
[0591] Step 2: Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)morpholine.
[0592] A mixture of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (118 mg, 0.3 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (62 mg, 0.3 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) chloride dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (245 mg, 0.75 mmol) in 1,4-dioxane / water (5 mL / 1 ml) was stirred at 90° C. for 16 h under argon atmosphere. The mixture was filtered, the filtrate was concentrated, and the residue was subjected to preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)morpholine (15.3 mg, 12%) as a light yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.48(s,1H),8.42(s,1H),8.15(s,1H),7.89(d,J=7.8Hz,2H),7.77(d,J=2.2Hz,1H),7.53(t,J=7.8Hz,1H),6 .74(d,J=2.2Hz,1H),3.94(s,3H),3.91(s,3H),3.75(d,J=4.8Hz,4H),3.71(d,J=4.7Hz,4H),3.40(s,3H).LCMS(ESI)m / z:432.2[M+H] + .
[0593] Example 45. Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N,2-di(pyridin-4-yl)pyrimidin-4-amine (Compound 53):
[0594]
[0595] A mixture of 4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-(pyridin-4-yl)pyrimidine (0.08 g, 0.2 mmol), pyridin-4-amine (0.04 g, 0.42 mmol), cesium carbonate (0.21 g, 0.64 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.02 g, 0.02 mmol) and 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (0.015 g, 0.03 mmol) in toluene (4 mL) was stirred at 100 °C for 4 h. The reaction mixture was concentrated and the residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A, mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N,2-di(pyridin-4-yl)pyrimidin-4-amine as a yellow solid (8.8 mg, 10%). 1H NMR(400MHz, DMSO-d6)δ8.79(dd,J=4.5,1.5Hz,2H),8.54(t,J=1.9Hz,2H),8.53(d, J=1.4Hz,1H),8.27(dd,J=4.5,1.6Hz,2H),8.05(dd,J=4.8,1.5Hz,2H),8.03(d,J=7 .9Hz,1H),7.95(d,J=7.8Hz,1H),7.79(d,J=2.2Hz,1H),7.62(t,J=7.8Hz,1H),6.78 (d,J=2.2Hz,1H),6.07(s,1H),3.92(s,3H),3.62(s,3H).LCMS(ESI)m / z:435.8[M+H] + .
[0596] Example 46. Synthesis of 5-methoxy-2-morpholino-6-(3-(oxazol-2-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 54)
[0597]
[0598] Step 1: Synthesis of 2-(3-bromophenyl)oxazole.
[0599] A mixture of 1-bromo-3-iodobenzene (0.5 g, 1.77 mmol), oxazole (0.12 g, 1.77 mmol), palladium acetate (0.04 g, 0.18 mmol), copper (I) iodide (0.068 g, 0.36 mmol) in N, N-dimethylacetamide (25 mL) was stirred at 140 ° C for 16 h in an argon atmosphere. The reaction mixture was concentrated, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (eluted with 30% to 60% ethyl acetate in petroleum ether) to give 2-(3-bromophenyl)oxazole (0.3 g, 76.7%) as an oil. LCMS (ESI) m / z: 223.8 [M+H] + .
[0600] Step 2: Synthesis of 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxazole.
[0601] A mixture of 2-(3-bromophenyl)oxazole (250 mg, 1.12 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (320 mg, 1.12 mmol), 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium(II) dichloromethane complex (92 mg, 0.112 mmol) and cesium carbonate (1.08 g, 3.36 mmol) in 1,4-dioxane / water (10 mL x 2 mL) was stirred at 100 °C for 3 h under an argon atmosphere. The mixture was concentrated, the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (base) to give 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxazole (180 mg, 59%) as a white solid. LCMS (ESI) m / z: 271.9 [M+H] + .
[0602] Step 3: Synthesis of 5-methoxy-2-morpholino-6-(3-(oxazol-2-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine.
[0603] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.31 mmol), 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxazole (84 mg, 0.31 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.031 mmol) and cesium carbonate (0.3 g, 0.93 mmol) in 1,4-dioxane / water (15 mL / 3 mL) was stirred for 3 h at 100° C. under an argon atmosphere. The mixture was concentrated, and the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (basic) to afford 5-methoxy-2-morpholino-6-(3-(oxazol-2-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine (23.4 mg, 17%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.41(s,1H),8.67(s,1H),8.42(s,2H),8.27(s,1H),8.17(d,J=7.7Hz,1H),8.09(d,J=7. 6Hz,1H),7.89(s,2H),7.69(t,J=7.7Hz,1H),7.43(s,1H),3.71(s,8H),3.48(s,3H).LCMS(ESI)m / z:430.8[M+H] + .
[0604] Example 47. Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol (Compound 55):
[0605]
[0606] Step 1: Synthesis of 1-(3-bromophenyl)piperidin-4-ol.
[0607] A mixture of 1,3-dibromobenzene (2.34 g, 10.0 mmol), piperidine-4-ol (870 mg, 10.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (458 mg, 0.5 mmol), 1,1'-binaphthyl-2,2'-diphenylphosphine (622 mg, 1.0 mmol) and potassium tert-butoxide (2.24 g, 20.0 mmol) in 1,4-dioxane (40 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The mixture was then poured into water and extracted with dichloromethane (200 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (10% methanol in dichloromethane) to give 1-(3-bromophenyl)piperidin-4-ol (300 mg, 12%) as a red oil. LCMS (ESI) m / z: 255.9 / 257.9 [M+H] + .
[0608] Step 2: Synthesis of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol.
[0609] A mixture of 1-(3-bromophenyl)piperidin-4-ol (275 mg, 1.1 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (559 mg, 2.2 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (90 mg, 0.11 mmol) and potassium acetate (216 mg, 2.2 mmol) in 1,4-dioxane (10 mL) was stirred for 4 h at 100° C. under a nitrogen atmosphere. The mixture was then poured into water and extracted with ethyl acetate (150 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (5% methanol in dichloromethane) to give 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol (250 mg, 74.5%) as a brown oil. LCMS (ESI) m / z: 304.2 [M+H] + .
[0610] Step 3: Synthesis of 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol.
[0611] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (100 mg, 0.38 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol (136 mg, 0.47 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (25 mg, 0.03 mmol) and cesium carbonate (201 mg, 0.62 mmol) in 1,4-dioxane / water (5 mL / 0.5 mL) was stirred at 100° C. for 16 h under a nitrogen atmosphere. The mixture was then poured into water and extracted with dichloromethane (100 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (15% methanol in dichloromethane) to give an impure product, which was further subjected to preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenyl)piperidin-4-ol (23.5 mg, 16%) as an off-white solid. 1H NMR (400MHz, DMSO-d6) δ9.12(s,1H),8.99(s,1H),8.34-8.16(m,2H),7.58(s,1H),7.35(m,3H),7.05(d,J=7.9Hz,1H),4.71(d,J= 4.1Hz,1H),3.71-3.37(m,14H),2.90(t,J=11.2Hz,2H),1.84(d,J=11.2Hz,2H),1.50(d,J=9.5Hz,2H); LCMS(ESI)m / z:463.2[M+H] + .
[0612] Example 48. Synthesis of 5-methoxy-2'-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-4,4'-bipyrimidin-6-amine (Compound 56):
[0613]
[0614] Step 1: Synthesis of 4-methoxy-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine.
[0615] A mixture of 2-chloro-4-methoxypyrimidine (1.44 g, 10.0 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.08 g, 10.0 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (163 mg, 0.2 mmol) and cesium carbonate (6.5 g, 20.0 mmol) in dioxane / water (50 mL / 6.0 mL) was stirred for 2 h at 100° C. under a nitrogen atmosphere. The resulting mixture was poured into water and extracted with ethyl acetate (200 mL*2). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (50% ethyl acetate in petroleum ether) to give 4-methoxy-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine (1.2 g, 63%) as a viscous liquid. LCMS (ESI) m / z: 191.1 [M+H] + .
[0616] Step 2: Synthesis of 2-(1-methyl-1H-pyrazol-3-yl)pyrimidin-4-ol.
[0617] A mixture of 4-methoxy-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine (1 g, 5.2 mmol) and concentrated hydrochloric acid (10.0 mL) was stirred at 65 ° C for 2 h. The mixture was poured into crushed ice, basified with solid sodium bicarbonate and extracted with dichloromethane (150 mL*5). The combined organic phases were concentrated and the residue was subjected to silica gel column chromatography (20% methanol in dichloromethane) to give 2-(1-methyl-1H-pyrazol-3-yl)pyrimidin-4-ol (650 mg, 54.7%) as a gray solid. LCMS (ESI) m / z: 177.0 [M+H] + .
[0618] Step 3: Synthesis of 4-chloro-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine.
[0619] A mixture of 2-(1-methyl-1H-pyrazol-3-yl)pyrimidin-4-ol (600 mg, 3.4 mmol) and phosphorus oxychloride (10.0 mL) was stirred at 100 ° C for 2 h. The mixture was concentrated, the residue was poured into crushed ice and extracted with dichloromethane (200 mL×3). The combined organic phase was concentrated, and the residue was subjected to silica gel column chromatography (5% methanol in dichloromethane) to give 4-chloro-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine (450 mg, 58.1%) as a gray solid. LCMS (ESI) m / z: 194.9 / 196.9 [M+H] + .
[0620] Step 4: Synthesis of 5-methoxy-2'-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-4,4'-bipyrimidin-6-amine.
[0621] A mixture of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (150 mg, 0.46 mmol), 1,1,1,2,2,2-hexamethyldistanane (229 mg, 0.7 mmol) and bis(triphenylphosphine)palladium(II) chloride (28 mg, 0.04 mmol) in dioxane (6 mL) was stirred for 2 h at 100° C. under nitrogen atmosphere. To the resulting mixture were added 4-chloro-2-(1-methyl-1H-pyrazol-3-yl)pyrimidine (90 mg, 0.46 mmol) and bis(tri-tert-butylphosphine)palladium (20 mg, 0.04 mmol) and stirring was continued at 100° C. for another 2 h. It was concentrated and the residue was subjected to silica gel column chromatography (10% methanol in dichloromethane) and then preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 5-methoxy-2'-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyridin-4-yl)-4,4'-bipyrimidin-6-amine (9.5 mg, 4.5%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ9.46 (s, 1H), 8.97 (d, J = 5.1Hz, 1H), 8.44 (d, J = 6.3Hz, 2H), 7.92-7.88 (m, 2H), 7.83(m,2H),6.95(d,J=2.2Hz,1H),3.96(s,3H),3.80(s,3H),3.69(s,8H); LCMS(ESI)m / z:445.8[M+H] + .
[0622] Example 49. Synthesis of 5-methoxy-2-morpholino-6-(5-(pyridazin-3-yl)pyridin-3-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 57).
[0623]
[0624] A solution of 6-chloro-5-methoxy-2-morpholino-N-(pyridin-4-yl)pyrimidin-4-amine (100 mg, 0.31 mmol), 3-(5-chloropyridin-3-yl)pyridazine (70 mg, 0.36 mmol), tetrakis(triphenylphosphine)palladium (34 mg, 0.06 mmol), bis(tri-tert-butylphosphine)palladium(0) (30 mg, 0.03 mmol) and hexamethyldistanane (153 mg, 0.46 mmol) in anhydrous 1,4-dioxane (10 mL) was stirred under argon atmosphere at 100° C. for 16 hours. The resulting mixture was filtered, the filtrate was concentrated, and the residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 5-methoxy-2-morpholino-6-(5-(pyridazin-3-yl)pyridin-3-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (12.7 mg, 9.26%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ9.45 (s, 1H), 9.39 (d, J = 2.2Hz, 1H), 9.32 (dd, J = 4.0, 1.8Hz, 2H), 9.09 (t, J = 2.1Hz, 1H), 8.42(dd,J=10.3,3.2Hz,3H),7.89(dd,J=7.7,5.8Hz,3H),3.72(s,8H),3.53(s,3H).LCMS(ESI)m / z:443.1[M+H] + .
[0625] Example 50. Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine (Compound 58):
[0626]
[0627] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine.
[0628] A mixture of 4-(4,6-dichloro-5-methoxypyrimidin-2-yl)morpholine (0.4 g, 1.70 mmol), quinolin-6-ylboronic acid (0.29 g, 1.70 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.14 g, 0.17 mmol) and cesium carbonate (1.39 g, 4.26 mmol) in 1,4-dioxane / water (20 mL / 3 mL) was stirred at 100 ° C for 2 h. The reaction mixture was concentrated, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was flash chromatographed (eluting with 30% to 60% ethyl acetate in petroleum ether) to give 4-(4-chloro-5-methoxy-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine (0.2 g, 33.1%) as a light yellow solid. LCMS (ESI) m / z: 356.8 [M+H] + .
[0629] Step 2: Synthesis of 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine.
[0630] A mixture of 4-(4-chloro-5-methoxy-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine (200 mg, 0.56 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (160 mg, 0.56 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (46 mg, 0.056 mmol) and cesium carbonate (0.54 g, 1.68 mmol) in 1,4-dioxane / water (10 mL / 2 mL) was stirred at 100° C. for 32 h. The mixture was concentrated, the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to preparative HPLC (basic) to afford 4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-6-(quinolin-6-yl)pyrimidin-2-yl)morpholine (59.6 mg, 22.3%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.99(d,J=4.1Hz,1H),8.76(s,1H),8.57(d,J=8.0Hz,1 H),8.48(s,1H),8.44(m,1H),8.15(d,J=8.9Hz,1H),7.98-7.91(m,2H),7.78(d, J=2.0Hz,1H),7.56(t,J=7.7Hz,1H),6.76(d,J=2.1Hz,1H),3.92(s,3H),3.81( d,J=4.1Hz,4H),3.75(d,J=4.0Hz,4H),3.27(s,3H).LCMS(ESI)m / z:478.6[M+H] + .
[0631] Example 51. Synthesis of 6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (Compound 59):
[0632]
[0633] Step 1: Synthesis of 4-(4,6-dichloro-5-(methylthio)pyrimidin-2-yl)morpholine.
[0634] To a solution of 4-(4,6-dichloropyrimidin-2-yl)morpholine (2.4 g, 10.2 mmol) in tetrahydrofuran (20 mL) was added n-butyl lithium (8 mL, 20.4 mmol) at -78 °C. The resulting mixture was stirred at -78 °C for 1 h, then 1,2-dimethyldisulfane (964 mg, 10.2 mmol) was added and stirred at -78 °C for another 1 h. The reaction was then quenched with water (15 mL) and the mixture was extracted with ethyl acetate (20 mL*3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel flash chromatography (petroleum ether: ethyl acetate = 75:25) to give 4-(4,6-dichloro-5-(methylthio)pyrimidin-2-yl)morpholine as a yellow oil (1.2 g, 42.5%). LCMS (ESI) m / z: 279.9 [M+H] + .
[0635] Step 2: Synthesis of 4-(4,6-dichloro-5-(methylsulfinyl)pyrimidin-2-yl)morpholine.
[0636] 3-Chlorobenzene peroxy acid (154 mg, 0.89 mmol) was added to a solution of 4-(4,6-dichloro-5-(methylthio)pyrimidin-2-yl)morpholine (250 mg, 0.896 mmol) in dichloromethane (10 mL), and the resulting mixture was stirred at room temperature for 8 h. The reaction was then quenched with water (15 mL) and the mixture was extracted with ethyl acetate (20 mL*3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel flash chromatography (petroleum ether: ethyl acetate = 75:25) to give 4-(4,6-dichloro-5-(methylsulfinyl)pyrimidin-2-yl)morpholine as a yellow solid. (215 mg, 81.1%). LCMS (ESI) m / z: 296.0 [M+H] + .
[0637] Step 3: Synthesis of 6-chloro-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0638] A mixture of 4-(4,6-dichloro-5-(methylsulfinyl)pyrimidin-2-yl)morpholine (215 mg, 0.726 mmol), pyridine-3-amine (68 mg, 0.726 mmol), tris(dibenzylideneacetone)dipalladium (30 mg, 0.05 mmol), 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (56 mg, 0.06 mmol) and potassium carbonate (201 mg, 1.45 mmol) in toluene (10 mL) was stirred at 85 ° C for 16 h. The reaction was then quenched with water (15 mL) and extracted with ethyl acetate (20 mL*3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel flash chromatography (petroleum ether:ethyl acetate=75:25) to give 6-chloro-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine as a yellow solid (180 mg, 70.3%). LCMS (ESI) m / z: 354.0 [M+H] + .
[0639] Step 4: Synthesis of 6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine.
[0640] To a solution of 6-chloro-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (180 mg, 0.508 mmol) in 1,4-dioxane (5 mL) and water (5 mL) was added 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (224 mg, 0.792 mmol), potassium carbonate (147 mg, 1.05 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane complex (50 mg, 0.196 mmol). The resulting mixture was stirred at 90°C for 2 h. The resulting mixture was filtered, diluted with water (10 mL) and extracted with ethyl acetate (10 mL×3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (0.05% ammonium bicarbonate:acetonitrile = 5% to 95%) to give 6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-5-(methylsulfinyl)-2-morpholino-N-(pyridin-3-yl)pyrimidin-4-amine (26.6 mg, 28.5%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ10.32(s,1H),8.78(d,J=2.4Hz,1H),8.31(dd,J=4.6,1.2Hz,1H),8.04(ddd,J=8.3,2.6,1.5Hz,1H),7.92-7.81(m,2H), 7.76(d,J=2.2Hz,1H),7.52-7.33(m,3H),6.76(d,J=2.3Hz,1H),3.90(s ,3H),3.74(s,4H),3.67(s,4H),2.98(s,3H).LCMS(ESI)m / z:475.6[M+H] + .
[0641] Example 52. Synthesis of 4-(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)-1-methylpiperazin-2-one (Compound 60):
[0642]
[0643] Step 1: Synthesis of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine.
[0644] 4-(4,6-Dichloro-5-methoxypyrimidin-2-yl)morpholine (782 mg, 3 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (852 mg, 3 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (245 mg, 0.3 mmol) and cesium carbonate (2445 mg, 7.5 mmol) in 1,4-dioxane / water (20 mL / 4 mL) were stirred at 90° C. for 16 h under argon atmosphere. The reaction mixture was filtered to remove the solid, the filtrate was concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether: acetate = 3: 1) to give 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (523 mg, 45%) as a white solid. LCMS (ESI) m / z: 386.2 [M+H] + .
[0645] Step 2: Synthesis of 4-(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)-1-methylpiperazin-2-one.
[0646] A mixture of 4-(4-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)pyrimidin-2-yl)morpholine (153.5 mg, 0.4 mmol), 1-methylpiperazin-2-one (45 mg, 0.4 mmol), tris(dibenzylideneacetone)dipalladium (37 mg, 0.04 mmol), 2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1-biphenyl (37 mg, 0.08 mmol) and sodium tert-butoxide (115 mg, 4.14 mmol) in toluene (10 mL) was stirred under argon atmosphere at 85° C. for 16 h. The reaction mixture was filtered to remove solids, the filtrate was concentrated, and the residue was subjected to preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 4-(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholinopyrimidin-4-yl)-1-methylpiperazin-2-one (64 mg, 34.5%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ8.29(s,1H),7.84-7.74(m,3H),7.47(t,J=7.7Hz,1H),6.70(d,J=2.1Hz,1H),4.26(s,2H),4.00(t,J =5.3Hz,2H),3.90(s,3H),3.65(d,J=2.3Hz,8H),3.46(t,J=5.3Hz,2H),3.31(s,3H),2.89(s,3H).LCMS(ESI)m / z:464.4[M+H] + .
[0647] Example 53. Synthesis of 4-(4-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-6-(4-phenyl-1H-imidazol-2-yl)pyrimidin-2-yl)morpholine (Compound 61):
[0648]
[0649] Step 1: Synthesis of methyl 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylate.
[0650] To a solution of 4-(4-(3-(1H-pyrazol-1-yl)phenyl)-6-chloro-5-methoxypyrimidin-2-yl)morpholine (400 mg, 1.08 mmol) in dimethyl sulfoxide (8 mL) and methanol (10 mL) was added palladium(II) acetate (20 mg, 0.088 mmol), 1,1'-bis(diphenylphosphino)ferrocene (244 mg, 0.44 mmol) and triethylamine (266 mg, 2.64 mmol), and the reaction mixture was stirred at 85°C under a carbon monoxide atmosphere for 16 hours. The mixture was extracted with dichloromethane (20 mL*2) and washed with water (10 mL*2). The organic layer was dried over sodium sulfate, filtered and the filtrate was concentrated. The residue was then subjected to silica gel column chromatography (3% methanol in dichloromethane) to give methyl 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylate (130 mg, 30%). LCMS (ESI) m / z: 395.9 [M+H] + .
[0651] Step 2: Synthesis of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylic acid.
[0652] To a solution of methyl 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylate (130 mg, 0.3 mmol) in tetrahydrofuran (5 mL) and water (1 mL) was added lithium hydroxide monohydrate (25 mg, 0.6 mmol) at 0°C and the reaction mixture was stirred at room temperature for 1 h. The mixture was then quenched by the addition of water (10 mL), and the mixture was then filtered to remove the solid. The filtrate was extracted with dichloromethane (10 mL*3), and the combined organic phases were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography (methanol: dichloromethane = 1:8) to give 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylic acid (110 mg, 90%) as a yellow solid. LCMS (ESI) m / z: 381.8 [M+H] + .
[0653] Step 3: Synthesis of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholino-N-(2-oxo-2-phenylethyl)pyrimidine-4-carboxamide.
[0654] To a stirred solution of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholinopyrimidine-4-carboxylic acid (110 mg, 0.27 mmol) and 2-amino-1-phenylethan-1-one (40 mg, 0.30 mmol) in N,N-dimethylformamide (10 mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetraethyluronium hexafluorophosphate (150 mg, 0.4 mmol) and N,N-diisopropylethylamine (130 mg, 1 mmol). The resulting mixture was stirred at 20° C. for 16 h and concentrated. The residue was subjected to flash chromatography (dichloromethane:methanol=50:1) to give 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholino-N-(2-oxo-2-phenylethyl)pyrimidine-4-carboxamide (125 mg, 90%) as a white solid. LCMS (ESI) m / z: 498.7 [M+H] + .
[0655] Step 4: Synthesis of 4-(4-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-6-(4-phenyl-1H-imidazol-2-yl)pyrimidin-2-yl)morpholine.
[0656] A solution of 6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholino-N-(2-oxo-2-phenylethyl)pyrimidine-4-carboxamide (125 mg, 0.24 mmol) and ammonium acetate (500 mg, 5.5 mmol) was stirred at 180 ° C. under argon atmosphere for 2 h. It was cooled and the mixture was diluted with ethyl acetate (25 mL) and washed with water (25 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was subjected to silica gel flash chromatography (petroleum ether: ethyl acetate = 1: 1) to give 4-(4-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-6-(4-phenyl-1H-imidazol-2-yl)pyrimidin-2-yl)morpholine (4.3 mg, 4%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ12.88(s,1H),8.59(d,J=2.4Hz,1H),8.52(s,1H),8.00(s,1H),7.98(s,1H),7.94(d,J=8.0Hz,3H),7.80(s,1H),7.65( t,J=7.9Hz,1H),7.41(t,J=7.6Hz,2H),7.26(s,1H),6.59(s,1H),3.86(s,4H),3.74(d,J=4.6Hz,4H),3.70(s,3H).LCMS(ESI)m / z:479.7[M+H] + .
[0657] Example 53. Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)-2-(pyridin-4-yl)pyrimidin-4-amine (Compound 62):
[0658]
[0659] Step 1: Synthesis of 2,6-dichloro-5-methoxy-N-(pyridin-3-ylmethyl)pyrimidin-4-amine.
[0660] A mixture of 2,4,6-trichloro-5-methoxypyrimidine (0.45 g, 2.11 mmol), pyridin-3-ylmethylamine (0.23 g, 2.11 mmol) and N,N-diisopropylethylamine (0.55 g, 4.22 mmol) in tert-butyl alcohol (15 mL) was stirred at room temperature for 5 h. It was concentrated and the residue was subjected to column chromatography (Biotage, 40 g silica gel, eluted with 5% to 15% 7N ammonia methanol in dichloromethane) to give 2,6-dichloro-5-methoxy-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (0.39 g, 65%) as a brown solid. LCMS (ESI) m / z: 284.8 [M+H] + .
[0661] Step 2: Synthesis of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine and 6-chloro-5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine.
[0662] A mixture of 2,6-dichloro-5-methoxy-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (0.35 g, 1.23 mmol), 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (314 mg, 1.1 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (100 mg, 0.12 mmol) and cesium carbonate (1 g, 3.07 mmol) in 1,4-dioxane / water (25 mL / 4 mL) was stirred at 95° C. for 16 h. It was concentrated, and the residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (base) to give 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (50 mg, 11.2%) and 6-chloro-5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (100 mg, 22.4%) as white solids. LCMS (ESI) m / z: 407.1 [M+H] + .
[0663] Step 3: Synthesis of 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)-2-(pyridin-4-yl)pyrimidin-4-amine.
[0664] A mixture of 2-chloro-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (40 mg, 0.098 mmol), pyridin-4-ylboronic acid (15 mg, 0.12 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (10 mg, 0.01 mmol) and cesium carbonate (0.08 g, 0.25 mmol) in 1,4-dioxane / water (5 mL / 1 mL) was stirred at 95 °C for 16 h. The mixture was concentrated and the residue was subjected to preparative HPLC (basic) to give 5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)-2-(pyridin-4-yl)pyrimidin-4-amine (5.9 mg, 13.4%) as a white solid. 1 H NMR (400MHz, CDCl3) δ8.77-8.66(m,3H),8.62-8.54(m,1H),8.48(t,J=1.6Hz,1H),8.28(dd,J= 4.5,1.6Hz,2H),8.04-7.99(m,1H),7.93(dd,J=7.8,1.4Hz,1H),7.78(d,J=7.8,1Hz,1H),7.53( t,J=7.8Hz,1H),7.42(d,J=2.2Hz,1H),7.31(dd,J=7.8,4.8Hz,1H),6.63(d,J=2.3Hz,1H),5.95 (t, J=6.0Hz, 1H), 4.89 (d, J=6.0Hz, 2H), 3.98 (s, 3H), 3.57 (s, 3H). LCMS (ESI) m / z: 450.1 [M+H].
[0665] Example 54. Synthesis of 5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)-6-(pyridin-4-yl)pyrimidin-4-amine (Compound 63):
[0666]
[0667] A mixture of 6-chloro-5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (70 mg, 0.17 mmol), pyridin-4-ylboronic acid (25 mg, 0.21 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex (14 mg, 0.02 mmol) and cesium carbonate (0.14 g, 0.43 mmol) in 1,4-dioxane / water (8 mL / 1 mL) was stirred at 95 °C for 16 h. The mixture was concentrated and the residue was subjected to preparative HPLC (basic) to give 5-methoxy-2-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pyridin-3-ylmethyl)-6-(pyridin-4-yl)pyrimidin-4-amine (22.9 mg, 30%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ8.80-8.73(m,3H),8.70(s,1H),8.44(dd,J=4.8,1.5Hz,1H),8.33(t, J=6.1Hz,1H),8.23(d,J=7.8Hz,1H),8.04(dd,J=4.6,1.5Hz,2H),7.90(d,J=7.9,1H),7.85(d, J=7.8Hz,1H),7.78(d,J=2.2Hz,1H),7.48(t,J=7.7Hz,1H),7.37(dd,J=7.8,4.8Hz,1H),6.73 (d,J=2.2Hz,1H),4.77(d,J=6.0Hz,2H),3.92(s,3H),3.60(s,3H).LCMS(ESI)m / z:450.1[M+H] + .
[0668] Example 55. Synthesis of 2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)-6H-pyrimido[5,4-c]quinolin-5-one (Compound 64) and 6-methyl-2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one (Compound 65):
[0669]
[0670] Step 1: Synthesis of 1-(3-bromo-4-nitro-phenyl)pyrazole.
[0671] 1H-pyrazole (619 mg, 9.09 mmol) and Na2CO3 (2.41 g, 22.73 mmol) were added to a solution of 2-bromo-4-fluoro-1-nitrobenzene (2 g, 9.09 mmol) in DMF (20 mL). The resulting mixture was stirred at 100°C for 12 h, then cooled to 15°C and poured into ice water (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL*3), and the combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography (ISCO 40 g silica, 0-30% ethyl acetate in petroleum ether, gradient over 20 min) to give 1-(3-bromo-4-nitro-phenyl)pyrazole (1.3 g, 53%) as a yellow solid.
[0672] Step 2: Synthesis of 1-[4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole.
[0673] To a solution of 1-(3-bromo-4-nitro-phenyl)pyrazole (1.15 g, 4.29 mmol) in dioxane (10 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (1.31 g, 5.15 mmol), Pd(dppf)Cl2 (314 mg, 429 umol) and KOAc (1.26 g, 12.87 mmol). The resulting mixture was stirred at 80° C. for 12 h. It was then filtered to remove the solids, and the filtrate was concentrated to give the crude product. This was purified by flash column chromatography (ISCO 40 g silica, 0-50% ethyl acetate in petroleum ether, gradient over 20 min) to afford 1-[4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (1 g, 74%) as a yellow solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.29 (d, J = 8.8 Hz, 1H), 8.05 (d, J = 2.6 Hz, 1H), 7.91-7.76 (m, 3H), 6.59-6.52 (m, 1H), 1.28 (s, 12H).
[0674] Step 3: Synthesis of ethyl 2-morpholino-4-(2-nitro-5-pyrazol-1-yl-phenyl)-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0675] 1-[4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (208 mg, 660 umol), K3PO4 (350 mg, 1.65 mmol) and [2-(2-aminophenyl)phenyl]-chloropalladium, dicyclohexyl-[2-(2,6-dimethoxyphenyl)phenyl]phosphane (43 mg, 55 umol) were added to a solution of ethyl 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylate (200 mg, 550 umol) in THF (5 mL) under a nitrogen atmosphere. The mixture was stirred at 80° C. for 4 h, then cooled to 15° C. and poured into ice water (15 mL). The aqueous phase was extracted with ethyl acetate (15 mL*3), the combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography (ISCO 10 g silica, 0-100% ethyl acetate in petroleum ether, gradient over 20 min) to give 2-morpholino-4-(2-nitro-5-pyrazol-1-yl-phenyl)-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (340 mg, 60%) as a yellow solid.
[0676] Step 4: Synthesis of 2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)-6H-pyrimido[5,4-c]quinolin-5-one.
[0677] Fe (249 mg, 4.45 mmol) and NH4Cl (238 mg, 4.45 mmol) were added to a solution of 2-morpholino-4-(2-nitro-5-pyrazol-1-yl-phenyl)-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (230 mg, 445 umol) in EtOH (3 mL) and H2O (1 mL). The mixture was stirred at 80 ° C for 8 h, and the iron powder was removed by filtration. The filtrate was then concentrated to give 2-morpholino-9-pyrazol-1-yl-4-(4-pyridylamino)-6H-pyrimido[5,4-c]quinoline-5-one (150 mg, crude product) as a black solid. The crude product (30 mg) was purified by preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give 2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)-6H-pyrimido[5,4-c]quinolin-5-one (2 mg, 4.75 umol) as a white solid. 1H NMR (400MHz, DMSO-d6) δ12.34(s,1H),8.75(d,J=2.4Hz,1H),8.58(d,J=2.4Hz,1H),8.50(d,J=5.4Hz,2H),8.13(dd,J=8. 9,2.6Hz,1H),7.81-7.66(m,3H),7.48(d,J=8.7Hz,1H),6.59(s,1H),3.80-3.79(m,4H),3.78(d,J=4.4Hz,4H).LCMS(ESI C23H20N8O2)[M+H] + :441.1.
[0678] Step 5: Synthesis of 6-methyl-2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one.
[0679] To a solution of 2-morpholino-9-pyrazol-1-yl-4-(4-pyridylamino)-6H-pyrimido[5,4-c]quinolin-5-one (100 mg, 227 umol) in DMF (1 mL) at 0°C was added NaH (18 mg, 454 umol, 60% suspension in oil). The mixture was warmed and stirred at 25°C for 0.5 h. Iodomethane (32 mg, 227 μmol) was then added to the mixture, which was stirred at 25°C for another 2 h. The mixture was then poured into ice water (2 mL) at 0°C, filtered, and the filtrate was concentrated to give a crude product. It was then dissolved in DMF (1 mL), allowed to stand for a day, and then the solid formed was removed by filtration, washed with H2O (1 mL*2), and the combined filtrate was concentrated to give 6-methyl-2-morpholino-9-pyrazol-1-yl-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one (9 mg, 8%). 1 H NMR(400MHz,DMSO-d6)δ12.21(bs,1H),8.68(bs,1H),8.56-8.33(m,3H),8.09-7.95(m,1 H),7.80(s,1H),7.61(bs,2H),7.48(bs,1H),6.58(bs,1H),4.08-3.38(m,11H).LCMS(ESI C24H22N8O2)[M+H] + :455.1.
[0680] Example 56. Synthesis of N,N-dimethyl-4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxamide (Compound 66):
[0681]
[0682] Step 1: Synthesis of 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester.
[0683] A solution of LDA (2M in THF, 17.94 mL) was added dropwise to a solution of 4-(4,6-dichloropyrimidin-2-yl)morpholine (7 g, 29.90 mmol) in anhydrous THF (70 mL) at -70°C to -60°C under a nitrogen atmosphere, and the mixture was stirred for 1 h. Ethyl chloroformate (8.68 g, 79.98 mmol) was then added via a syringe, and the mixture was stirred for another 2 h at -70°C to -60°C. The contents were warmed to 25°C and stirred for another 0.5 h. It was then poured into ice water (100 mL), and the aqueous phase was extracted with ethyl acetate (100 mL*3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography (ISCO 40 g silica, 0-20% ethyl acetate in petroleum ether, gradient over 20 min) to afford 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester (8.4 g, 92%) as a white solid.
[0684] Step 2: Synthesis of ethyl 4-chloro-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0685] To a solution of pyridin-4-amine (0.96 g, 10.20 mmol) in DMSO (15 mL) was added NaH (392 mg, 9.80 mmol, 60% suspension) at 0°C. The mixture was stirred at 20°C for 0.5 h, cooled to 0°C again, and then 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester (1.5 g, 4.90 mmol) was added. The mixture was stirred at 20°C for another 2 h, and then poured into ice water (30 mL). The aqueous phase was extracted with ethyl acetate (30 mL*3), and the combined organic phases were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-100% ethyl acetate in petroleum ether, gradient over 20 min) to afford ethyl 4-chloro-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (850 mg) as a light yellow solid. LCMS (ESI) m / z: 364.0 [M+H] + .
[0686] Step 3: Synthesis of ethyl 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0687] To a solution of ethyl 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylate (500 mg, 1.37 mmol) in dioxane (7 mL) and H2O (0.7 mL) was added 1-methyl-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (586 mg, 2.06 mmol), K2CO3 (570 mg, 4.12 mmol) and Pd(PPh3)4 (159 mg, 137 umol). The resulting mixture was stirred at 100°C under nitrogen atmosphere for 3 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. 10 mL of water was added to the residue and the aqueous mixture was extracted with ethyl acetate (10 mL*2). The combined organic layers were washed with brine (10 mL) and dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0 to 87% ethyl acetate in petroleum ether, gradient over 20 min) to afford ethyl 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (520 mg, 78%) as a light yellow solid. 1 H NMR (400 MHz, chloroform-d) δ8.51 (d, J = 6.3 Hz, 2H), 7.93-7.80 (m, 2H), 7.69-7.61 (m, 2H), 7.49-7.33 (m, 3H), 6.56 (d, J = 2.3 Hz, 1H), 4.04-3.86 (m, 9H), 3.80 (bs, 4H), 0.76 (t, J = 7.2 Hz, 3H); LCMS (ESI) m / z: 486.3 [M+H] + .
[0688] Step 4: Synthesis of 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid.
[0689] To a solution of ethyl 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (500 mg, 1.03 mmol) in THF (4 mL), MeOH (2 mL) and H2O (2 mL) was added LiOH.H2O solution (129 mg, 3.09 mmol). The mixture was stirred at 25°C for 12 h and concentrated. The residue was diluted with 5 mL of H2O, and saturated aqueous citric acid solution was added to the mixture at 0°C until pH = 3-4. The resulting precipitate was collected by filtration, washed with water and dried in vacuo to give 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (450 mg, 96%) as a yellow solid. LCMS (ESI) m / z: 458.2 [M+H] + .
[0690] Step 5: Synthesis of N,N-dimethyl-4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxamide.
[0691] To a mixture of 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylic acid (120 mg, 262 umol) and N,N-dimethylamine (2M in THF, 1 mL) was added HATU (120 mg, 315 umol) and DIPEA (102 mg, 787 umol). The mixture was stirred at 20 ° C for 2 h, and then 1 mL of water was added. The mixture was extracted with ethyl acetate (3 mL * 2), and the combined organic layers were washed with brine (1 mL) and dried over Na2SO4 and concentrated. The residue was subjected to preparative HPLC [Welch Xtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give N,N-dimethyl-4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxamide (51 mg, 40%) as a white solid. 1HNMR (400MHz, chloroform-d) δ8.47(d,J=5.8Hz,2H),8.14-8.09(m,1H),7.97(d,J=7.8Hz,1H),7.77-7.66(m,2H),7.61(d,J=7.8Hz,1H),7.51-7.44(m,1 H),7.42(d,J=2.1Hz,1H),6.59(d,J=2.3Hz,1H),4.06-3.89(m,7H),3.88-3.79(m,4H),2.85(s,3H),2.37(s,3H).LCMS(ESI)(C26H28N8O2)[M+H] + :485.3.
[0692] Example 57. Synthesis of 4-(3-cyanophenyl)-N,N-dimethyl-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxamide (Compound 67):
[0693]
[0694] Step 1: Synthesis of ethyl 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0695] To a solution of ethyl 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylate (400 mg, 1.10 mmol) in dioxane (5 mL) and H2O (0.5 mL) was added (3-cyanophenyl)boronic acid (242 mg, 1.65 mmol), K2CO3 (456 mg, 3.30 mmol) and Pd(PPh3)4 (127 mg, 110 umol). The mixture was stirred at 100°C under a nitrogen atmosphere for 3 h. It was then filtered, the filtrate was concentrated, and the residue was diluted with 5 mL of water. The aqueous phase was extracted with ethyl acetate (5 mL*2), and the combined organic layers were washed with brine (5 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-80% ethyl acetate in petroleum ether, gradient over 20 min) to afford ethyl 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (250 mg, 53%) as a yellow solid. LCMS (ESI) m / z: 431.1 [M+H] + .
[0696] Step 2: Synthesis of 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid.
[0697] To a solution of ethyl 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (240 mg, 558 umol) in THF (2 mL), MeOH (1 mL) and H2O (1 mL) was added LiOH.H2O (70 mg, 1.67 mmol). The mixture was stirred at 25°C for 12 h and concentrated. To the residue was added 3 mL of water and saturated aqueous citric acid solution at 0°C until pH = 4. The resulting precipitate was collected by filtration, washed with water and dried in vacuo to give 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (220 mg, 98%) as a yellow solid. LCMS (ESI) m / z: 403.1 [M+H] + .
[0698] Step 3: Synthesis of 4-(3-cyanophenyl)-N,N-dimethyl-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxamide.
[0699] To a mixture of 4-(3-cyanophenyl)-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (110 mg, 273 umol) and N,N-dimethylamine (2M in THF, 1 mL) was added HATU (125 mg, 328 umol) and DIPEA (106 mg, 820 umol). The mixture was stirred at 25 ° C for 2 h and concentrated. The residue was subjected to preparative HPLC (Phenomenex C1875*30 mm*3 um column; 10-55% acetonitrile in 10 mM aqueous ammonium hydroxide solution, 8 min gradient) to give 4-(3-cyanophenyl)-N,N-dimethyl-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxamide (8 mg, 7%) as a white solid. 1 H NMR (400MHz, chloroform-d) δ8.77(s,1H),8.50(d,J=5.8Hz,2H),8.11(t,J=1.5Hz,1H),7.87(td,J=8.2,1.4Hz,1H),7.77(td,J=7.8 ,1.4Hz,1H),7.57-7.51(m,3H),3.93(bs,4H),3.86-3.81(m,4H),2.89(s,3H),2.38(s,3H).LCMS(ESI)(C23H23N7O2)[M+H] + :430.3.
[0700] Example 58. Synthesis of azetidin-1-yl-[4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidin-5-yl]methanone (Compound 68):
[0701]
[0702] Step 1: Synthesis of ethyl 4-chloro-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0703] NaH (131 mg, 3.27 mmol, 60% suspension) was added portionwise to a solution of pyridine-4-amine (154 mg, 1.63 mmol) in DMSO (30 mL) at 0°C. The mixture was then stirred at 25°C for 0.5 h, and then 4,6-dichloro-2-morpholino-pyrimidine-5-carboxylic acid ethyl ester (500 mg, 1.63 mmol) was added to the above mixture at 0°C. The resulting mixture was stirred at 25°C for 2 h, then poured into a saturated NH4Cl aqueous solution (30 mL) at 0°C, and the aqueous phase was extracted with ethyl acetate (30 mL*3). The combined extracts were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was flash chromatographed (ISCO 40 g silica, 0-56% ethyl acetate in petroleum ether, gradient over 20 min) to give ethyl 4-chloro-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (1.66 g, 28%) as a yellow solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 10.82 (s, 1H), 8.46 (d, J = 6.1 Hz, 2H), 7.49 (d, J = 6.2 Hz, 2H), 4.36 (q, J = 7.1 Hz, 2H), 3.86-3.72 (m, 8H), 1.39 (t, J = 7.2 Hz, 3H).
[0704] Step 2: Synthesis of ethyl 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate.
[0705] 1-Methyl-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (879 mg, 2.47 mmol), K2CO3 (855 mg, 6.18 mmol) and Pd(PPh3)4 (238 mg, 206 umol) were added to a solution of ethyl 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylate (1 g, 2.06 mmol) in dioxane (15 mL) and H2O (1.5 mL). The resulting mixture was stirred at 100° C. under nitrogen atmosphere for 3 h. The reaction mixture was then diluted with water and extracted with ethyl acetate (20 mL*2). The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash chromatography (ISCO 20 g silica, 0-77% ethyl acetate in petroleum ether, gradient over 20 min) to afford ethyl 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylate (600 mg, 60%) as a light yellow solid. LCMS (ESI) m / z: 486.3 [M+H] + .
[0706] Step 3: Synthesis of 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid.
[0707] To a solution of 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (200 mg, umol) in THF (4 mL), MeOH (2 mL) and H2O (2 mL) was added LiOH.H2O (52 mg, 1.24 mmol). The mixture was stirred at 25°C for 12 h and concentrated. The residue was diluted with 5 mL H2O, and saturated aqueous citric acid solution was added to the mixture at 0°C until pH = 5-6. The resulting precipitate was filtered and dried in vacuo to give a crude product (300 mg). 150 mg of this product was purified by preparative HPLC (Waters Xbridge Prep OBD C18 150*40 mm*10 um; 5%-45% acetonitrile in 10 mM aqueous ammonium bicarbonate solution, 8 min gradient) to give compound 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (78 mg, 41%) as a white solid. 1HNMR (400MHz, DMSO-d6) δ11.00-10.64(m,1H),8.50-8.42(m,2H),7.84(s,1H),7.81(td,J=1.5,7.4Hz,1H),7.74(d,J=2.1Hz,1H),7.72-7. 67(m,2H),7.45-7.35(m,2H),6.71(d,J=2.3Hz,1H),3.88(s,3H),3.85-3.78(m,4H),3.71(d,J=4.1Hz,4H).LCMS(ESI)(C24H23N7O3)[M+H] + :458.1.
[0708] Step 4: Synthesis of azetidin-1-yl(4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-5-yl)methanone.
[0709] To a solution of 4-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-6-(4-pyridinylamino)pyrimidine-5-carboxylic acid (150 mg, 327.88 umol) in DMF (2 mL) was added azetidine (423 mg, 7.41 mmol), HATU (150 mg, 393 umol) and DIPEA (127 mg, 984 umol). The mixture was stirred at 25 °C for 2 h, and the whole mixture was subjected to preparative HPLC (Waters Xbridge Prep OBD C18 150*40mm*10um column; 25-55% acetonitrile in 10 mM aqueous ammonium hydroxide solution, 8 min gradient) to give azetidin-1-yl(4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2-morpholino-6-(pyridin-4-ylamino)pyrimidin-5-yl)methanone (78 mg, 48%) as a white solid. 1 H NMR (400MHz, chloroform-d) δ9.79 (s, 1H), 8.48 (d, J = 6.3Hz, 2H), 8.18 (t, J = 1.6Hz, 1H),7.99(td,J=7.8,1.3Hz,1H),7.73-7.60(m,3H),7.52-7.45(m,1H),7.4 2(d,J=2.3Hz,1H),6.61(d,J=2.3Hz,1H),4.04-3.93(m,8H),3.90-3.73(m ,5H),3.42-3.27(m,2H),2.07-1.99(m,2H).LCMS(ESI)(C27H28N8O2)[M+H] + :497.3.
[0710] Example 59. Synthesis of N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxamide (Compound 69):
[0711]
[0712] Step 1: Synthesis of ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylate.
[0713] 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole (371 mg, 1.37 mmol), Pd(PPh3)4 (159 mg, 137 umol) and K2CO3 (570 mg, 4.12 mmol) were added to a solution of ethyl 4-chloro-2-morpholino-6-(3-pyridylamino)pyrimidine-5-carboxylate (500 mg, 1.37 mmol) in dioxane (5 mL) and H2O (0.5 mL). The mixture was stirred at 100° C. under nitrogen atmosphere for 3 h, then diluted with 10 mL of water, and the aqueous mixture was extracted with ethyl acetate (5 mL*3). The combined organic layers were dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 12 g silica, 0-60% ethyl acetate in petroleum ether, 30 min gradient) to afford ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylate (500 mg, 46%) as a yellow oil. LCMS (ESI) [M+H] + :472.2.
[0714] Step 2: Synthesis of 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylic acid.
[0715] To a solution of ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylate (500 mg, 530 umol) in THF (4 mL) and MeOH (2 mL) at 0°C was added a solution of LiOH.H2O (67 mg, 1.59 mmol) in H2O (2 mL). The mixture was then warmed and stirred at 20°C for 3 h and concentrated. It was then diluted with 8 mL of water, and the mixture was extracted with ethyl acetate (5 mL*3). The organic phase was discarded, and the aqueous phase was treated with saturated aqueous citric acid solution under ice bath conditions until pH = 5. The solid formed was collected by filtration and dried under reduced pressure to give 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylic acid (150 mg, 64%) as a yellow solid. LCMS (ESI) [M+H] + :444.1.
[0716] Step 3: Synthesis of N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxamide.
[0717] To a solution of 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxylic acid (120 mg, 271 umol) in DMF (2 mL) was added N-methylmethylamine (2M, 406 uL), HATU (123 mg, 406 uL) and DIPEA (105 mg, 812 umol). The mixture was stirred at 20°C for 14 h and concentrated. The residue was subjected to preparative HPLC [WelchXtimate C18 21.2×250 mm, 10 um, mobile phase acetonitrile / water (10 mM NH4HCO3 and NH3·H2O)] to give N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidine-5-carboxamide (82 mg, 65%) as a white solid. 1 H NMR (400MHz, chloroform-d) δ8.95(d,J=2.4Hz,1H),8.56(s,1H),8.32(d,1H,J=3.6Hz),8.09(s,1H),7.99(s,1H),7.84(q,J=1.4Hz,2H),7.58(s,1H) ,7.53-7.52(m,1H),7.52-7.51(m,1H),7.29-7.28(m,1H),6.51(s,1H),3.89(s,4H),3.80-3.78(m,4H),2.88(s,3H),2.45(s,3H).LCMS(ESI C25H26N8O2)[M+H] +:471.2.
[0718] Example 60. Synthesis of [2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidin-5-yl]methanol (Compound 70).
[0719]
[0720] To a solution of ethyl 2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridylamino)pyrimidine-5-carboxylate (210 mg, 445 umol) in THF (3 mL) was added LiAlH4 (34 mg, 891 umol) portionwise at 20°C. The resulting mixture was stirred at 20°C for 12 h. The reaction was then quenched with Na2SO4.10H2O (2 eq) at 0°C, and the mixture was warmed and stirred at 20°C for 30 min. The resulting heterogeneous mixture was filtered to remove the solids, and the filtrate was concentrated. The residue was then subjected to preparative HPLC (Phenomenex luna C1880*40mm*3um column; 8-28% acetonitrile in 0.04% hydrochloric acid aqueous solution, 7min gradient), and then again subjected to additional preparative HPLC conditions (Phenomenex luna C1880*40mm*3um column; 18-33% acetonitrile in 0.04% hydrochloric acid aqueous solution, 6min gradient) to give [2-morpholino-4-(3-pyrazol-1-ylphenyl)-6-(3-pyridinylamino)pyrimidin-5-yl]methanol (17 mg, 8%) as a light yellow viscous liquid. 1 H NMR(400MHz, methanol-d)δ=9.37(d,J=1.6Hz,1H),8.80(d,J=8.4Hz,1H),8.71(d,J=5.6Hz,1H),8.38(s,1H),8.11-8.05(m,3H),7 .82(d,J=1.6Hz,1H),7.76-7.74(m,1H),7.62-7.60(m,1H),6.62(t,J=2.0Hz,1H),4.62(s,2H),3.83-3.79(m,8H).LCMS(ESI C23H23N7O2)[M+H] + :430.0.
[0721] Example 61. Synthesis of 6-methyl-9-(1-methylpyrazol-3-yl)-2-morpholino-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one (Compound 71):
[0722]
[0723] Step 1: Synthesis of tert-butyl N-(2-bromo-4-iodo-phenyl)carbamate.
[0724] To a solution of 2-bromo-4-iodo-aniline (4 g, 13.43 mmol) in THF (40 mL) was added NaHMDS (1 M, 20.14 mL) at 0°C. The mixture was stirred at 0°C for 30 min, and then a solution of Boc2O (3.22 g, 14.77 mmol) in THF (10 mL) was added dropwise at 0°C. The mixture was stirred at 25°C for 2 h, and a saturated NH4Cl aqueous solution (80 mL) was carefully added to the flask. The resulting mixture was extracted with ethyl acetate (20 mL*3), and the combined organic layers were washed with brine (15 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-3% ethyl acetate in petroleum ether, 10 min gradient) to give tert-butyl N-(2-bromo-4-iodo-phenyl)carbamate (3 g, 56%) as a yellow solid. LCMS (ESI) m / z: 397.1 [M+H] + .
[0725] Step 2: Synthesis of tert-butyl N-(2-bromo-4-iodo-phenyl)-N-methylcarbamate.
[0726] To a solution of tert-butyl N-(2-bromo-4-iodo-phenyl)carbamate (3 g, 7.54 mmol) in THF (40 mL) was added NaH (361 mg, 9.04 mmol, 60% suspension in oil) portionwise at 0°C. The resulting heterogeneous mixture was stirred at 0°C for 30 min, and then CH3I (2.14 g, 15.07 mmol) was added. The mixture was warmed and stirred at 25°C for 2 h, and then 50 mL of saturated NH4Cl aqueous solution was added. The resulting mixture was then extracted with ethyl acetate (30 mL*2), and the combined organic layers were washed with brine (3 mL), dried over Na2SO4 and concentrated to give tert-butyl N-(2-bromo-4-iodo-phenyl)-N-methylcarbamate (3 g, 96%) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.95 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 3.13 (s, 3H), 1.36 (s, 9H).
[0727] Step 3: Synthesis of tert-butyl N-[2-bromo-4-(1-methylpyrazol-3-yl)phenyl]-N-methylcarbamate.
[0728] To a solution of tert-butyl N-(2-bromo-4-iodo-phenyl)-N-methylcarbamate (1.7 g, 4.13 mmol) in dioxane (20 mL) and H2O (2 mL) was added 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (858 mg, 4.13 mmol), Cs2CO3 (2.69 g, 8.25 mmol) and Pd(dppf)Cl2 (301 mg, 412 umol). The resulting mixture was stirred at 80°C under argon atmosphere for 5 h. It was then diluted with 40 mL of water, and the mixture was extracted with ethyl acetate (20 mL*3). The combined organic layers were washed with brine (15 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-30% ethyl acetate in petroleum ether, 20 min gradient) to afford tert-butyl N-[2-bromo-4-(1-methylpyrazol-3-yl)phenyl]-N-methylcarbamate (900 mg, 59%) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.05 (s, 1H), 7.70 (dd, J = 8.1, 1.6 Hz, 1H), 7.38-7.26 (m, 1H), 7.22 (d, J = 8.1 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 3.96 (s, 3H), 3.17 (s, 3H), 1.35 (s, 9H).
[0729] Step 4: Synthesis of 2-bromo-N-methyl-4-(1-methylpyrazol-3-yl)aniline.
[0730] A solution of tert-butyl N-[2-bromo-4-(1-methylpyrazol-3-yl)phenyl]-N-methylcarbamate (850 mg, 2.32 mmol) in HCl / EtOAc (4M, 580 uL) was stirred at 25°C for 2 h and concentrated. The residue was dissolved in water (5 mL) and then basified with saturated aqueous NaHCO3 at 0°C. The resulting mixture was extracted with ethyl acetate (10 mL*2), and the combined organic layers were washed with brine (5 mL), dried over Na2SO4 and concentrated to give 2-bromo-N-methyl-4-(1-methylpyrazol-3-yl)aniline (600 mg, 97%) as a yellow oil. LCMS (ESI) m / z: 266.2 [M+H] + .
[0731] Step 5: Synthesis of N-methyl-4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline.
[0732] 2-Bromo-N-methyl-4-(1-methylpyrazol-3-yl)aniline (600 mg, 2.25 mmol), Pd(dppf)Cl2 (165 mg, 225 umol) and AcOK (443 mg, 4.51 mmol) were added to a solution of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (687 mg, 2.71 mmol) in dioxane (10 mL). The resulting mixture was stirred at 80° C. under an argon atmosphere for 5 h, then diluted with 20 mL of water. It was then extracted with ethyl acetate (10 mL*3), and the combined organic layers were dried over Na2SO4 and concentrated. The residue was then subjected to flash column chromatography (ISCO 20 g silica, 30%-100% ethyl acetate in petroleum ether, 30 min gradient) to afford N-methyl-4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (400 mg, 57%) as a yellow oil. LCMS (ESI) m / z: 314.2 [M+H] + .
[0733] Step 6: Synthesis of 6-methyl-9-(1-methylpyrazol-3-yl)-2-morpholino-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one.
[0734] To a solution of 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (140 mg, 384 umol) and N-methyl-4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (132 mg, 423 umol) in THF (3 mL), [2-(2-aminophenyl)phenyl]-chloro-palladium; dicyclohexyl-[2-(2,6-dimethoxyphenyl)phenyl]phosphane (27 mg, 38 umol) and K3PO4 (245 mg, 1.15 mmol) were added. The resulting reaction mixture was stirred at 80° C. under an argon atmosphere for 4 h and concentrated. The residue was then subjected to preparative HPLC (Phenomenex Luna C18 75*30mm*3um column; 10%-50% acetonitrile in 0.05% formic acid aqueous solution, 8min gradient) to give 6-methyl-9-(1-methylpyrazol-3-yl)-2-morpholino-4-(4-pyridinylamino)pyrimido[5,4-c]quinolin-5-one (3 mg, 1.40%) as a light yellow solid. 1H NMR (400MHz, methanol-d4) δ8.96(s,1H),8.40(d,J=6.1Hz,2H),8.02(d,J=8.9Hz,1H),7.78(d,J=5.8Hz,2H),7.67(s,1 H),7.48(d,J=8.5Hz,1H),6.68(d,J=2.3Hz,1H),4.03-4.01(m,6H),3.85-3.83(m,5H),3.68(s,3H).LC-MS:(ESI C25H24N8O2)m / z:469.1[M+H] + .
[0735] Example 62. Synthesis of N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]naphthalene-2-carboxamide (Compound 72)
[0736]
[0737] Step 1: Synthesis of 2-bromo-4-(1-methylpyrazol-3-yl)aniline.
[0738] 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (838 mg, 4.03 mmol), CsCO (2.62 g, 8.06 mmol) and Pd(dppf)Cl (295 mg, 403 umol) were added to a solution of 2-bromo-4-iodo-aniline (1.2 g, 4.03 mmol) in dioxane (10 mL) and H2O (1 mL). The mixture was stirred at 80 ° C for 5 h under an argon atmosphere. It was then diluted with 20 mL of water and extracted with ethyl acetate (10 mL*3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-30% ethyl acetate in petroleum ether, 20 min gradient) to afford 2-bromo-4-(1-methylpyrazol-3-yl)aniline (620 mg, 61%) as a yellow oil. 1 H NMR (400 MHz, chloroform-d) δ7.87 (d, J = 1.8 Hz, 1H), 7.53 (dd, J = 8.3, 1.8 Hz, 1H), 7.34 (d, J = 2.1 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 6.41 (d, J = 2.1 Hz, 1H), 4.14 (s, 2H), 3.94 (s, 3H); LCMS (ESI) m / z: 253.9 [M+H] + .
[0739] Step 2: Synthesis of 4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline.
[0740] 2-Bromo-4-(1-methylpyrazol-3-yl)aniline (600 mg, 2.38 mmol), Pd(dppf)Cl2 (174 mg, 238 umol) and KOAc (584 mg, 5.95 mmol) were added to a solution of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (725 mg, 2.86 mmol) in dioxane (10 mL). The mixture was stirred at 90° C. under argon atmosphere for 15 h, then diluted with 20 mL of water. It was extracted with ethyl acetate (20 mL*3), and the combined organic phases were washed with brine, dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-100% ethyl acetate in petroleum ether, 20 min gradient) to afford 4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (400 mg, 56%) as a yellow oil. LCMS (ESI) m / z: 300.2 [M+H] + .
[0741] Step 3: Synthesis of 9-(1-methylpyrazol-3-yl)-2-morpholino-4-(4-pyridinylamino)-6H-pyrimido[5,4-c]quinolin-5-one.
[0742] To a solution of 4-chloro-2-morpholino-6-(4-pyridylamino)pyrimidine-5-carboxylic acid ethyl ester (200 mg, 549 umol) and 4-(1-methylpyrazol-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (181 mg, 605 umol) in THF (2 mL), [2-(2-aminophenyl)phenyl]-chloro-palladium; dicyclohexyl-[2-(2,6-dimethoxyphenyl)phenyl]phosphane (40 mg, 55 umol) and K3PO4 (350 mg, 1.65 mmol) were added. The reaction mixture was stirred at 80° C. under an argon atmosphere for 4 h and concentrated. The residue was subjected to preparative HPLC (Waters Xbridge Prep OBD C18 150*40mm*10um column; 25%-65% acetonitrile in 0.05% ammonium hydroxide and 10mM sodium bicarbonate aqueous solution, 8min gradient) to give 9-(1-methylpyrazol-3-yl)-2-morpholino-4-(4-pyridinylamino)-6H-pyrimido[5,4-c]quinolin-5-one (7 mg, 3%) as a light yellow solid. 1H NMR (400MHz, DMSO-d6) δ12.36(s,1H),11.83(s,1H),8.75(d,J=2.0Hz,1H),8.48(d,J=6.0Hz, 2H),8.04(dd,J=8.6,1.9Hz,1H),7.80-7.74(m,3H),7.38(d,J=8.5Hz,1H),6.78(s,1H),4.00 -3.76(m,7H),3.79(t,J=4.4Hz,4H).LC-MS:(ESIC24H22N8O2)m / z:455.1[M+H] + .
[0743] Example 63. Synthesis of 6-[3-(1-methylpyrazol-3-yl)phenyl]-N-(1-methylpyridin-1-ium-4-yl)-2-morpholino-5-oxazol-2-yl-pyrimidin-4-amine (Compound 73) and 6-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-5-oxazol-2-yl-N-(4-pyridinyl)pyrimidin-4-amine (Compound 74):
[0744]
[0745] Step 1: Synthesis of 3-(3-bromophenyl)-1-methyl-pyrazole.
[0746] To a solution of 3-(3-bromophenyl)-1H-pyrazole (5 g, 19.50 mmol) in DMF (35 mL) was added NaH (1.17 g, 29.25 mmol, 60% suspension in oil) portionwise at 0°C, and the mixture was stirred at 0°C for 0.5 h. Then, under an argon atmosphere, MeI (4.15 g, 29.25 mmol) was added dropwise to the mixture at 0°C, and stirring was continued at 25°C for 12 h. The reaction was quenched with H2O (10 mL) at 0°C, and the mixture was extracted with ethyl acetate (30 mL*2). The combined organic layers were washed with brine (30 mL), dried over Na2SO4 and concentrated. The residue was subjected to flash column chromatography (ISCO 20 g silica, 0-17% ethyl acetate in petroleum ether, 20 min gradient) to give 3-(3-bromophenyl)-...
Claims
1. Compounds of formula I: or a pharmaceutically acceptable salt thereof, in V is -NH-, -NR 5 -、-CH2NH-、-CH2NR 5 -, -O-, -CO-, or -CHOH-; R 1 is optionally substituted morpholin-4-yl, pyridin-4-yl, pyridin-3-yl, optionally substituted 2-oxo-pyrrolidin-1-yl, optionally substituted piperidin-1-yl or optionally substituted pyridazin-4-yl; R 2 It is a halogen, -(CH2) n OH, optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ; and R 3 is optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl; or R 2 and R 3 Together with the ring to which they are attached, they combine to form an optionally substituted C4-C 12 heteroaryl; n is 1, 2, 3, 4, 5, or 6; k is 0, 1, or 2; R 4 is optionally substituted pyridin-4-yl, optionally substituted 1-methylpyridin-1-ium-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl, or -NHR 8 ; R 5 is an optionally substituted C1-C6 alkyl group; R 6 is H or optionally substituted C1-C6 alkyl; R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl; R 7c , R 7d and R 7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 an alkoxy group or a hydroxy group; and R 8 is optionally substituted phenyl or optionally substituted C3-C6 cycloalkyl.
2. The compound of claim 1, wherein R 1 is optionally substituted morpholin-4-yl.
3. The compound as claimed in claim 1, wherein R 1 is optionally substituted pyridin-4-yl.
4. The compound of claim 1, wherein R 1 is optionally substituted pyridin-3-yl.
5. The compound as claimed in claim 1, wherein R 1 yes 6. The compound of claim 1, wherein R 1 yes 7. The compound of claim 1, wherein R 1 It is morpholin-4-yl.
8. The compound of claim 1, wherein R 1 is optionally substituted piperidin-1-yl.
9. The compound of claim 1, wherein R 1 yes 10. The compound of any one of claims 1 to 9, wherein V is -NH-.
11. The compound of any one of claims 1 to 9, wherein V is -CH2NH-.
12. The compound of any one of claims 1 to 9, wherein V is -O-.
13. The compound of any one of claims 1 to 9, wherein V is -CO-.
14. The compound of any one of claims 1 to 9, wherein V is -CHOH-.
15. The compound of any one of claims 1 to 9, wherein V is -NR 5 -.
16. The compound of any one of claims 1 to 9, wherein V is -CH2NR 5 -.
17. The compound of claim 10, wherein R 4 Yes - NHR 8 .
18. The compound of claim 11, wherein R 8 It is an optionally substituted C3-C6 cycloalkyl group.
19. The compound of claim 12, wherein R 8 It is cyclopropyl.
20. The compound of claim 11, wherein R 8 is optionally substituted phenyl.
21. The compound of claim 14, wherein R 8 It is phenyl.
22. The compound of claim 20 or 21, wherein R 4 It is optionally substituted pyridin-4-yl, optionally substituted 1-methylpyridin-1-ium-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl.
23. The compound of claim 22, wherein R 4 It is optionally substituted pyridin-4-yl, optionally substituted pyridin-3-yl, optionally substituted 1-methylpiperidin-3-yl, optionally substituted pyridazin-3-yl.
24. The compound of claim 23, wherein R 4 is optionally substituted pyridin-4-yl or optionally substituted pyridin-3-yl.
25. The compound of claim 24, wherein R 4 It is pyridin-4-yl or pyridin-3-yl.
26. The compound of any one of claims 1 to 25, wherein R 2 and R 3 Together with the ring to which they are attached, they combine to form an optionally substituted C4-C 12 Heteroaryl.
27. The compound of claim 26, wherein R 2 and R 3 Together with the ring to which they are attached they combine to form an optionally substituted C4-C9 heteroaryl.
28. The compound of claim 27, wherein the compound has the following structure:
29. The compound of any one of claims 1 to 25, wherein R 2 It is a halogen, -(CH2) n OH, optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e .
30. The compound of claim 29, wherein R 2 is an optionally substituted C 1-6 alkoxy, optionally substituted C2-C9 heteroaryl, optionally substituted 2-oxo-pyrrolidin-1-yl, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e .
31. The compound of claim 30, wherein R 2 is an optionally substituted C 1-6 Alkoxy.
32. The compound of claim 31, wherein R 2 It is -OCH3.
33. The compound of claim 30, wherein R 2 Yes - (CO)NR 7a R 7b .
34. The compound of claim 29, wherein R 7a and R 7b Each is independently an optionally substituted C1-C6 alkyl group.
35. The compound of claim 30, wherein R 7a and R 7b Each is a methyl group.
36. The compound of claim 29, wherein R 7a and R 7b Together with the nitrogen atom to which they are attached, they combine to form an optionally substituted C2-C9 heterocyclic group.
37. The compound of claim 36, wherein -(CO)NR 7a R 7b yes 38. The compound of claim 30, wherein R 2 Yes-P(O)R 7c R 7d or -S(O) k R 7e .
39. The compound of claim 38, wherein R 2 yes 40. The compound of claim 30, wherein R 2 is an optionally substituted C2-C9 heteroaryl group.
41. The compound of claim 40, wherein R 2 yes 42. The compound of claim 29, wherein R 2 It's a halogen.
43. The compound of claim 36, wherein R 2 It is Cl.
44. The compound of claim 29, wherein R 2 Yes - (CH2) n OH.
45. The compound of claim 44, wherein n is 1.
46. A compound as described in any one of claims 29 to 45, wherein R 3 is optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl.
47. The compound of claim 46, wherein R 3 is optionally substituted pyridin-3-yl, optionally substituted pyridin-4-yl or optionally substituted C6-C 10 Aryl.
48. The compound of claim 47, wherein R 3 is an optionally substituted C6 aryl group.
49. The compound of claim 48, wherein R 3 yes 50. The compound of claim 47, wherein R 3 is optionally substituted pyridin-3-yl or optionally substituted pyridin-4-yl.
51. The compound of claim 50, wherein R3 is 52. The compound of claim 46, wherein R 3 is optionally substituted pyridin-2-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridazin-3-yl or optionally substituted pyrimidin-4-yl.
53. The compound of claim 52, wherein R 3 yes 54. Compounds of formula II: or a pharmaceutically acceptable salt thereof, in R 9 is optionally substituted morpholin-4-yl, optionally substituted morpholin-3-ylalkoxy, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted 1-methylpiperazin-2-yl, or optionally substituted C6-C 10 Aryl; R 10 is an optionally substituted C 1-6 Alkoxy, -(CO)NR 7a R 7b 、-P(O)R 7c R 7d or -S(O) k R 7e ; R 7a and R 7b are each independently H or optionally substituted C1-C6 alkyl; or R 7a and R 7b Combined together with the nitrogen atom to which they are attached to form an optionally substituted C2-C9 heterocyclyl; R 7c , R 7d and R 7e are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy or hydroxyl; k is 0, 1, or 2; R 11 is optionally substituted morpholin-4-yl, optionally substituted pyridin-4-yl, optionally substituted pyrazol-4-yl, optionally substituted 1H-imidazol-2-yl, optionally substituted quinolin-6-yl or optionally substituted C6-C 10 aryl; and R 12 is optionally substituted 1-methylpiperazin-2-one, optionally substituted 2-(pyridin-2-yl)alkoxy, optionally substituted N-(pyridin-3-ylmethyl)amine, optionally substituted N-(pyridin-4-yl)amine or optionally substituted C6-C 10 Aryl.
55. The compound of claim 54, wherein R 9 It is morpholin-4-yl.
56. The compound of claim 54, wherein R 9 is optionally substituted morpholin-3-ylalkoxy.
57. The compound of claim 56, wherein R 9 yes 58. The compound of claim 54, wherein R 9 is optionally substituted 2-(pyridin-2-yl)alkoxy.
59. The compound of claim 58, wherein R 9 yes 60. The compound of claim 54, wherein R 9 is optionally substituted 1-methylpiperazin-2-yl.
61. The compound of claim 60, wherein R 9 yes 62. The compound of claim 54, wherein R 9 is an optionally substituted C6-C 10 Aryl.
63. The compound of claim 62, wherein R 9 yes 64. The compound of any one of claims 54 to 63, wherein R 10 is an optionally substituted C 1-6 Alkoxy.
65. A compound as described in any one of claims 54 to 64, wherein R 11 It is morpholin-4-yl.
66. A compound as described in any one of claims 54 to 64, wherein R 11 It is pyridin-4-yl.
67. A compound as described in any one of claims 54 to 64, wherein R 11 is optionally substituted pyrazol-4-yl.
68. The compound of claim 67, wherein R 11 yes 69. A compound as described in any one of claims 54 to 64, wherein R 11 is optionally substituted 1H-imidazol-2-yl.
70. The compound of claim 69, wherein R 11 yes 71. The compound of any one of claims 54 to 64, wherein R 11 is optionally substituted quinolin-6-yl.
72. The compound of claim 71, wherein R 11 yes 73. A compound as described in any one of claims 54 to 64, wherein R 11 is an optionally substituted C6-C 10 Aryl.
74. The compound of claim 73, wherein R 11 yes 75. A compound as described in any one of claims 54 to 74, wherein R 12 is optionally substituted 1-methylpiperazin-2-one.
76. The compound of claim 75, wherein R 12 yes 77. A compound as described in any one of claims 54 to 74, wherein R 12 is optionally substituted 2-(pyridin-2-yl)alkoxy.
78. The compound of claim 77, wherein R 12 yes 79. The compound of any one of claims 54 to 74, wherein R 12 is optionally substituted N-(pyridin-3-ylmethyl)amine.
80. The compound of claim 79, wherein R 12 yes 81. A compound as described in any one of claims 54 to 74, wherein R 12 is an optionally substituted N-(pyridin-4-yl)amine.
82. The compound of claim 81, wherein R 12 yes 83. A compound as described in any one of claims 54 to 74, wherein R 12 is an optionally substituted C6-C 10 Aryl.
84. The compound of claim 83, wherein R 12 yes 85. A compound having the structure of any one of Compounds 1-78 in Table 1.
86. A compound having the following structure: or a pharmaceutically acceptable salt thereof.
87. A compound having the following structure: or a pharmaceutically acceptable salt thereof.
88. A compound having the following structure or a pharmaceutically acceptable salt thereof.
89. A pharmaceutical composition comprising a compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
90. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of any one of claims 1 to 88 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 89.
91. The method of claim 90, wherein the neurological disorder is FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.
92. The method of claim 90, wherein the neurological disorder is ALS.
93. A method of inhibiting protein-related toxicity in a cell, the method comprising contacting the cell with a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 88 or a pharmaceutical composition according to claim 89.
94. The method of claim 93, wherein the toxicity is TDP-43 related toxicity.
95. The method of claim 93, wherein the toxicity is C9orf72-related toxicity.
96. A method of inhibiting PIKfyve in a cell expressing PIKfyve protein, the method comprising contacting the cell with a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 88 or a pharmaceutical composition according to claim 89.
97. The method of any one of claims 93 to 96, wherein the cell is a mammalian neural cell.
98. The method of any one of claims 93 to 97, wherein the cell is in a subject.
99. The method of claim 98, wherein the subject suffers from a neurological disorder.
